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Snake venoms are rich collections of enzymes, proteins, peptides and other 
components that can cause a wide range of physiological, neurological and 
haemostatic effects on their prey in an attempt to immobilise them and aid in digestion. 
Among these effects, the venom components that affect mammalian haemostasis have 
been most well studied for more than 150 years. They have contributed to elucidation 
of the detailed mechanisms of the coagulation cascade (e.g. platelet aggregation and 
inhibition, mechanism of defibrination, DIC, various coagulopathies, etc), elucidation 
of various clinical disorders (e.g. congenital haemorrhagic disorder, various blood 
factor deficiencies, etc), development of many diagnostics (e.g. Styphen or Reptilase® 
time) and therapeutics (e.g. ancrod and batroxobin). Therefore venoms have been 
regarded as ‘gold mines’ for researchers, pharmaceutical companies, clinical analysts 
as well as medical practitioners and surgeons. 
 
An anticoagulant proteinase, named agkistase, was isolated from the venom of 
pit viper, Agkistrodon halys halys, through successive ion-exchange and size exclusion 
liquid chromatography. Its purity was checked by high resolution HPLC, capillary 
electrophoresis and mass spectrophotometry. It is a serine protease with α,β-
fibrinogenase activity, which cleaves plasmatic fibrinogen chain α and β rendering it 
unclottable by thrombin. Agkistase was found to be fibrinogenolytic with slight 
fibrinolytic activity and did not affect other coagulation factors nor cause platelet 
aggregation. This fibrinogenase activity is unaffected by pH 5 ~ 9 and salt 
concentrations up to 0.8 M NaCl but was inhibited by serine protease inhibitors (e.g. 
PMSF and aprotinin). It has an α-fibrinogenase and β-fibrinogenase activities of 15.1 
 xvi 
and 0.25 mg min-1 mg enzyme-1, respectively. Thrombelastographic analyses revealed 
a prolongation in r and k values but unchanged MA, with extension in incubation with 
whole blood samples. This observation is usually seen for haemophilic blood samples, 
evident of abnormalities in one or more coagulation factors – in this case, fibrinogen. 
 
Human blood coagulation assays on agkistase showed that it has EC50 values of 
5.1 ± 1.5, 0.26 ± 0.1 and 0.5 ± 0.2 µg/ml on prothrombin time, recalcification time and 
thrombin time, respectively, in vitro. In vivo studies on C57BL mice showed that it is 
not toxic, haemorrhagic or thrombogenic up to 1.67 mg/kg when injected 
intravenously. These mice also showed no signs of thrombocytopenia. Evaluation of 
its anti-thrombotic potential on a thrombotic mouse model exhibited positive results in 
both reductions in thrombi occurrence and size, at agkistase concentration of only     
50 ng/kg mouse when injected intravenously. We concluded that it will be a promising 
new anti-thrombotic drug different from current available snake venom thrombin-like 
enzymes (SVTLEs) due to: (i) its low effective concentration with no observable 
negative effects, (ii) fast and specific fibrinogenolytic activities, (iii) presence of mild 
secondary fibrinolytic activities, and (iv) successful demonstration of its anti-
thrombotic capability on a mouse model. 
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CHAPTER 1: INTRODUCTION 
 
1.1 PIT VIPERS FROM THE GENUS AGKISTRODON 
Vipers and pit vipers are mainly classified into the taxonomic subfamily 
Viperinae and Crotalinae (Order: Squamata; Suborder: Serpentes; Infraorder: 
Alethinophidae; Family: Viperidae). This group of snakes were first studied in the late 
1950s by a renowned American herpetologist, the late Prof Howard Kay Gloyd (1902-
1978). After Prof Gloyd’s death in 1978, the colossal task of completing their 
identification and taxonomic organisation was passed onto the late Isabelle Hunt 
Conant.   The description of the genus Agkistrodon as well as its subspecies A. halys 
halys in this dissertation was based mainly on the work of Gloyd and Conant (1990), 
who obtained and studied over 6000 specimens found on several continents spanning 
over 11,000 kilometres. This is by far the most number of specimens studied 
unsurpassed by any other field taxonomists or herpetologists to-date. However, 
taxonomic classification is not the major focus in this dissertation. Hence only 
simplistic reference is presented to aid and/or resolve identification. 
 
A. halys complex has confused many taxonomists for almost a century. Three 
full species, A. blomhoffii, A. halys and A. intermedius, and all their many subspecies 
were conveniently categorised as “halys” for decades. According to the classification 
of Gloyd, the genus Agkistrodon halys complex was split into four separate and 
distinct genera – Deinagkistrodon, Agkistrodon, Calloselasma and Hypnale. Of these 
genera, Agkistrodon is presumed to comprise the largest species and has the greatest 
diversity – 7 species were reported in Asia and 3 from North America. The North 
American species were thought to have evolved from an ancestral lineage from the 
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Asian species that crossed the Bering Land Bridge during the late Oligoscene or early 
Miocene. This remarkable diversification of Agkistrodon snakes, which created many 
controversies of identification before the 1950s, was attributed to intergradation 
between species. 
 
Snakes of the Agkistrodon complex are reported to possess the following 
characteristics: (i) anal plate is single (not divided), (ii) a single pair of enlarged chin 
shields (although remnants of a posterior pair are occasionally evident),                     
(iii) nine symmetrically arranged scutes or plates, (iv) pre-oculars are almost always 
two in number, (v) presence of a maxillary (facial) pit, which is a chief characteristic 
of crotaline snakes, and (vi) triads (a group of large dark spots occupying a 
ventrolateral position in conjuction with each dark dorsal crossband) only 
characteristic of the North American forms.  
 
A summarised directive for identification of A. h. halys is presented in Table 1.1 
below.  
 
Table 1.1: Agkistrodon halys halys directives as described by Gloyd and Conant (1990). 
 Males Females 
 N Range Mean N Range Mean 
Ventrals 5 164-173 169.4 5 171-178 174.0 
Subcaudals 5 45-49 47.2 5 42-45 42.8 
Undivided subcaudals 5 0 - 5 0 - 
Scale rows at midbody* 14 - 22.9 - - - 
Supralabials* 20 - 7.8    
Infralabials* 20 - 10.7    
Postoculars plus suboculars* 26 - 2    
Crossbands 5 33-41 37.5 5 31-47 39.3 
Ratio of tail length to total length (%) 5 14-15 14.6 5 12-15 12.8 
Snout-vent lengths (mm)   450   590 
Total lengths (mm)†   530   590 
Dentary tooth counts* 4  11    
Pterygoid tooth counts* 4  10.5    
Palatine tooth counts* 4  3    
*Sexes were not determined in the reported specimens, † longest measured was 750 mm 
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Yenisey river, Russia  
Courtesy of EarthTrends (http://earthtrends.wri.org) 
Prof Peter Simon Pallas 
(1741-1811)  
Courtesy of Wikipedia 
(http://www.wikipedia.com) 
A. h. halys was first reported by Prof Peter Simon 
Pallas (1741-1811), a German botanist and zoologist. The 
pit viper, which was named A. h. Pallas, was discovered in 
Southern Siberia and Mongolia. Due to variation of 
morphology and great diversity of this subspecies, it was 
given many other names – Coluber halys Pallas (Pallas 
1776), Vipera halys (Latreille, 1802), Echidna aspis, var. 
pallasii (Merrem, 1820), Trigonocephalus halys (Lichtenstein, 1823), Halys pallasii 
(Günther, 1864), Trigonocephalus intermedius (Strauch, 1876), Ancistrodon halys 
(Boulenger, 1896), Agkistrodon halys (Stejneger, 1907), Ancistrodon halys halys 
(Nikol’skii, 1916), Agkistrodon halys intermedius (Schmidt, 1927), and finally 
Agkistrodon halys halys (Mertens and Müller, 1928). Hence Mertens and Müller were 
the first to name this species the present-day name of Agkistrodon halys halys. The 
Mongols referred to this snake as 
mogoi, their name for serpents in 
general; the Tungus as abù; the 
Mongol name given by Obst     
(Obst, 1963) was uulyn mogoj; and 
the Chinese named it 蝰科蝮蛇. The 
first properly documented 
indications showed that halys was 
first discovered on the Upper Yenisey by Strauch in 1873. The Yenisey river in Russia 
has its origin in Mongolia flowing due north into the Kara sea. 
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The geographical distribution of A. h. halys was mainly confined to Asia, in 
southern Siberia, Inner Mongolia, Mongolia and several provinces in central and upper 
China (Gloyd and Conant, 1990; Pope, 1935; Zhao and Adler, 1993; Zhao, 1990). This 
species thrived in rocky, sunny and arid deserts and mountains commonly 
uninhabitable by other snakes. A picture of A. h. halys is presented in Figure 1.1. 
 
Figure 1.1: A picture of Agkistrodon halys halys.  
 
Courtesy of Venomous snakes in China (Zhao, 1990). 
 
1.2 PIT VIPER ENVENOMATION 
Snake bites are a serious medical problem, especially in the Southeast Asia 
region (Warrell, 1989), causing many lethalities as well as a host of clinical symptoms 
including local tissue injury, flaccid paralysis, systemic myolysis, cardiotoxicity, renal 
damage and failure as well as haemorrhage and coagulopathy (White et. al., 1992; 
White, 2004; White and Fassett, 1983; White and Williams, 1989; Williams and White, 
1997; Yatziv et. al., 1974). It is estimated that global venomous snakebites affects 
greater than 2.5 million humans annually, of whom more than 100,000 die (Chippaux, 
1998). Such a high rate of morbidity and mortality is greater in the rural tropics (Laing 
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et. al., 1995; Lalloo et. al., 1995) than other localities. Each of the venom components 
may cause a number of clinical symptoms and secondary effects with potential 
morbidity and mortality. Any single species of snake may show activity in one or more 
of these categories – haemorrhagic, neurogenic, myotoxic, etc. In the past it was 
believed that vipers cause local and/or haemorrhagic effects whereas elapids cause 
purely systemic, non-haemorrhagic effects. 
 
Viperid bites are now considered to cause medically significant effects, i.e. 
coagulopathy, haemorrhage and thrombosis with deep vein thrombosis (DVT) and 
pulmonary embolism (PE), on the haemostatic system with their abundant disintegrins 
and haemorrhagins (White, 2005). Certainly, the diverse clinical symptoms reported 
reflects the numerous venom components found in each species. These symptoms can 
essentially be categorised into: (i) reduced coagulability of blood, resulting in an 
increased tendency to bleed, (ii) bleeding due to damage of the blood vessels,            
(iii) secondary effects of increased bleeding, ranging from hypovolemic shock to 
secondary organ damage, such as intracerebral haemorrhage, anterior pituitary 
haemorrhage or renal damage, (iv) direct pathologic thrombosis and its consequences, 
particularly pulmonary embolism. Viperid venoms are found to harbour many 
components that mainly cause such clinical symptoms, whether directly or indirectly. 
They are the procoagulants (e.g. thrombin-like enzymes) (Markland, 1998a), 
anticoagulants (e.g. fibrinogenases) (Markland, 1998a), platelet effectors (Clemetson 
et. al., 2005; Kamiguti, 2005) and haemorrhagins (e.g. HTa and HTb from Bitis 
gabonica) (Marsh et. al., 1995). 
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Srilekha Karthik from St John’s Medical College Hospital, Bangalore, India 
reported a 12-year old boy, who was admitted with oliguric acute renal failure (ARF), 
showed all clinical symptoms of coagulopathy including oedema, micro-angiopathic 
haemolytic anaemia, thrombocytopenia, prolonged coagulation parameters and 
disseminated intravascular coagulation (DIC), 4 days after a reported snakebite (snake 
could not be identified) (Karthik and Phadke, 2004). He was discharged after 17 days 
with a normal coagulation profile and with improving renal function. Another report 
from Hung Dong-Zong, Institute of Toxicology and Pharmacology, National Taiwan 
University involves two cases of Russell’s viper bites where, unfortunately, one patient 
underwent amputation and the other died of complications. The first patient was a 67-
year-old male farmer who developed haemolysis, rhabdomyolysis, acute renal failure, 
thrombocytopenia, coagulopathy and bleeding from the genitourinary and 
gastrointestinal tracts, which later extended into drowsy consciousness, left upper limb 
flaccid paralysis and multiple ecchymosis patches over his trunk. He was discharged 
after 61 days in the hospital with amputated toes due to gangrenous tissues. The other 
patient was a 52-year-old female field worker who hovered between consciousness, 
developed high blood pressure, haematuria and bloody vomits. Despite efforts to 
reverse her deterioration of renal function, pulmonary oedema, myocardial ischaemia, 
arterial thrombosis, DIC and haemorrhage, the patient died of multiple septic condition 
after 49 days of hospitalisation (Koo et. al., 2002). 
 
Snakebites from Agkistrodon halys were reported to have similar symptoms and 
severity to those reported above. However, due to the difficulty in capture of the 
snakes and identification, precise reports of envenomation by this species are scanty. 
One such case was reported from Guangxi Medical University, China involving a    
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27-year-old male who was showing local oedema and bleeding symptoms; subsequent 
laboratory results showed a reduction in platelet aggregation rate (37-52%), reduced 
anti-thrombin III activity (56-84%), reduced α2-PI activity (30-49%), low fibrinogen 
(0-131 mg/dL) and presence of fibrin degradation products (FDP) (< 2.5 µg/ml) 
suggesting DIC (Li et. al., 2000). An analysis of cDNA library construction, EST 
sequencing and clustering on Agkistrodon sp performed by Qinghua et. al. (Qinghua et. 
al., 2006) estimated the composition of putative cellular proteins in venom to comprise 
mainly of metalloproteinases (32.08%), C-type lectins (5.22%), bradykinin-
potentiating peptides (0.90%), serine proteases (0.51%), nucleotidase and nuclease 
(0.41%), phospholipase A2 (0.30%), disintegrins (0.05%), cytokine-like molecules 
(0.06%) and other proteins (0.63%) (Liu et. al., 2006). This finding helps to explain the 
predominant clinical symptoms exerted by viper venoms which comprise a variety of 
coagulation-related complications as more than 40% identified ESTs are known to 
affect coagulation to some degree.  
 
 8 
1.3 MAMMALIAN BLOOD COAGULATION SYSTEM 
The mammalian blood coagulation system is an intricate but tightly-regulated 
process involving innumerable serine proteases, coenzymes, phospholipids, blood cells, 
platelets, vessel walls, etc – all interrelated and affecting each other directly or 
indirectly in a dynamic manner (Jenny and Mann, 2002). Haemostasis can generally be 
divided into three main components, namely vessel wall, thrombocytes and plasmatic 
coagulation system. Consequently, haemostatic disorders are clinically categorised into 
vasculopathies, thrombocytopathies and coagulopathies, respectively, according to 
their primary defect. The vessel wall plays a double role in haemostasis: (i) a 
neurogenic contraction after an injury, lasting 20 to 30 sec, which permits the 
formation of a primitive platelet plug and the activation of the plasmatic clotting 
system, and (ii) injured or irritated endothelial cells release chemical signals that 
reversibly activate thrombocytes and the plasmatic clotting system. Thrombocytes, or 
platelets, are small anuclear corpuscles derived from megakaryocytes. Under 
physiological conditions blood contains 200 – 400 x 109 platelets per litre of blood. In 
their inactive form thrombocytes have an oval, disk-shaped form with an equatorial 
diameter of 2 – 4 µm and a thickness of 1 – 2 µm. In this form they are unable to 
adhere to an intact vascular wall, to other cells, or to each other. But when 
thrombocytes are exposed to agonists, e.g. during an injury, they undergo rapid and 
dramatic changes in cell shape, converting from discs into spiny forms within seconds. 
At the same time platelets also undergoes an exocytosis of storage granules, releasing 
mediators that enhance platelet plug formation by attracting additional platelets to the 
surface of the wound (aggregation) and initiating cellular repair reactions (signalling). 
Lastly, the plasmatic coagulation system consists of 13 major coagulation factors, 
mainly proteases that activate its downstream targets in an amplification manner 
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eventually leading to formation of fibrin clots from soluble fibrinogen. These three 
components dynamically influence one another in haemostasis giving rise to a well-
controlled circulation system that is responsive to external and internal stimuli. 
 
Many serine proteases, which affect the coagulation cascade, reside in the 
plasmatic blood system. The first rational theory explaining blood coagulation was 
formulated by Schmidt and Morawitz as early as 1892 and 1905, respectively. They 
proposed that thromboplastin (factor III), liberated from the tissue, changes 
prothrombin (factor II) in the presence of Ca2+ (factor IV) into thrombin, which in turn 
converts fibrinogen (factor I) to insoluble fibrin. This classic theory may be an over-
simplistic model but was valid for over 50 years. It has been modified by the discovery 
of additional clotting factors, most of them discovered between 1940 and 1960. The 
coagulation system is best explained by the waterfall or cascade theory formulated 
more than 44 years ago by MacFarlane (1964) and Davie and Ratnoff (1964). 
However, recent findings have redefined the original coagulation cascade as a 
complex, threshold-limited, highly interwoven array of physical, cellular and 
biochemical processes that contribute to haemostasis (Broze, Jr. and Majerus, 1980; 
Butenas and Mann, 1996; Gailani and Broze, Jr., 1991; Giesen and Nemerson, 2000; 
Hoffman, 2003; Krishnaswamy et. al., 1988; Krishnaswamy, 1990; Lawson et. al., 
1993; Morrissey et. al., 1993). This new cell-based model, which explains haemostatic 
processes in vivo more extensively, has evolved to emphasise the role of cells in 
localising activated procoagulant substances from spreading throughout the vascular 
system. It describes several key points in the classical blood coagulation cascade as 
protein complexes, e.g. extrinsic tenase, intrinsic tenase and prothrombinase, 
congregated on phospholipid membrane exerting their influence locally (Figure 1.2). 
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Figure 1.2: Schematic diagram of cell-based haemostatic system 
 
Schematic diagram of cell-based haemostatic system emphasises the role of phospholipid 
membrane (   ) with the protein complexes. Extrinsic tenase complex is made up of tissue 
factor (cofactor), factor IX and X (zymogens) and factor VIIa; intrinsic tenase complex is made 
up of light and heavy chain of factor VIIIa (cofactor), factor X (zymogen) and factor IXa; 
prothrombinase complex is made up of light and heavy chain of factor Va (cofactor), factor II 
(zymogen) and factor Xa. FDP = fibrin degradation product 
 
1.4 PROTHROMBINASE AND FIBRINOLYSIS PATHWAY 
Prothrombin and fibrinogen are the key proteins in plasmatic coagulation and 
also major targets of snake toxins. Prothrombin is one of a few vitamin K-dependent 
enzymes (the others being factors VII, X and IX) and is synthesised in the liver 
whereas fibrinogen is a large, symmetrical dimeric molecule made up of three dimer 
chains (Aα, Bβ and γ) held together by disulphide bridges. The transformation of 
soluble fibrinogen into fibrin clot proceeds in three steps: (i) fibrinopepride cleavage 
by thrombin, which involves cleavage of fibrinopeptide A (FPA) and fibrinopeptide B 
(FPB) at two specific Arg-Gly bonds near the N-terminal of the fibrinogen molecule 
(Figure 1.3) (1951), (ii) fibrin polymerisation, where the cleaved dimeric structure 
undergoes a conformational change into elongated protofibrils, and finally (iii) fibrin 
stabilisation, where FXIIIa covalently crosslinks the protofibrils into a fibrin clot. 
 


































The human fibrinogen molecule is a 340 kDa molecule and can be described by 
the formula Aα2Bβ2γ2, where Aα represents the alpha chain (63.5 kDa each), Bβ 
represents the beta chain (56.0 kDa each), and γ represents the gamma chain (47.0 kDa 
each) (McKee et. al., 1966; McKee et. al., 1970). 
 
Figure 1.3: Schematic model of a fibrinogen molecule (NDS knot)  
 
Schematic model of a fibrinogen molecule (NDS knot) depicting all 3 interlinked polypeptide 
chains, Aα, Bβ and γ. The dotted lines are intermolecular disulphide bridges whereas the 
dotted arrows represents thrombin cleavage sites on the N-terminal of Aα and Bβ chains. 
Adapted from Snake Toxins (Kornalik, 1991). 
 
Upon activation of the upstream tenases, the formation of prothrombinase 
complex on a phospholipid membrane activates zymogen prothrombin (factor II) to   
α-thrombin (factor IIa) through either meizothrombin or prethrombin-2 intermediates. 
This generation of low levels of key enzymes, e.g. α-thrombin, is an important 
initiation phase. Coagulation is propagated by the maximal activities of the 
procoagulant enzymatic complexes that assemble on the sites provided by the 
subendothelial matrix and peripheral blood cells. The principal result of propagation is 
a burst of α-thrombin activity through the combined activities of the procoagulant 
complexes. α-Thrombin converts soluble fibrinogen into an insoluble fibrin matrix, 








Fibrin-stabilising factor (factor XIIIa), a transglutaminase enzyme, in proximity then 
crosslinks the fibrin clot covalently hence strengthening the fibrin matrix. 
 
Clot elimination is an essential step in tissue repair and wound healing, which 
constitutes the final steps in the coagulation process. It involves breaking down of the 
haemostatic plug into soluble fibrin peptides. The most important enzyme catalysing 
this process is plasmin that is generated from circulating zymogen plasminogen 
through the action of urokinase-type plasminogen activator (uPA) or tissue-type 
plasminogen activator (tPA). The breakdown of clots by plasmin generates various 
fibrin degradation products (FDPs), namely fragments X (240 kDa), Y (155 kDa),      
D (83 kDa) and E (50 kDa), as depicted in Figure 1.4. The neo-antigen fragment D 
(crosslinked D-dimer) is particularly important as a marker for immunodetection assay 
for disseminated intravascular coagulation (DIC), deep vein thrombosis, myocardial 
infarction and pulmonary embolism (Chang-Liem et. al., 1991; Chapman et. al., 1990; 
de Maat et. al., 2000; Speiser et. al., 1990). 
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Arrows indicate the sequence of formation of the fragments X, Y, D and E. Adapted from 
Kornalik, F., chapter 9, Snake Toxins (Kornalik, 1991). N denotes N-terminal; C denotes C-
terminal. 
 
1.5 THROMBOSIS AND EMBOLISM   
There are interacting systems which either promote or inhibit the process of 
blood coagulation in haemostasis. Under certain pathological circumstances, these 
dynamics may be disrupted leading to the formation of a solid mass of blood products 
in a vessel lumen; this process is known as thrombosis, and the mass of blood products 
is referred to as a thrombus. It is important to distinguish thrombosis, a dynamic 
process occurring in flowing blood, from coagulation which is a process that takes 
place in static blood to form a blood clot and involves coagulation factors only. 
Thrombosis is often the result of a clinical symptom (whether it is due to inherited 
thrombophilia, acquired deep-vein thrombosis, acquired pulmonary embolism or 
secondary complications of disseminated intravascular coagulation) than a 























platelets bound together by fibrin strands with variable numbers of erythrocytes and 
leucocytes trapped in the tangled mass and contributing to the bulk of the thrombus. 
Thrombosis may occur in any part of the circulation but most particularly in large 
veins, large arteries, in the heart chambers and on heart valves. Three major factors, 
alone or in combination, predispose to thrombosis. These are often referred to as 
Virchow's Triad: (i) damage to the vessel wall, particularly the endothelium, is the 
main cause of arterial and intracardiac thrombosis; in arteries it is due to atheroma, in 
the heart to endocardial damage; (ii) disordered blood flow, relative stasis is important 
in initiating thrombus in slow-flowing blood such as in veins. Turbulent blood flow 
predisposes to thrombus formation in arterial vessels and the heart; (iii) abnormally 
enhanced haemostatic properties of the blood, increased platelet concentration or 
stickiness, or factors promoting blood clotting or diminished fibrinolysis contribute to 
both arterial and venous thrombosis. Changes in blood viscocity such as occur in 
dehydration, major illness, disseminated carcinoma and the post-operative state are 
included in this category. 
 
A thrombus has a defined architecture and consistency which reflects the manner 
and stages of its formation and the nature of blood flow in the vicinity. For example, a 
thrombus formed in an artery is usually dense and composed mainly of aggregated 
platelets and fibrin, whereas a thrombus formed in slowed or static blood more closely 
resembles clotted blood in that it contains masses of erythrocytes and leucocytes. 
 
Thrombosis was shown to be indicator and/or onset for many debilitating clinical 
conditions like myocardial infarction, deep-vein thrombosis, thrombocytopenia, 
artherosclerosis, endothelial dysfunction, vascular purpura, disseminated intravascular 
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coagulation, ischaemia, which may lead to fatality or 'reduction in quality of life'. 
Thrombin and fibrinogen are two main molecules that can influence formation or 
dissolution of thrombi (Huntington and Baglin, 2003). In the last few decades, much 
attention was focused on components isolated from snake venoms, e.g. thrombin-like 
enzymes (Stocker et. al., 1982), fibrinolytic proteases (Kornalik and Styblova, 1967; 
Sun et. al., 2006), anti-thrombins (Zingali et. al., 2005), plasminogen activators (Liu et 
al, 2006), for treating thrombosis and other coagulopathies albeit with various degrees 
of success. Broadly these proteins aim to dissolve thrombi by mainly inhibiting 
thrombin action or promoting plasmin activity, both of which will lead to a similar 
result – increased fibrinolysis. 
 16 
CHAPTER 2: PURIFICATION AND  




2.1.1 Liquid Chromatography 
Chromatography is a long-established purification method since it was first 
described by Michael S. Tswett (1903) when he first used a chalk column to separate 
pigments from green leaves. He referred to the process as chromatography because the 
term seemed to describe the coloured zones moving through the column. Today, it is 
generally recognised that chromatography is the most powerful separation method with 
regard to resolution and versatility, having superior resolving power to centrifugation 
and ultrafiltration and capable of isolating larger quantities of protein than 
electrophoresis. Many different types of chromatographic methodologies have 
evolved, e.g. paper, thin layer and gas chromatography, but liquid chromatography 
remains the most widely used chromatographic method of all. 
 
Liquid chromatography involves the isolation of components in a mixture using 
a medium through which a flow of liquid is passed causing differential migration of 
the individual components. In current research laboratories, the flow is mostly driven 
by pressure although gravity may still be in used. The solutes are separated according 
to their interactions with the column matrix, resulting in differential mobilities down a 
column of solid particles in the presence of a mobile phase. Chromatographic 
techniques are flexible in that they allow separations to be modified by changes in 
packing chemistry and elution buffers, giving rise to four basic standard 
 17 
chromatographic techniques: (i) gel filtration, (ii) ion exchange, (iii) hydrophobic 
interaction, and (iv) affinity chromatography. Improvements in column 
chromatography technology have resulted from new packings that afford better 
resolution, higher capacity and enhanced physical stability. High performance (also 
known as high pressure or high speed) liquid chromatography (HPLC) is the widely 
used chromatographic technology these days. It is distinguished from conventional 
liquid chromatography by the use of sophisticated instrumentation and high efficiency 
columns. The advantages of HPLC over conventional liquid chromatography are 
increased speed, higher resolution, higher sensitivity, usually better sample recovery, 
and better reproducibility. 
 
2.1.2 Proteins and Peptides Isolated from Snake Venoms 
Snake venoms are rich sources of enzymes and other proteins. Snakes first 
captured the interest or rather struck fear into the hearts of humans from their many 
lethal and debilitating pathological and physiological symptoms developed in 
snakebite victims thousands of years ago. With the progress of knowledge in science 
and medicine, this mortal fear of snakes slowly transformed into a fascination in 
counteracting their venom effects and studying of their individual components. Many 
components of venoms, e.g. hyaluronidases, acetylcholinesterases, hydrolases, 
procoagulants, anticoagulants, haemolysins, haemorrhagic factors, cardiotoxins, 
neurotoxins and even nerve growth factors, from various families of snakes were 
isolated particularly in the last few decades (Hider et. al., 1991). 
 
Components isolated from snake venoms can generally be categorised into 
three main groups – enzymes, polypeptide toxins and low-molecular-weight 
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components. Enzymes (molecular weight 13,000 – 150,000), constituting a large 
portion in all venom, are mainly hydrolases and possess a digestive role. They 
composed of exopeptidases, endopeptidases, phosphodiesterases and phospholipases. 
Some enzymes are found in all venoms, e.g. hyaluronidase (4.2.99.1), l-amino acid 
oxidase (1.4.3.2), phosphodiesterase (3.1.4.1), 5’-nucleotidase (3.1.3.5), 
phophomonoesterase (3.1.3.2), deoxyribonuclease (3.1.4.6), ribonuclease (2.7.7.16), 
adenosine triphosphatase (3.6.1.8), and NAD-nucleosidase (3.2.2.5), although their 
levels differ markedly. For example, the enzyme levels of viperid and crotalid venoms 
fall in the range 80 – 95% of the total dry matter, whereas the corresponding range for 
elapid venoms is only 25 – 70% (Mebs, 1969). Several classes of enzymes induce 
direct toxic effects. Polypeptide toxins are particularly abundant in elapid venoms but 
are relatively scarce in viperid and crotalid venoms. However, some crotalid species do 
possess a low-molecular-weight (5 kDa) myotoxin (Fox et. al., 1979). Other such 
toxins include κ-neurotoxins (which can bind to neuronal nicotinic cholinoceptors) 
(Wolf et. al., 1988), cardiotoxins (Condrea, 1974), and dendrotoxins (which facilitate 
neurotransmitter release) (Harvey and Anderson, 1985). The last group of low-
molecular-weight components in venoms consist of metals, peptides, lipids, 
nucleosides, carbohydrates and amines (Bieber, 1979; Devi, 1968) and are generally 
less active biologically. 
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2.2 METHODS AND MATERIALS 
 
2.2.1. Snake Venom and Materials 
The lyophilised Agkistrodon halys halys (Ahh) venom was obtained from the 
Venom and Toxin Research Programme (VTRP) collection from the National 
University of Singapore (NUS). It is a pale yellowish powder without any detectable 
odour. 
 
Purified coagulation factors and chromogenic substrates were purchased from 
Chromogenix, Milano, Italy. Prepacked chromatography columns were purchased 
from Pharmacia (Uppsala, Sweden). Reagents for protein sequencing were from 
Applied Biosystems, Foster City, CA, US. Acetonitrile was purchased from Fluka. 
Fibrometer and Fibrotube Disposable Plastic Coagulation Cups were from Becton 
Dickinson, NJ, US. HPLC grade water was obtained by using a Milli-Q purification 
system (Millipore). All other chemicals were the highest grade possible purchased 
from Sigma.  
 
2.2.2 Purification of Anti-Coagulant Protein, Agkistase (AFg) 
Protein purification was carried out using a LCC-501 Fast Protein Liquid 
Chromatography (FPLC) system from Pharmacia, Uppsala, Sweden. 
 
2.2.3 Ion-Exchange Chromatography 
Approximately 420 mg of lyophilised crude venom was dissolved in 50 mM 
Tris-HCl, pH 7.8 buffer. Undissolved material was removed by centrifugation at 
10,000 g for one minute. The supernatant was loaded onto Q Sepharose Fast Flow 
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column, 1.6 x 10 cm (Pharmacia, Uppsala, Sweden) pre-equilibrated with 50 mM Tris-
HCl, pH 7.8. Bound proteins were eluted with a linear gradient of 10-50% 0.5 M NaCl 
in the same buffer at a rate of 0.4 ml/min (30.6 cm/hr). Eluted proteins were monitored 
by absorbance at 280 nm. Fractions collected were assayed for proteolytic and 
fibrinogenolytic activity and fractions with highest activities were pooled and 
concentrated for further purification. Proteolytic activity was assayed with 
chromogenic substrate, S-2302, as described in section 3.2.2 Proteolytic Assay on 
Chromogenic Substrates whereas fibrinogenolytic activity was assayed as described in 
section 3.2.8 Fibrino(geno)lytic Assay. 
 
2.2.4 Size Exclusion Chromatography 
Pooled active fractions from ion-exchange chromatography were loaded onto 
Superdex 200 HiLoad 16/60 column (Pharmacia, Uppsala, Sweden) pre-equilibrated 
with 50 mM Tris-HCl, pH 7.8, 0.15 M NaCl. Proteins were fractionated at a flow rate 
of 0.5 ml/min (15 cm/hr). Eluted proteins were monitored by absorbance at 280 nm. 
Fractions collected were assayed for proteolytic and fibrinogenolytic activity and 
fractions with highest activities were pooled, concentrated, lyophilised and stored at     
-80oC. 
 
2.2.5 Reverse-Phase HPLC 
Reverse-phase HPLC was used as a physical method in determining the 
homogeneity of the purified protein, which was not subsequently used for biological 
measurements. Purified protein was loaded onto Sephasil Peptide C18 column, 5µ, ST 
4.6/250 mm (Phenomenex, Torrance, CA, USA) pre-equilibrated with running buffer 
(0.1% TFA). Bound protein was washed with 2 CV and then eluted with an increasing 
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concentration of elution buffer (0.1% TFA, 80% ACN, from 25% to 65%) at a flow 
rate of 1 ml/min (60 ml/hr). Fractions were collected at 1 ml/tube. Eluted proteins were 
monitored by absorbance at 280 nm. 
 
2.2.6 SDS-PAGE (Reducing/Non-Reducing) and Tris-Tricine Gel 
Discontinuous polyacrylamide gels were prepared fresh according to Laemmli 
(Laemmli, 1970). The composition of each 10% and 12% gel with their 8% stacking 








Running buffer (15.1 g/L Tris, 72 g/L glycine, 5g/L SDS) was filled into the 
buffer compartment of Mini Protean II gel electrophoresis tank. Samples for SDS-
PAGE were diluted and added to 4X loading dye (0.1% (w/v) bromophenol blue, 10% 
(w/v) SDS and 10% glycerol in 0.05M Tris-HCl, pH 6.8) accordingly and boiled at 
98oC for 5 min prior to loading. Empty wells were loaded with similar volume of 1X 
loading dye. Gels were run at constant current of 25 mA per gel for about 45-60 min 
until the dye front was about 0.5 cm from the bottom of gels. The gels were then 
removed and stained with Coomassie Blue dye (0.1% Coomassie Brilliant Blue R-250, 
30% ethanol, 10% acetic acid) or silver-staining (Bio-Rad Laboratories, Hercules CA 
94547). Protein bands were compared with an internal control of 5 µg broad range 
 stacking gel separating gel 
 8% 10% 12% 
Deionised water 2.7 ml 4.0 ml 3.3 ml 
0.5 M Tris, pH 6.8 0.5 ml - - 
1.5 M Tris, pH 8.8 - 2.5 ml 2.5 ml 
30% acrylamide:bis (29:1) 0.67 ml 3.3 ml 4.0 ml 
10% SDS 40 µl 100 µl 100 µl 
10% APS 40 µl 100 µl 100 µl 
TEMED 10 µl 10 µl 10 µl 
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marker (Bio-Rad Laboratories) comprising myosin 200 kDa, β-galactosidase 116 kDa, 
phosphorylase B 97 kDa, bovine serum albumin 66 kDa, ovalbumin 45 kDa, carbonic 
anhydrase 31 kDa, trypsin inhibitor 21 kDa and lysozyme 14 kDa. 
 
Tris-Tricine gels were prepared with a different concentration of 








2.2.7 Isoelectric Focusing (IEF) 
IEF gels were purchased from Bio-Rad Laboratories, Hercules, CA, US. The 
gel was set up in a Mini Protean II (Bio-Rad) system at 4oC. Anode compartment was 
filled with 7 mM phosphoric acid, pH 1.95 whereas cathode compartment was filled 
with 20 mM lysine, 20 mM arginine, pH 10.85. IEF marker (Bio-Rad) and 5 µg of 
sample were mixed with IEF sample buffer (50% glycerol) then loaded into wells. IEF 
marker comprised three phytocyanin bands (pI 4.45, 4.65, 4.75; 232 kDa),                  
β-lactoglobulin B (pI 5.1; 18.4 kDa), bovine carbonic anhydrase (pI 6.0; 31 kDa), 
human carbonic anhydrase (pI 6.5; 28 kDa), equine myoglobin minor band (pI 6.8; 
17.5 kDa), equine myoglobin (pI 7.0; 17.5 kDa), human haemoglobin A (pI 7.1; 64.5 
kDa), human haemoglobin C (pI 7.5; 64.5 kDa), 3 lentil lectin bands (pI 7.80, 8.00, 
 stacking gel separating gel 
 1 gel 2 gels 1 gel 2 gels 
Deionised water 1.4 ml 2.8 ml 1.56 ml 3.3 ml 
Buffer 0.5 ml 1.0 ml 1.56 ml 3.3 ml 
Acrylamide (49.5%T 6%C) - - 1.56 ml 3.3 ml 
Acrylamide (49.5%T 3%C) 0.15 ml 0.3 ml - - 
10% APS 15 µl 30 µl 25 µl 50 µl 
TEMED 1.5 µl 3.0 µl 2.5 µl 5.0 µl 
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8.20;  49 kDa) and cytochrome c (pI 9.6; 12.2 kDa). Electrophoresis was run in three 
stages: 
(i) 100 V, 25 mA for 1 hr, 
(ii) 200 V, 25 mA for 1 hr, and 
(iii) 500 V, 25 mA for 30 min. 
The gel was removed, fixed and stained with Coomassie Blue. 
 
2.2.8 Capillary Electrophoresis 
CE was performed on a CE-L1 Capillary Electrophoresis System (CE 
Resources Pte. Ltd., Singapore) with reference to Capillary Electrophoresis of 
Proteins and Peptides, Unit 10.20, Current Protocols in Molecular Biology (Burgi and 
Smith, 2007). In capillary zone electrophoresis (CZE), agkistase (~1 µg) was injected 
into a PVA coated capillary (I.D. 50 µm x O.D. 360 µm, total length 68 cm with 40 cm 
effective length) under low pressure mode (0.3 p.s.i.), 15 sec and resolved in 50 mM 
phosphate buffer (pH 2.5) under 22 kV from positive to negative for 25 min. Migration 
was monitored at 205 nm using a Shimadzu UV detector. The capillary was rinsed 
after every run prior to continuation. In capillary isoelectric focusing (CIEF), ~1 µg of 
sample was mixed with BioLyte 3/10 Ampholyte, 40% (Bio-Rad Laboratories) in 1:50 
and injected into a capillary. Anolyte used was 20 mM phosphoric acid, 2% 
hydroxypropylenemethylene cellulose (HPMC) and catholyte used was 40 mM NaOH, 
2% HPMC. The proteins were resolved in 20 kV for 10 min and then eluted under low 
pressure mode (0.3 p.s.i.) while maintaining 20 kV from negative to positive polarity 
for 15 min. The wavelength of 280 nm was observed for CIEF measurements. The 
following standards were used to determine the protein’s pI - cytochrome c (pH 9.6), 
lentil lectin (pH 8.2 & 7.8), human haemoglobin C (pH 7.5), human haemoglobin A 
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(pH 7.1), human carbonic anhydrase (pH 6.5), bovine carbonic anhydrase (pH 6.0), β-
lactoglobulin B (pH 5.1) and phytocyanin (pH 4.6). All spectrums were averaged from 
3 separate electrophoretic runs. 
 
2.2.9 Mass Spectrophotometry 
Matrix-assisted laser desorption ionisation – time of flight mass spectroscopy 
(MALDI-TOF MS) was carried out on a Voyager DE-STR Biospectrometry Work 
Station (Applied Biosystems, Foster City, CA, US) (Burgi and Smith, 2007). The 
matrix used was saturated with 3,5-dimethoxy-4-hydroxycinnamic acid in 1:1 
acetonitrile:water containing 0.3% TFA. Sample was spotted onto a stainless steel 
sample plate with 1 µl of matrix solution and dried off. The accelerating voltage was 
set at 25,000 V, and the grid and guide wire voltages were set at 93.0% and 0.3%, 
respectively. Molecular ions were generated using a nitrogen laser (at 337 nm) at an 
intensity of 1800-2200. Extraction of ions was delayed by 800 ns. The spectrum was 
calibrated using external standards. 
 
2.2.10 Mass Protein Finger-printing 
Bands excised from SDS-PAGE gel were finely cut into a 200 µl tube and 
ground into small pieces with a clean spatula. One hundred microlitres of 50 mM 
ammonium bicarbonate:acetonitrile (1:1) was added, vortexed and allowed to stand for 
5 min. The solution was then removed and the step repeated for another 2-3 times. 
Acetonitrile (50 µl) was added into the tube. The tube was again vortexed, left for 5 
min and solution was removed. The process was repeated for another 2-3 times. The 
ground gel pieces were dried thoroughly in a vacuum centrifuge. To reduce the 
proteins in the gel, a fresh solution of 10 mM dithiothreitol (DTT) in 100 mM 
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ammonium bicarbonate was added and then the tube was flushed with nitrogen gas 
before sealing the tube. The tube was then incubated at 57oC for 60 min. After which, 
the mixture was cooled to room temperature and the excess solution was removed. To 
alkylate the protein, 55 mM iodoacetamide solution in 100 mM ammonium 
bicarbonate was added. The tube was again flushed with nitrogen gas, sealed and 
wrapped in aluminium foil. The tube was incubated at room temperature for 60 min 
with intermittent vortexing. The gel was washed 3 times with 100 µl of 100 mM 
ammonium bicarbonate solution for 5 min at room temperature, treated twice with 100 
µl acetonitrile for 5 min and then dried using a vacuum centrifuge. Digestion was 
performed by adding 15-30 µl of 12.5 µg/ml trypsin in 50 mM ammonium bicarbonate 
and incubated overnight (6-15 hours) at 37oC. The mixture was cooled to room 
temperature. The digested peptides were collected by multiple washes with 20 mM 
ammonium bicarbonate followed by 5% formic acid in 50% aqueous acetonitrile. The 
supernatant collected from these washes were pooled and dried in a vacuum 
centrifuge. Digested peptides were redissolved into Tris-HCl buffer, pH 8.5 and 
digested with trypsin (1:50, by mol) and chymotrypsin (1:50, by mol) separately. 
Peptide fragments were separated using reverse-phase HPLC and sequenced using ABI 
Procise 494 Protein Sequencer and Micromass Q-Tof Tandem Mass Spectrometer. 
MS/MS data obtained were analysed with Mascot (Matrix Science Ltd.) and Scaffold 
(Proteome Software, Inc), and compared with online databases UniProt 
(http://www.ebi.uniprot.org/index.shtml) and NCBI Entrez 
(http://www.ncbi.nlm.nih.gov/entrez/) to determine the possible de novo sequences. 
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2.2.11 Edman Degradation Protein Sequencing 
Purified agkistase was resuspended in 100 µl of denaturant buffer (50 mM Tris, 
1 mM EDTA, pH 8.0) containing 10 mM dithiothreitol (DTT). The solution was 
incubated at 65oC for 30 min. Subsequently, 1.5-fold molar excess (over sulfhydryl 
groups) of 4-vinylpyridine was added and kept in dark at room temperature for 30 min. 
After that, the sample was desalted by reverse-phase HPLC. N-terminal sequencing of 
the native and pyridylethylated protein was done by automated Edman degradation 
using a PerkinElmer Life Sciences 494 pulsed liquid phase protein sequencer (Procise) 
with an on-line 785A phenylthiohydantoin-derivative analyzer. 
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2.3 DATA AND RESULTS 
 
2.3.1 Preliminary screening and general activities of Agkistrodon halys halys 
venom 
Venom from various sources were screened for proteolytic and defibrinating 
activities (Table 2.1). The venom from vipers and black scorpion, i.e. Trimeresurus 
stegnegeri, T. mucrosquamatus, Agkistrodon halys, A. actus, Tityrus, were found to be 
most active in these activities. Proteolytic activites were performed in accordance to 
3.2.2 Proteolytic Assays on Chromogenic Substrates whereas defibrinating activity 
was performed in accordance to 3.2.8 Fibrino(geno)lytic Assay. The venom of A. halys 
was selected for further purification and analysis. 








Naja naja (Indian cobra) - - - 
Ophiophagus hannah (king cobra) ++ + ++ 
Bungarus candidus + + - 
Bungarus fasciatus (banded krait) + + - 
Trimeresurus stegnejeri (green tree viper) ++++ ++++ ++++ 
Trimeresurus mucrosquamatus (saw-scaled viper) ++++ ++++ ++++ 
Agkistrodon halys (Mongolian pit viper) ++++ ++++ ++++ 
Agkistrodon actus (hundred-paced viper) ++++ ++++ ++++ 
Viper +++ +++ ++ 
Androctonus crassicauda (Black scorpion) ++++ ++++ ++++ 
Red scorpion ++ ++ - 
 
 
2.3.2 Purification of agkistase from Agkistrodon halys halys venom 
The venom appeared as a pale yellowish powder with few tiny crystals. It 
readily dissolved into most common ionic buffers. The venom of A. halys was 
reconstituted into 50 mM Tris-HCl, pH 7.8 (10 mg/ml). Undissolved material was 
removed by centrifugation.  
 
 28 
A. halys venom was desalted (through a PD-10 column, Amersham) and then 
dissolved into 50 mM Tris, pH 7.8 and fractionated on a Q Sepharose column (1.6 x 10 
cm) pre-equilibrated with the same buffer. Bound proteins were eluted with a linear 
increasing concentration of 1 M NaCl and fractions collected were assayed for 
proteolytic and fibrinogenolytic activity (Figure 1A). Under these conditions, the 
venom resolved into 7 peaks and peak IV showed fibrinogenolytic activity and the 
highest proteolytic activity. The active fractions were combined, desalted and resolved 
on a Superdex 200 HiLoad 16/60 column using the same buffer (Figure 1B). Peak IV 
was subsequently fractionated into two major peaks where proteolytic and 
fibrinogenolytic activity were both found at peak ii. The active fractions from the peak 
were then concentrated, desalted and lyophilised. This fraction was termed agkistase. 
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Figure 2.1: Purification profile of Agkistrodon halys halys venom 
 
A, The purification profile of Agkistrodon halys halys venom on Q Sepharose Fast Flow 
column (1.6 x 10 cm). Salt gradient (%B) was shown as a gray line; B, The 
purification profile of concentrated peak IV from the previous column on Superdex 200 
HiLoad 16/60 (Pharmacia). The dashed lines (- - -) showed the specific activity of 
fractions against chromogenic substrate S-2302 as described in section 3.2.2. 
 
 






mg/ml mg % 
Specific activity, 
U/mg (x 10-6) 






Crude venom 2.0 100 200 100 0.38 75.6 100% 1 
Q Sepharose 14.0 3.14 43.9 22.0 1.17 51.4 68.0% 3.1 
Superdex 200 7.0 4.39 30.73 15.4 1.63 50.1 66.3% 4.3 
Agkistase was successfully isolated from the venom of Agkistrodon halys halys through a two-
step chromatography procedure. Its purification factor was 4.3 with 66.3% yield. Specific 
activity was assayed against chromogenic substrate S-2302 as described in section 3.2.2. 
 
2.3.3 Homogeneity determination of agkistase 
Purified agkistase was dissolved into 50 mM Tris-HCl, pH 7.8 with 8 M urea to 
dissociate possible presence of co-eluted proteins and/or non-covalently bound 
Fraction number






























subunits. When fractionated through a Superdex 200 HiLoad 16/60 column using the 
same buffer, the protein eluted out as a single peak with a corresponding elution time 
to peak IV-ii (Figure 2.2), as determined previously. 
 
Figure 2.2: Elution profile of purified agkistase under reducing condition 
  
Elution profile of purified agkistase under conditions of 8 M urea ( — ; 
continuous line) compared with its prior Superdex 200 profile ( - - - ; 
discontinuous line). The overlapped profiles showed agkistase peak 
appearing at close ve (91.3 ml). 
 
However these data only showed that purified agkistase was homogeneous, free 
of co-elution proteins and did not contain any non-covalently bound subunits. 
 
SDS-PAGE, both reducing and non-reducing conditions, were used to determine 
if it comprised intra- and/or intermolecular disulphide bonds. Agkistase appeared as a 
single protein band under both reducing and non-reducing conditions (Figure 2.3). It is 
hence evident that agkistase is a monomeric protein with intramolecular disulphide 
bonds, as shown by the difference in the relative mobility index between their reduced 
and non-reduced forms. Tris-Tricine gel was also used to check the homogeneity of the 
band as it offers a better resolution for proteins with smaller molecular size. Agkistase 
was resolved as a single band in the gel (data not shown). 
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Figure 2.3: SDS-PAGE of agkistase 
 
A. Purification profile of agkistase – 1: crude venom; 2: peak IV 
from first column; 3: peak ii from second column. B. Elution of 
agkistase on a 10% gel under reducing (R) and non-reducing 
(NR) conditions. Broad range marker in the middle is indicated 
with the molecular markers: bovine serum albumin 66 kDa, 
ovalbumin 45 kDa, carbonic anhydrase 31 kDa, trypsin inhibitor 
21 kDa. 
 
To further ascertain the purity and molecular weight of purified agkistase, it was 
subjected to HPLC and MALDI-TOF analysis (Figure 2.4). It gave a single peak in 
HPLC (Figure 2.4a) and showed a size of 29,209.8 Da in MALDI-TOF (Figure 2.4b). 
 














Figure 2.4: HPLC and MALDI-TOF analyses of agkistase. 
 
A. RP-HPLC of agkistase. B. Mass spectrometry of agkistase  with a molecular mass 
of 29 kDa. 
 
Elution volume (Ve) obtained from both gel filtration chromatography and 
capillary electrophoresis (Figure 2.11 in later section 2.3.5 Physical properties of 
agkistase) corresponded to a molecular size around 30 kDa, which is significantly 
close to its size determined by mass spectrometry. Taken together, it is evident that the 
protein has a molecular mass of 29 kDa and consists of a single polypeptide chain.  
 
2.3.4 Molecular sequencing and homology alignment of agkistase with other 
snake venom proteins 
The primary amino acid sequence of agkistase was determined using Edman 
degradation chemistry and tandem mass spectroscopy. Purified agkistase was reduced 
with 10 mM DTT and alkylated with 1.5-fold molar excess (over sulphydryl groups) of 
4-vinylpyridine prior to enzymatic digestion with trypsin (1:50, by mol) or 
chymotrypsin (1:50, by mol) separately. Pyridylethylated protein and peptide 
fragments generated through the digests were analysed using a PerkinElmer Life 
Sciences 494 pulsed liquid phase protein sequencer (Procise) with an online 785A 
phenylthiohydantoin-derivative analyser. The chemistry of Edman degradation is 
shown in Figure 2.5. 
a b 
 33 





Another set of peptides were subjected to tandem mass spectroscopy for de novo 
sequencing. An example of the MS/MS spectra obtained analysed with Scaffold 
software is given in Figure 2.6. 
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0 250 500 750 1000 1250
1314.39 AMU, +2 H (Parent Error: -100 ppm)
 
A typical output of tandem mass results from Scaffold software depicting a calculated 
sequence of MFYSNEDEHK with Mascot ion score of 54.0 and Mascot identity score of 45.9. 
 
The sequences of the fragments (Figure 2.7) were overlapped and aligned with 
similar functional proteins reported from snake venoms. Closely homologous protein 
sequences obtained from BLAST were included for comparison and discussion    
(Figure 2.8 and 2.9). 
 
Figure 2.7: Short sequences obtained from Edman and de novo MS/MS sequencing 
 
Sequences Calc mass Exp mass 
    5   10   15   20   25   30   35   
   
De novo MS/MS sequences 
  
KGMVLPGTKC + Oxidation (M) 817.44 817.39 
(I/L)VSPPVCGNELLEV 1368.7 1368.69 
K(I/L)PCAPEDVKC 970.48 970.37 
K(I/L)PCAPEDVKC + Carbamidomethyl (C) 1027.5 1027.41 
KK(I/L)PCAPEDVKC + Carbamidomethyl (C) 1155.6 1155.44 
ESNTKGNYYGYCRKEN + Carbamidomethyl (C) 1738.77 1738.6 
KDNSPGQNNPCKM 1172.49 1172.46 
KMFYSNEDEHKG 1298.52 1298.36 
KMFYSNEDEHKG + Oxidation (M) 1314.52 1314.46 
KGNYYGYCRK + Carbamidomethyl (C) 1051.42 1051.30 
   
KDNSPGQNNPCKMFYSNEDDEHKGMVLPGTKCADC 4082.404  
IVSPPVGGNELLEVGEECDCGTPPN 2406.616  
AKNGQPMLDNYVSNGH 1589.646  
GADVYEAEDSPFVGEEDYGGPPHDYD 2649.242  
MFYSNEDEHKGMSKNGPMVDNKVPSNGHCVDVATAY 3723.816  
DNKVPSNGHCVDVATAY 1771.722  
KIPCAPEDVK 1203.6321 1203.6222 
IPCAPEDVK 1075.5371 1075.7921 
MFYSNEDEHKGMSKNGPM 2081.9702 2081.9883 




IVSPPVCGNELLEVGEEADDGTPE 2451.128  
AKNGQPMLDNYVPSNGH 1824.008  
GADVYEAEDSPFEVNPKKDYGGPPHDYND 3305.120  
SNEDEHKGM 1027.860  
KIPCAPEDVK  1196.286  
SLADAHPGEGHPGATAY 1632.606  
IVSPPVCGNELLEVGEE 1765.587  
ALSVGADVYEAEPSTGYV 1809.740  
MFYSNEDEHKGMVLPGTK 2065.151  
   
 
 
Figure 2.8: BLAST results of agkistase sequences 
 
Program: NCBI BLASTP 2.2.16 [Mar-25-2007] 
 
Database: Non-redundant SwissProt sequences 
           247,743 sequences; 93,466,512 total letters 
                                                                           Score      E 
Sequences producing significant alignments:                       (Bits)  Value 
 
sp|P30431|DISJ_BOTJA  Venom metalloproteinase jararhagin precu... 70.9    8e-12 
sp|Q9W6M5|ACLE_AGKAC  Acutolysin-E precursor                       67.4    8e-11 
sp|P20164|HR1B_TRIFL  Hemorrhagic metalloproteinase HR1b precu... 52.0    4e-06 
sp|Q9PSN7|HRT1_CRORU  Hemorrhagic metalloproteinase HT-1 (Hemorrh  51.6    5e-06 
sp|Q7LZ61|RVVX_DABRU  Coagulation factor X-activating enzyme h... 51.2    6e-06 
 
 
Database: All non-redundant GenBank CDS 
translations+PDB+SwissProt+PIR+PRF excluding environmental samples 
from WGS projects 
           5,119,764 sequences; 1,771,675,735 total letters 
                                                                           Score      E 
Sequences producing significant alignments:                       (Bits)  Value 
 
dbj|BAF56420.1|  vascular apoptosis-inducing protein 2A [Crotalus  75.1    6e-12 
gb|AAC59672.1|  catrocollastatin precursor                         74.3    1e-11 
gb|ABA42117.1|  metalloproteinase P-III [Crotalus durissus duriss  73.6    2e-11 
gb|AAM09693.1|AF490534_1  metalloproteinase precursor [Bothrops i  73.2    2e-11 
gb|AAC61986.2|  bothropasin precursor [Bothrops jararaca]          73.2    3e-11 
gb|AAD02652.1|  metalloprotease [Gloydius halys]                   72.4    4e-11 
sp|P30431|DISJ_BOTJA  Venom metalloproteinase jararhagin precu... 70.9    1e-10 
gb|AAS57937.1|  acurhagin precursor [Deinagkistrodon acutus]       68.9    5e-10 
sp|Q9W6M5|ACLE_AGKAC  Acutolysin-E precursor >gb|AAD27891.1|AF... 67.4    1e-09 
gb|AAK82974.1|  halysetin [Gloydius halys]                         67.0    2e-09 
gb|AAB30855.1|  jararhagin-C=28 kda disintegrin homolog [Bothr... 64.3    1e-08 
gb|ABG77583.1|  scutiarin [Crotalus scutulatus scutulatus] >gb... 64.3    1e-08 
gb|AAC18911.1|  metalloproteinase-disintegrin-like protein [Ag... 54.7    8e-06 
sp|P20164|HR1B_TRIFL  Hemorrhagic metalloproteinase HR1b precu... 52.0    5e-05 
emb|CAJ01683.1|  Group III snake venom metalloproteinase [Echis o  51.6    7e-05 
emb|CAJ01688.1|  Group III snake venom metalloproteinase [Echis o  51.6    7e-05 
sp|Q9PSN7|HRT1_CRORU  Hemorrhagic metalloproteinase HT-1 (Hemo... 51.6    8e-05 
sp|Q7LZ61|RVVX_DABRU  Coagulation factor X-activating enzyme h... 51.2    1e-04 
gb|AAL47169.1|AF450503_1  berythractivase [Bothrops erythromelas]  50.8    1e-04 
gb|ABG77585.1|  catroriarin [Crotalus atrox]                       50.1    2e-04 
 
BLAST alignment returns similar sequences with a high identity towards venom 
metalloproteinases isolated from other vipers. Arbitrarily, only matching sequences with a 
score of 50 and above are displayed. 
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Figure 2.9: Sequence alignment of similar BLAST proteins 
Acurhagin                          GTDIISPPLCGNELLEVGEECDCGTPENCQNECCDAATCKLKSGSQCGHG 445 
Acutolysin                         GTDIISPPLCGNELLEVGEECDCGTPENCQNECCDAATCKLKSGSQCGHG 444 
Agkistase                          ---IVSPPVCGNELLEVGEECDCGTPE----------------------- 24 
Berythractivase                    RTDIISPPVCGNELLEVGEECDCGTPENCRDPCCNATTCKLTPGSQCVEG 447 
Bothropasin                        GTDIVSPPVCGNELLEVGEECDCGTPENCQNECCDAATCKLKSGSQCGHG 445 
Catrocollastatin                   GTDIISPPVCGNELLEVGEECDCGTPENCQNECCDAATCKLKSGSQCGHG 444 
Catroriarin                        ------------------------------NPCCDAATCKLKSGSQCGHG 20 
Group III snake venom metallo      RTDIVSPPVCGNDLLEKGEECDCGSPENCQNPCCDAASCKLHSWIECEFG 450 
Halysetin                          ---IVSPPVCGNELLEVGEECDCGTPENCQNECCDAATCKLKSGSQCGHG 47 
Haemorrhagic                       GTDIISPPVCGNELLEVGEECDCGFPRNCRDPCCDATTCKLHSWVECESG 51 
Jararhagin                         ---IISPPVCGNELLEVGEECDCGTPENCQNECCDAATCKLKSGSQCGHG 47 
Metalloprotease                    GTDIVSPPVCGNELLEVGEECDCGTPENCQNECCDAATCKLKSGSQCGHG 445 
Meta2                              GTDIISPPVCGNELLEVGEECDCGTPENCQNECCDAATCKLKSGSQCGHG 444 
Meta3                              GTDIVSPPVCGNELLEVGEECDCGTPENCQNECCDAATCKLKSGSQCGHG 445 
Meta4                              GTDIVSPPVCGNELLEVGEECDCGSPTNCQNPCCDAATCKLTPGSQCADG 446 
Russellysin                        RKDIVSPPVCGNEIWEEGEECDCGSPANCQNPCCDAATCKLKPGAECGNG 256 
Scutiarin                          ------------------------------NPCCDAATCKLKSGSQCGHG 20 
Trimerelysin                       KTDIVSPPVCGNELLEAGEECDCGSPENCQYQCCDAASCKLHSWVKCESG 445 
Vascular                           GTDIISPPVCGNELLEVGEECDCGTPENCQNECCDAATCKLKSGSQCGHG 444 
                                                                                     
Sequence of agkistase is aligned with other similar BLAST proteins using Clustal W ver 1.82. Consensus sequence is highlighted in red. The proteins are 
acurhagin [acurhagin precursor, Deinagkistrodon acutus (AAS57937)], acutolysin [acutolysin-E precursor, Deinagkistrodon acutus (Q9W6M5)], berythractivase 
[Bothrops erythromelas (AAL47169)], bothropasin [bothropasin precursor, Bothrops jararaca (AAC61986)], catrocollastatin [catrocollastatin precursor, 
Crotalus atrox (AAC59672)], catroriarin [Crotalus atrox (ABG77585)], group III snake venom metallo [Group III snake venom metalloproteinase, Echis 
ocellatus (CAJ01683)], halysetin [Gloydius halys, (AAK82974)], haemorrhagic [haemorrhagic toxin I, Crotalus ruber ruber (Q9PSN7)], jararhagin [Bothrops 
jararaca (AAB30855)], metalloprotease [Gloydius halys (AAD02652)], meta2 [metalloprotease P-III, Crotalus durissus durissus (ABA42117)], meta3 
[metalloproteinase precursor, Bothrops insularis (AAM09693)], meta4 [metalloproteinase-disintegrin-like protein, Agkistrodon contortrix laticinctus 
(AAC18911)], russellysin [RVV-X heavy chain, Daboia russellii siamensis (Q7LZ61)], scutiarin [Crotalus scutulatus scutulatus (ABG77583)], trimerelysin 
[trimerelysin I, Trimeresurus flavoviridis (P20164)] and vascular [vascular apoptosis-inducing protein 2A, Crotalus atrox (BAF56420)]. Clustal W symbols: * = 
identical, : = conserved, . = semi-conserved. 
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Acurhagin                          DCCEQCKFRTSGTECRA--SMSECDPAEHCTGQSSECPADVFHKNGEPCL 493 
Acutolysin                         KCCEQCKFRTSGTECRA--SMSECDPAEHCTGQSSECPADVFHKNGEPCL 492 
Agkistase                          ------------------------------------------AKNGQPML 32 
Berythractivase                    LCCDQCRFRKTGTECRA--AKHDCDLPESCTGQSADCPMDDFQRNGHPCQ 495 
Bothropasin                        DCCEQCKFSKSGTECRA--SMSECDPAEHCTGQSSECPADVFHKNGQPCL 493 
Catrocollastatin                   DCCEQCKFSKSGTECRA--SMSECDPAEHCTGQSSECPADVFHKNGQPCL 492 
Catroriarin                        DCCEQCKFSKSGTECRA--SMSECDPAEHCTGQSSECPADVFHKNGQPCL 68 
Group III snake venom metallo      ECCEQCRFKPAGTECRG--IRNECDLPEYCTGQSAECPIDRSHRNGKPCL 498 
Halysetin                          DCCEQCKFSKSGTECRE--SMSECDPAEHCTGQSSECPADVFHKNGQPCL 95 
Haemorrhagic                       ECCGQCKFTSAGNECRP--ARSECDIAESCTGQSADCPMDDFHRNGQPCL 99 
Jararhagin                         DCCEQCKFSKSGTECRA--SMSECDPAEHCTGQSSECPADVFHKNGQPCL 95 
Metalloprotease                    DCCEQCKFSKSGTECRE--SMSECDPAEHCTGQSSECPADVFHKNGQPCL 493 
Meta2                              DCCEQCKFSKSGTECRA--SMSECDPAEHCTGQSSECPADVFHKNGQPCL 492 
Meta3                              DCCEQCKFSKSGTECRA--SMSECDPAEHCTGQSSECPADVFHKNGQPCL 493 
Meta4                              VCCDQCRFTRAGTECRQ--AKDDCDMADLCTGQSAECPTDRFQRNGHPCL 494 
Russellysin                        LCCYQCKIKTAGTVCRTRRARDECDVPEHCTGQSAECPRDQLQQNGKPCQ 306 
Scutiarin                          DCCEQCKFSKSGTECRA--SMSECDPAEHCTGQSSECPADVFHKNGQPCL 68 
Trimerelysin                       ECCDQCRFRTAGTECRA--AESECDIPESCTGQSADCPTDRFHRNGQPCL 493 
Vascular                           DCCEQCKFSKSGTECRA--SMSECDPAEHCTGQSSECPADVFHKNGQPCL 492 
                                                                              :**.*   
 
Sequence of agkistase is aligned with other similar BLAST proteins using Clustal W ver 1.82. Consensus sequence is highlighted in red. The proteins are 
acurhagin [acurhagin precursor, Deinagkistrodon acutus (AAS57937)], acutolysin [acutolysin-E precursor, Deinagkistrodon acutus (Q9W6M5)], berythractivase 
[Bothrops erythromelas (AAL47169)], bothropasin [bothropasin precursor, Bothrops jararaca (AAC61986)], catrocollastatin [catrocollastatin precursor, 
Crotalus atrox (AAC59672)], catroriarin [Crotalus atrox (ABG77585)], group III snake venom metallo [Group III snake venom metalloproteinase, Echis 
ocellatus (CAJ01683)], halysetin [Gloydius halys, (AAK82974)], haemorrhagic [haemorrhagic toxin I, Crotalus ruber ruber (Q9PSN7)], jararhagin [Bothrops 
jararaca (AAB30855)], metalloprotease [Gloydius halys (AAD02652)], meta2 [metalloprotease P-III, Crotalus durissus durissus (ABA42117)], meta3 
[metalloproteinase precursor, Bothrops insularis (AAM09693)], meta4 [metalloproteinase-disintegrin-like protein, Agkistrodon contortrix laticinctus 
(AAC18911)], russellysin [RVV-X heavy chain, Daboia russellii siamensis (Q7LZ61)], scutiarin [Crotalus scutulatus scutulatus (ABG77583)], trimerelysin 
[trimerelysin I, Trimeresurus flavoviridis (P20164)] and vascular [vascular apoptosis-inducing protein 2A, Crotalus atrox (BAF56420)]. Clustal W symbols: * = 
identical, : = conserved, . = semi-conserved. 
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Acurhagin                          DNYGYCYNGNCPIMYHQCYALFGADIYEAEDSCFESNKKGNYYGYCRKEN 543 
Acutolysin                         DNYGYCYNGNCPIMYHQCYALFGAEVYEAEDSCFESNKKGNYYGYCRKEN 542 
Agkistase                          DNYVP-SNGHALSV--------GADVYEAEPSPFEVGEE-DYGG--PPHD 70 
Berythractivase                    NNNGYCYNGKCPTMENQCIDLVGPKATVAEDSCFKDNQKGNDYGYCRKEN 545 
Bothropasin                        DNYGYCYNGNCPIMYHQCYALFGADVYEAEDSCFKDNQKGNYYGYCRKEN 543 
Catrocollastatin                   DNYGYCYNGNCPIMYHQCYDLFGADVYEAEDSCFERNQKGNYYGYCRKEN 542 
Catroriarin                        DNYGYCYNGNCPIMYHQCYDLFGADVYEAEDSCFERNQKGNYYGYCRKEN 118 
Group III snake venom metallo      NNYGYCYNGTCPIMYHQCYALFGPKAVVGQDVCFEENKRGESYFYCRKEN 548 
Halysetin                          DNYGYCYNGNCPIMYHQCYALWGADVYEAEDSCFESNTKGNYYGYCRKEN 145 
Haemorrhagic                       NNFGYCYNGNCPILYHQCYALFGSNVYEAEDSCFERNQKGDDDGYCRKEN 149 
Jararhagin                         DNYGYCYNGNCPIMYHQCYALFGADVYEAEDSCFKDNQKGNYYGYCRKEN 145 
Metalloprotease                    HNYGYCYNGNCPIMYHQCYALWGADVYEAEDSCFESNKKGNYYGYCRKEN 543 
Meta2                              DNYGYCYNGNCPIMYHQCYDLFGADVYEAEDSCFERNQKGNYYGYCRKEN 542 
Meta3                              DNYGYCYNGNCPIMYHQCYALFGADVYEAEDSCFKDNQKGNYYGYCRKEN 543 
Meta4                              NDNGYCYNRTCPTLKNQCIYFFGPNAAVAKDSCFKGNQKSNNHTYCRKEN 544 
Russellysin                        NNRGYCYNGDCPIMRNQCISLFGSRANVAKDSCFQENLKGSYYGYCRKEN 356 
Scutiarin                          DNYGYCYNGNCPIMYHQCYDLFGADVYEAEDSCFERNQKGNYYGYCRKEN 118 
Trimerelysin                       YNHGYCYNGKCPIMFYQCYFLFGSNATVAEDDCFNNNKKGDKYFYCRKEN 543 
Vascular                           DNYG--YNGNCPIMYHQCYDLFGADVYEAEDSCFERNQKGNYYGYCRKEN 540 
                                    :     *  . :        *.   .:   *: . . .      .: 
 
Sequence of agkistase is aligned with other similar BLAST proteins using Clustal W ver 1.82. Consensus sequence is highlighted in red. The proteins are 
acurhagin [acurhagin precursor, Deinagkistrodon acutus (AAS57937)], acutolysin [acutolysin-E precursor, Deinagkistrodon acutus (Q9W6M5)], berythractivase 
[Bothrops erythromelas (AAL47169)], bothropasin [bothropasin precursor, Bothrops jararaca (AAC61986)], catrocollastatin [catrocollastatin precursor, 
Crotalus atrox (AAC59672)], catroriarin [Crotalus atrox (ABG77585)], group III snake venom metallo [Group III snake venom metalloproteinase, Echis 
ocellatus (CAJ01683)], halysetin [Gloydius halys, (AAK82974)], haemorrhagic [haemorrhagic toxin I, Crotalus ruber ruber (Q9PSN7)], jararhagin [Bothrops 
jararaca (AAB30855)], metalloprotease [Gloydius halys (AAD02652)], meta2 [metalloprotease P-III, Crotalus durissus durissus (ABA42117)], meta3 
[metalloproteinase precursor, Bothrops insularis (AAM09693)], meta4 [metalloproteinase-disintegrin-like protein, Agkistrodon contortrix laticinctus 
(AAC18911)], russellysin [RVV-X heavy chain, Daboia russellii siamensis (Q7LZ61)], scutiarin [Crotalus scutulatus scutulatus (ABG77583)], trimerelysin 
[trimerelysin I, Trimeresurus flavoviridis (P20164)] and vascular [vascular apoptosis-inducing protein 2A, Crotalus atrox (BAF56420)]. Clustal W symbols: * = 
identical, : = conserved, . = semi-conserved. 
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Acurhagin                          GKKIPCASEDVKCGRLYCKDDSPGQNNPCKMFYSNDDEHKGMVLPGTKCA 593 
Acutolysin                         GKKIPCASEDVKCGRLYCKDDSPGQNNPCKMFYSNDDEHKGMVLPGTKCA 592 
Agkistase                          YDKIPCAPEDVK------KDNSPGQNNPCKMFYSNEDEHKGMSKNGP-MV 113 
Berythractivase                    GKKIPCEPQDVKCGRLYCNDNSPGQNNPCKCIYFPRNEDRGMVLPGTKCA 595 
Bothropasin                        GKKIPCAPEDVKCGRLYCKDNSPGQNNPCKMFYSNDDEHKGMVLPGTKCA 593 
Catrocollastatin                   GNKIPCAPEDVKCGRLYCKDNSPGQNNPCKMFYSNEDEHKGMVLPGTKCA 592 
Catroriarin                        GNKIPCAPEDVKCGRLYSKDNSPGQNNPCKMLCSNEDEHKGRFLEQT--G 166 
Group III snake venom metallo      DVKIPCAPEDIKCGRLFCRH----DIYECRYDYS-ENPNYGMVEEGTKCG 593 
Halysetin                          GIKIPCAPEDVKCGRLYCKDNSPGQNNPCKMFYSNEDEHKGMVLPGTKCG 195 
Haemorrhagic                       GEKIPCAPEDVKCGRLYCKDNSPGPNDSCKTFNSNEDDHKEMVLPGTKCA 199 
Jararhagin                         GKKIPCAPEDVKCGRLYCKDNSPGQNNPCKMFYSNDDEHKGMVLPGTKCA 195 
Metalloprotease                    GKKIPCAPEDVKCGRLYCKDNSPGQNNPCKMFYSNEDEHKGMVLPGTKCG 593 
Meta2                              GNKIPCAPEDVKCGRLYCKDNSPGQNNPCKMFYSNEDEHKGMVLPGTKCA 592 
Meta3                              GKKIPCAPEDVKCGRLYCKDNSPGQNNPCKMFYSNDDEHKGMVLPGTKCA 593 
Meta4                              GKKIPCAPQDIKCGRLYCFRNLPGKKNICSVIYTPTDEDIGMVLPGTKCE 594 
Russellysin                        GRKIPCAPQDVKCGRLFCLNNSPRNKNPCNMHYSCMDQHKGMVDPGTKCE 406 
Scutiarin                          GNKIPCAPEDVKCGRLYCKDNSPGQNNPCKMFYSNEDEHKGMVLPGTKCA 168 
Trimerelysin                       EKYIPCAQEDVKCGRLFC-DN---KKYPCHYNYS-EDLDFGMVDHGTKCA 588 
Vascular                           GNKIPCAPEDVKCGRLYCKDNSPGQNNSCKMFYSNEDEHKGMVLPGTKCA 590 
                                      ***  :*:*                *       : .      .   
 
Sequence of agkistase is aligned with other similar BLAST proteins using Clustal W ver 1.82. Consensus sequence is highlighted in red. The proteins are 
acurhagin [acurhagin precursor, Deinagkistrodon acutus (AAS57937)], acutolysin [acutolysin-E precursor, Deinagkistrodon acutus (Q9W6M5)], berythractivase 
[Bothrops erythromelas (AAL47169)], bothropasin [bothropasin precursor, Bothrops jararaca (AAC61986)], catrocollastatin [catrocollastatin precursor, 
Crotalus atrox (AAC59672)], catroriarin [Crotalus atrox (ABG77585)], group III snake venom metallo [Group III snake venom metalloproteinase, Echis 
ocellatus (CAJ01683)], halysetin [Gloydius halys, (AAK82974)], haemorrhagic [haemorrhagic toxin I, Crotalus ruber ruber (Q9PSN7)], jararhagin [Bothrops 
jararaca (AAB30855)], metalloprotease [Gloydius halys (AAD02652)], meta2 [metalloprotease P-III, Crotalus durissus durissus (ABA42117)], meta3 
[metalloproteinase precursor, Bothrops insularis (AAM09693)], meta4 [metalloproteinase-disintegrin-like protein, Agkistrodon contortrix laticinctus 
(AAC18911)], russellysin [RVV-X heavy chain, Daboia russellii siamensis (Q7LZ61)], scutiarin [Crotalus scutulatus scutulatus (ABG77583)], trimerelysin 
[trimerelysin I, Trimeresurus flavoviridis (P20164)] and vascular [vascular apoptosis-inducing protein 2A, Crotalus atrox (BAF56420)]. Clustal W symbols: * = 
identical, : = conserved, . = semi-conserved. 
   40  
Acurhagin                          DGKVCSN-GHCVDVTTAY--------- 610 
Acutolysin                         DGKVCSN-GHCVDVTTAY--------- 609 
Agkistase                          DNKVPSN-GHCVDVATAY--------- 130 
Berythractivase                    DGKVCSN-RHCVDVATAY--------- 612 
Bothropasin                        DGKVCSN-GHCVDVATAY--------- 610 
Catrocollastatin                   DGKVCSN-GHCVDVATAY--------- 609 
Catroriarin                        RGKVCSN-RQ----------------- 175 
Group III snake venom metallo      DGKVCSK-RHCVDVTTAY--------- 610 
Halysetin                          DGKVCSN-GHCVDVATAY--------- 212 
Haemorrhagic                       DGKVCSN-GHCVDVASAY--------- 216 
Jararhagin                         DGKVCSN-GHCVDVATAY--------- 212 
Metalloprotease                    DGKVCSN-GHCVDVATAY--------- 610 
Meta2                              DGKVCSN-GHCVDVATAY--------- 609 
Meta3                              DGKVCSN-GHCVDVATAY--------- 610 
Meta4                              DGKVCSN-GHCVDVNIAYKSTTGFSQI 620 
Russellysin                        DGKVCNNKRQCVDVNTAYQSTTG---- 429 
Scutiarin                          DGKVCSN-RQ----------------- 177 
Trimerelysin                       DGKVCSN-RQCVDVNEAYKSTTVFSLI 614 
Vascular                           DGKVCSN-GHCVDVATAY--------- 607 
                                    .** .:  :         
 
Sequence of agkistase is aligned with other similar BLAST proteins using Clustal W ver 1.82. Consensus sequence is highlighted in red. The proteins are 
acurhagin [acurhagin precursor, Deinagkistrodon acutus (AAS57937)], acutolysin [acutolysin-E precursor, Deinagkistrodon acutus (Q9W6M5)], berythractivase 
[Bothrops erythromelas (AAL47169)], bothropasin [bothropasin precursor, Bothrops jararaca (AAC61986)], catrocollastatin [catrocollastatin precursor, 
Crotalus atrox (AAC59672)], catroriarin [Crotalus atrox (ABG77585)], group III snake venom metallo [Group III snake venom metalloproteinase, Echis 
ocellatus (CAJ01683)], halysetin [Gloydius halys, (AAK82974)], haemorrhagic [haemorrhagic toxin I, Crotalus ruber ruber (Q9PSN7)], jararhagin [Bothrops 
jararaca (AAB30855)], metalloprotease [Gloydius halys (AAD02652)], meta2 [metalloprotease P-III, Crotalus durissus durissus (ABA42117)], meta3 
[metalloproteinase precursor, Bothrops insularis (AAM09693)], meta4 [metalloproteinase-disintegrin-like protein, Agkistrodon contortrix laticinctus 
(AAC18911)], russellysin [RVV-X heavy chain, Daboia russellii siamensis (Q7LZ61)], scutiarin [Crotalus scutulatus scutulatus (ABG77583)], trimerelysin 
[trimerelysin I, Trimeresurus flavoviridis (P20164)] and vascular [vascular apoptosis-inducing protein 2A, Crotalus atrox (BAF56420)]. Clustal W symbols: * = 
identical, : = conserved, . = semi-conserved.      
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2.3.5 Physical properties of agkistase 
A pre-cast pH 3-10 IEF gel (Bio-Rad) was used to determine the pI of 
agkistase as described. When electrophoresis was completed at 500V, 25 mA at 4oC, 
the gel was stained with Coomassie Blue. A single protein band corresponding to 4.65 
(phytocyanin) were observed (Figure 2.10). 
 
Figure 2.10: Isoelectric focusing of agkistase 
 
Isoelectric focusing of agkistase on pre-cast Bio-Rad gel pH 3-10. The 
single protein band corresponded to 4.65 (phytocyanin) as indicated by 
the arrow. 
 
Purified agkistase was subjected to high resolution capillary electrophoresis. 
When native agkistase was resolved by its m/z, it appeared at 12 min under the 
influence of 22 kW (Figure 2.11A). Another independent run was carried out under 
CIEF conditions. The agkistase peak appeared at 22.5 min (Figure 2.11B) and has a 
corresponding pI of 4.6 when compared to standards of cytochrome c (pH 9.6), lentil 
lectin (pH 8.2 and 7.8), human haemoglobin C (pH 7.5), human haemoglobin A (pH 
7.1), human carbonic anhydrase (pH 6.5), bovine carbonic anhydrase (pH 6.0),           
β-lactoglobulin B (pH 5.1) and phytocyanin (pH 4.6). 
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Figure 2.11: CE analysis of agkistase 
 
A – CZE profile of agkistase under the influence of 22 kV in 50 mM phosphate buffer, pH 2.5 
and elution was monitored at 205 nm. B – Agkistase emerged as a single peak under CIEF 
separation at 22.5 min in corresponding to pH 4.6. 
 
These capillary electrophoresis results ascertained the homogeneity of 
agkistase as well as its molecular weight of 29 kDa and pI of 4.6 from prior SDS-
PAGE/mass spectroscopy and IEF gel, respectively.  
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2.4 DISCUSSION 
In the last 20 years, many different types of bioactive proteins have been 
isolated from venomous creatures, ranging from hornet (Argiolas and Pisano, 1984), 
wasps (Schmidt et. al., 1986), stonefish (Khoo, 2002), cone snails (Heading, 2002), 
scorpions (Gwee et. al., 2002), snakes (Bailey and Wilce, 2001; Bjarnason and Fox, 
1994; Campbell, 1975; Hati et. al., 1999; Kornalik, 1991; Kornalik and Styblova, 
1967; S.B.Henriques and Olga B.Henriques, 1971; Tsetlin, 1999) and even platypus 
(de Plater et. al., 1995) through simple, established column methods mainly involving 
a permutation in principles of size exclusion, ion exchange, hydrophobic interaction 
and affinity chromatography, often to high purity. Despite the low amounts of proteins 
and peptides found in snake venoms as well as the complicated protein-protein 
interactions between them, hundreds of proteins were reportedly isolated using 
chromatographic and HPLC methods. 
 
In this report, we describe the purification of a proteinase, agkistase, from the 
venom of Mongolian pit viper (Agkistrodon halys halys) using consecutive anion 
exchange and size exclusion principles on a fast protein liquid chromatography 
(FPLC) system. The venom of the aforementioned pit viper was selected for its strong 
proteinase and defibrinating activities from simple screening assays. Lyophilised 
venom powder dissolved into Tris buffer were rapidly desalted and fractionated with 
an ion-exchanger. Focusing on purification speed and capacity in the capture phase, we 
were able to eliminate a large portion of other proteins although the method did not 
produce a clean, baseline separation (Figure 2.1A, 2.3A and 2.12). 
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Figure 2.12: SDS-PAGE analysis on ion-exchange column peaks 
 
Lanes 1-9 showed the proteins resolved from ion-exchange peaks on a 
SDS-PAGE gel corresponding to peaks I, II, III, IV, V, V-VI, VI, VII and 
empty lane, respectively. Peak IV is indicated by an asterisk (*). Note the 
presence of the agkistase band shown by an arrow. A large amount of 
other proteins were removed as shown in the bands present in other 
lanes. 
 
Subsequent baseline fractionation of peak IV on a gel filtration column 
separated the proteins into two major peaks, which consisted mainly of the higher 
molecular weight (~66 kDa) proteins that appeared as a diffused peak and a sharp 
agkistase peak (Figure 2.1B), achieving both satisfactory resolution and recovery 
(66.3%).  Several medium sized toxins in the range of 23 – 38 kDa have been isolated 
from the venom of viper snakes since 1979, e.g. α- and β-fibrinogenases from            
T. gramineus (23.5 and 25 kDa, respectively) (Ouyang and Huang, 1979), plasminogen 
activator from T. stejnegeri (33 kDa) (Zhang et. al., 1995a), protease from C. atrox 
(Pandya and Budzynski, 1984), two fibrinolytic enzymes from C. basilicus basilicus 
(22.5 and 23.5 kDa) (Retzios and Markland, 1992), two serine proteinases from          
B. moojeni (34 and 38 kDa) (Serrano et. al., 1993b), crotalase-like protease from C. 
atrox (30 kDa) (Chiou et. al., 1992), anticoagulant proteinase from V. lebetina  (23.7 
kDa) (Siigur and Siigur, 1991), fibrinolytic enzyme from A. contortrix contortrix (23 
kDa) (Guan et. al., 1991c), with recovery as highly varied as their biological activities. 









This variance, possibly due to the different isolation strategies employed and 
experimental variations, prevents any meaningful comparison of purification recovery. 
 
Homogeneity of agkistase was determined using high resolution HPLC and 
MALDI-TOF (Figure 2.4). Both methods showed a single protein peak, which was 
shown to have a molecular mass of 29,209.8 Da. Further analyses on SDS-PAGE, on 
both reducing and non-reducing conditions (Figure 2.3), as well as subjecting 
agkistase to gel filtration chromatography under 8 M urea reducing condition (Figure 
2.2) were carried out to determine if the protein comprises inter-disulphide-bonded 
subunits and co-eluted bound protein through Van der Waals interactions, respectively. 
It is apparent from the profile, the elution time of agkistase under normal and reduced 
conditions were comparable (Figure 2.3B) hence there was no presence of any co-
eluted proteins in the final product. The protein migrated as a single band in both 
reducing and non-reducing conditions in SDS-PAGE thereby showing that it contained 
a single polypeptide with possible intra-molecular disulphide bondings, as 
demonstrated from the different migratory Rf values on the gel. Together with earlier 
HPLC and MALDI-TOF data, these results reconfirmed that agkistase is a single 
polypeptide of 29 kDa. 
 
The sequence of agkistase (as depicted in Figure 2.13 below) is assembled from 
peptide sequences obtained from Edman degradation and MS/MS results (Figure 2.6 
and 2.7). The calculated mass of the aligned partial sequence is 13908.92, which is 
approximately 47.6% of its native mass of the 29.209.8 Da protein (Figure 2.4b). It 
was found to have high degree of homology with other reported metalloproteases and 
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C-type lectin proteins, not only from proteins isolated from one family of Agkistrodon 
snakes but also to other vipers, i.e. Bothrops and Crotalus (Figure 2.8).  
 
Figure 2.13: Partial sequence of agkistase aligned from Edman and MS/MS results 






The assembled sequence comprises 130 amino acids and a combined mass of 
13908.92 Da. 
 
The high homology of agkistase to these proteins is not unexpected as it has 
been shown that similar classes of snake venom proteins have very analogous 
sequences. Many researchers believed this observation is evidence for the various 
evolutionary points of ancestral harmless proteins converting into highly specialised 
toxin components in venom (Ohno et. al., 1998). This theory is supported by our 
findings that the sequence of our protease is more similar to pit viper proteases from 
Agkistrodon, Bothrops, and Trimeresurus than viper proteases from Crotalus, 
Deinagkistrodon and Daboia in its primary structure (Figure 2.14). 
 
The complete sequence of agkistase in this project was difficult to obtain due to 
two major limitations: (i) insufficient funding for a complete sequencing using Edman 
degradation chemistry, and (ii) background noise in MALDI-TOF mass analysis that 
masks peptides smaller than 1000 Da. Edman degradation chemistry is a powerful tool 
in protein sequencing, however its repetitive cycles in separating and eluting         
AZT-amino acid utilise large amounts of chemicals, which increase its overhead costs 
in proportion to the amino acid length of a linearised, alkylated protein. In contrast, 
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sequencing of a protein by means of mass determination is unaffected by the length of 
a protein and requires only a fraction of the cost. The sequence of a protein can also be 
determined putatively through fishing out its mRNA, reverse transcribing into cDNA, 
amplifying it using polymerase chain reaction and finally sequencing with Sangers 
dideoxy method. Unfortunately neither fresh venom glands nor the snake was 
obtainable despite many attempts. 
 
Figure 2.14: Phylogenetic tree of similar proteases in BLAST 
 
Agkistase (current study); berythractivase (AAL47169); meta4 (AAC18911); group 
(CAJ01683); trimerelysin (P20164); russellysin (Q7LZ61); haemorrhagic (Q9PSN7); 
bothropasin (AAC61986); meta3 (AAM09693); jararhagin (AAB30855); acurhagin 
(AAS57937); acutolysin (Q9W6M5); halysetin (AAK82974); metalloproteases 
(AAD02652); catroriarin (ABG77585); catrocollastatin (AAC59672); meta2 (ABA42117); 
vascular (BAF56420); scutiarin (ABG77583). 
 
The proteins with similar sequences to agkistase strongly suggests it to be an 
enzyme involved in proteolytic activities, explaining its capability in converting 
tripeptidic chromogenic substrates into their corresponding coloured compounds in the 
early screening tests. The lack of closely homologous proteins, with the available 
sequences, in BLAST searches suggests agkistase to be a newly found proteinase from 
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A. halys halys despite reports of other similar proteins isolated from this taxonomically 
controversial family of snakes. 
 
With these initial results and indication, the enzymatic identity of agkistase can 
be further determined through various biochemical assays. However, it will present a 
challenge to further characterise this proteinase and demonstrate its uniqueness amidst 
over 60 other similar enzymes isolated from colubrids, elapids, viperids, crotalids and 
especially agkistrodons. It will also be interesting to determine whether agkistase’s 
distinct activities against tripeptidic sequences for coagulation proteins (S-2222,        
S-2238 and S-2302) as well as the widely reported symptoms of viper bites 
coagulopathies are related. If so, to what extent does it exert its effects on the 
coagulation system? 
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CHAPTER 3: IN-VITRO STUDIES OF AGKISTASE 




3.1.1 SNAKE VENOM TOXINS AND THE COAGULATION SYSTEM 
Snake venoms are a plethora of toxins that include cardiotoxins, neurotoxins, 
hyaluronidases, dendrotoxins, phospholipases, fasciculins, serine proteases, and last 
but not least, metalloproteases. Venoms of the Agkistrodon family have been the 
subject of many studies on topics as diverse as its species/subspecies, ranging from 
biochemistry, immunology, toxicity, envenomation, anti-venin, epidemiology, blood 
coagulation effects, etc. Arguably the most studied effect of venoms is directly or 
indirectly related to the mammalian coagulation system. This is not surprising as rapid 
immobilisation of prey in pit viper envenomation is caused by the combination of 
various proteases, like haemorrhagins, procoagulants and anticoagulants (Dambisya et. 
al., 1994; Khadwal et. al., 2003; Sellahewa and Kumararatne, 1994; Vest and Kardong, 
1980), as well as neurotoxins, channel blockers, etc. Several components or toxins 
isolated from venoms of Agkistrodon pit vipers have been found closely related to the 
blood coagulation system, e.g. acurhagin, a 48 kDa fibrinogenolytic metalloprotease 
from A. acutus (Wang and Huang, 2002); fibrolase, a fibrinolytic enzyme from A. c. 
contortrix (Ahmed et. al., 1990); piscivorase I & II (23.4 and 29 kDa, respectively), 
two fibrinolytic enzymes from A. piscivorus piscivorus (Hahn et. al., 1995); a 22.9 kDa 
fibrinogenase from A. c. mokasen (Moran and Geren, 1981b); agkislysin, a 22 kDa 
fibrinogenolytic P-I metalloprotease from A. acutus (Wang et. al., 2004); a 24 kDa 
fibrinolytic and fibrinogenolytic enzyme from A. acutus (Ouyang and Teng, 1976); 
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AaHI, a proteolytic haemorrhagic toxin from A. acutus (Zhang et. al., 1984); ABUSV-
PA, a 28 kDa plasminogen activator from A. blomhoffii ussurensis (Liu et al, 2006); 
ussurenase, a 23 kDa fibrinolytic enzyme from A. blomhoffii ussurensis (Sun et. al., 
2006b); kangshuanmei, a 34 kDa thrombin-like serine protease from A. halys 
brevicaudus stejneger (Zhang et. al., 2001); shedaoenase, a 36 kDa  α,β-fibrinogenase 
from A. shedaoenthesis Zhao (Jiao et. al., 2005); brevinase, 16.5 kDa and 17 kDa 
heterogeneous two-chain fibrinolytic enzyme from A. blomhoffii brevicaudus (Lee et. 
al., 1999). A thrombin-like enzyme, ancrod isolated in 1976 from a close species, 
Calloselasma rhodostoma (formerly known as Agkistrodon rhodostoma) by Nolan et. 
al. (Nolan et. al., 1976) is the most well-known toxin isolated as a therapeutic for 
coagulation complications and will be discussed in more detail later. 
 
3.1.2 FIBRINOGEN-TARGETING TOXINS 
The most extensively studied coagulation-affecting proteases from snake venoms 
are those that act on fibrinogen. These proteases are classified into three groups,  
distinguished with respect to their action on fibrinogen: (i) thrombin-like enzymes 
(thrombic protease, or TP for short, was the name recommended for thrombin-like 
enzymes by the sub-committee on Nomenclature of the International Society on 
Thrombosis and Haemostasis) (Pirkle and Stocker, 1991), (ii) 
fibrinogenolytic/fibrinolytic enzymes (Markland, 1998b), and (iii) plasminogen-
activating enzymes (Liu et al, 2006; Park et. al., 1998; Sanchez et. al., 2000; Zhang et 
al, 1995a). Thrombin-like enzymes catalyse the release of FPA or FPB, or both, from 
fibrinogen molecule (Figure 1.3) and they act as in vitro procoagulants changing 
fibrinogen to fibrin, while causing benign defibrination in vivo. Fibrinogenolytic 
enzymes directly cleave fragments mostly from the carboxyl terminals (COOH) of     
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α, β and even γ chains of fibrinogen, rendering it unclottable by thrombin. Hence they 
generally cause anti-coagulation both in vitro and in vivo. Finally the plasminogen 
activators, like innate uPA and tPA, act as indirect fibrinolysins by converting 
plasminogen to plasmin thereby triggering fibrinolysis. Due to the interesting effects of 
these toxins on blood coagulation, many of them are proposed as thrombolytic and 
anti-thrombotic agents for treating clinical coagulopathies (Verstraete et. al., 1995). 
 
There is a large collection of purified snake venom components (particularly 
from the viperids and crotalids) studied hitherto and many more are being discovered 
to have either direct or indirect haemostatic effects on the mammalian coagulation 
system (Bell, 1997; Bjarnason and Fox, 1994; Braud et. al., 2000; Kini et. al., 2001; 
Kornalik, 1985; Kornalik, 1991; Markland, 1998b; Meier and Stocker, 1991; Stocker 
et al, 1982; Tans and Rosing, 2001; W.H.Seegers and C.Ouyang, 1979). Their 
individual effects on the plasmatic coagulation system, thrombocytes and vessel wall 
are as diverse as their specific modes of action, points of effect, target molecules as 
well as their clinical and physiological symptoms. Despite the definitive endpoints of 
procoagulation and anticoagulation in fibrin clot formation and dissolution 
respectively, these individual venom toxins target almost every molecule and pathway 
in the entire mammalian coagulation cascade from the extrinsic tenase (Atoda and 
Morita, 1989; Banerjee et. al., 2005a; Banerjee et. al., 2005b; Cox, 1993; Farid et. al., 
1993; Komori et. al., 1990; Lee et. al., 1995; Li et. al., 2005; Maruyama et. al., 1992a; 
Pukrittayakamee et. al., 1983; Samel et. al., 2003; Sundell et. al., 2001; Tans and 
Rosing, 2001; Xu and Liu, 2001; Yamada et. al., 1997; Zhang et. al., 1995b) and the 
intrinsic tenase (Brinkhous et. al., 1983; Gable et. al., 1997) to fibrin formation (Pirkle, 
1998; Pirkle and Stocker, 1991; Stocker et al, 1982; Zhang et al, 2001) and 
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plasminolysis (Liu et al, 2006; Park et al, 1998; Sanchez et al, 2000; Zhang et al, 
1995a). This has provided the basis of many toxins being developed into various 
specific therapeutics and diagnostic agents. Therefore elucidation of the mechanism of 
the toxin and its actual point of action onto which the specific product being generated 
and released is important in both the determination of the identity of the toxin and its 
therapeutic value. In this chapter, the mechanism and target molecule(s) of agkistase 
are initially screened with various biochemical assays on synthetic peptides mimicking 
specific target sequences of several important complexes in the coagulation pathway. 
A complete analysis of the haemolytic properties, platelet-affecting properties and 
coagulation studies using purified factors provided more direct evidence for 
agkistase’s mode of action and finally the overall haemostatic effects of agkistase was 
studied using thrombelastography, which is a powerful and comprehensive method to 
understand the effects of the toxin in real time in the presence of all coagulation factors 
under normal physiological concentrations. The specific mechanism and biochemical 
classification of the toxin could be determined with these assays. 
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3.2 METHODS AND MATERIALS 
 
3.2.1 Blood collection and storage 
Blood from various sources (human, rabbit and mouse) were used in this 
project. Their collection and treatment were similar unless otherwise stated. Blood was 
collected from healthy individuals into sterile tubes with 0.129M trisodium citrate 
(9:1) and gently mixed to prevent lysis caused by mechanical disruption. Citrated 
blood was separated into whole blood, platelet-rich plasma (PRP; supernatant at 120 g 
for 10 min), platelet-poor plasma (PPP; supernatant at 1500 g for 15 min after PRP 
preparation) and washed red blood cells (pellet at 120 g after PRP preparation, with 
multiple washes of PBS, pH 7.4). Collected blood or its components were used within 
4 hours of collection and the balance was kept at -80oC for various assays where 
applicable. 
 
3.2.2 Proteolytic Assays on Chromogenic Substrates 
Synthetic peptidic substrates were purchased from Chromogenix 
(Chromogenix, Viale Monza, 338, 20128 Milano – Italy). Each chromogenic substrate 
is generally a synthetic construction of a short peptide (mainly 3–5 amino acid long), 
which serves as a specific recognition site for a unique protease, chemically linked to 
p-nitroaniline (–pNA·HCl). Free pNA will be liberated when hydrolysed to give off a 
yellow colour detected at 405 nm with a Bio-Rad model 680 microplate reader, 
microplate manager 5.2 software (Bio-Rad). The details of the synthetic substrates 
used were listed under 3.3.1 Enzymatic activities of agkistase. Proteolytic assays were 
performed in reference to manufacturer's suggestions with minor modifications to 
adapt to optimal enzymatic conditions of crude venom and agkistase. Kinetic assays 
 54 
(Appendix 3H, Kinetic Assay Methods, Current Protocols in Molecular Biology (Burgi 
and Smith, 2007)) were performed; KM and Vmax were calculated from double-
reciprocal plots with Michaelis-Menten assumptions. All assays were performed in 
triplicates. 
 
3.2.3 Haemolytic Assay 
The haemolytic assay was adapted from the method of Shin et. al. (Shin et. al., 
1999). Human and rabbit erythrocytes were both used to test the haemolytic activities 
of Agkistrodon venom and purified agkistase. Whole blood was collected in a sterile, 
citrated, borosilicate tube and washed with 0.9% saline. Erythrocytes were obtained as 
previously described. Erythrocyte suspensions were adjusted to 0.8% for the assay. 
Serial two-fold dilutions of the toxins were prepared in 0.9% saline, and 100 µl 
aliquots were added to equal volumes of 0.8% erythrocyte suspension in sterile 96-
well microtitre plates (Nunclon ∆ surface; Nunc) in triplicates. The plates were 
incubated at 37oC for up to 4 hours. Subsequently, intact erythrocytes were pelleted by 
centrifugation at 1,000 g for 5 min at 4oC. One hundred microlitres of supernatant from 
each well was transferred accordingly to a new 96-well microtitre plate, and the 
amount of haemoglobin released into the supernatant was determined by reading the 
absorbance at 414 nm against a reference wavelength of 490 nm. A positive control 
with 100 µl of 0.4% erythrocyte lysed in 1% Triton X-100 was taken as 100% lysis. 
The negative control was untreated erythrocytes suspended in 0.9% saline, which gave 
minimal lysis, and taken as 0% lysis. 
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3.2.4 Thrombin Time Assay 
Thrombin time (TT) assay (Clauss, 1957) was performed with an electro-
mechanical instrument BBL Fibrometer, Becton Dickinson. Reaction mixture 
consisting of 0.1 ml pre-calibrated citrated rabbit plasma and 0.2 ml of 0.05 M Tris 
buffer, pH 7.8 was incubated for 5 min at 37oC in a plastic Fibrometer cup. Fifty µl of 
sample and 50 µl of thrombin (67 U/ml) was added into the mixture and the timer 
(accurate to 0.1 sec) was started simultaneously. Upon the formation of fibrin clot, a 
complete circuit is formed and the timer will stop. Assays were performed in 
replicates. The content of fibrinogen in collected rabbit plasma was standardised with 
the QFA Thrombin provided. 
 
3.2.5 Prothrombin Time Assay 
Prothrombin time (PT) assay (Quick and Hussey, 1955) was performed by 
mixing 100 µl of citrated rabbit plasma and 100 µl of 50 mM Tris-HCl, 0.1 M NaCl, 
pH 7.4 (with different concentrations of agkistase) and incubated for 5 min at 37oC in 
a plastic Fibrometer cup. Clotting was initiated by addition of 200 µl thromboplastin 
with calcium. Clotting time was recorded using a BBL Fibrometer. 
 
3.2.6 Recalcification Time Assay 
Recalcification time (RT) was performed by initiating clotting with CaCl2     
(10 mM final concentration) into a pre-warmed mixture of 100 µl of citrated rabbit 
plasma and 100 µl of 50 mM Tris-HCl, 0.1 M NaCl, pH 7.4 (with different 
concentrations of agkistase). Clotting time was recorded using a BBL Fibrometer. 
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3.2.7 Platelet Aggregation Assay 
Platelet aggregation studies were performed using a Whole Blood 
Aggregometer (Chrono-log Corporation, Havertown, PA, USA) using rabbit plasma 
and whole blood. The plasma or whole blood (250 µl) was mixed with 250 µl 
phosphate-buffered saline (PBS) into a 1 ml disposable vial and prewarmed to 37oC. 
Ten microlitre of test sample was added into the mixture and stirred at 1000 rpm. 
Baseline and gain were calibrated and presence of aggregation was monitored by 
following the impedance generated. Data obtained were analysed using the software 
supplied. Aggregation in the control was initiated using 5 µg of collagen. 
 
3.2.8 Fibrino(geno)lytic Assay 
Fibrino(geno)lytic assay was performed according to the method by Shacter 
1995 (Shacter et. al., 1995). Bovine fibrinogen (45 µl; 2 mg/ml in 50 mM Tris, pH 7.4) 
was incubated with 5 µg of sample at 37oC. At various time intervals, reactions were 
stopped by adding denaturing solution (5% β-mercaptoethanol, 2% SDS, 1% glycerol, 
0.5 M Tris, pH 6.8) and boiled for 5 min. The sample was then resolved on a 10% gel 
under constant current of 50 mA and stained with Coomassie Blue stain. Negative 
controls were buffered fibrinogen incubated at the same conditions and time intervals 
without addition of sample.  
 
3.2.9 Fibrinolytic Assay 
Fibrinolytic activity of agkistase was analysed using SDS-PAGE. Bovine 
fibrinogen (45 µl; 2 mg/ml in 50 mM Tris, pH 7.4) was clotted with thrombin reagent 
(2 U/ml, Chromogenix, Italy) at 37oC. Fibrin was then pelleted by centrifugation at 
120 g for 10 min. The resultant supernatant was aspirated and fibrin clot was washed 
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three times with PBS, pH 7.4. Approximately 5-10 µg of fibrin clot was incubated 
separately with: (i) 2 U/ml plasmin, (ii) 5 µg/ml agkistase, and (iii) control PBS, up to 
a final reaction volume of 100 µl for 1 hour at 37oC. Reaction samples were reduced, 
linearised and resolved on an 8% SDS-PAGE gel, with fibrinogen as control. 
 
3.2.10 Fibrin Plate Lysis 
Fibrin plate method was adapted from Souza (Souza et. al., 2001). A fibrin-
agarose gel was prepared by mixing 2 mg/ml of human fibrinogen with cooled, melted 
solution of 0.5% agarose in PBS, pH 7.4. The mixture was poured onto a sterile petri 
dish and clotting was initiated with an addition of thrombin (2 U/ml). On top of the 
polymerised agar, 10 µl of each of the following solution: (i) PBS, pH 7.4, (ii) 2 U/ml 
plasmin, (iii) 0.5 mg/ml crude venom, (iv) 4, 40 and 400 µg/ml agkistase, was placed 
into each of six equal agar segments. The agar was incubated for 16 hours at 37oC in a 
humidified oven. Subsequently the agar was stained with protein assay dye reagent 
(Bio-rad Protein Assay, Bio-rad) (1:5 dilution). The diameter of clear zones of lysis 
was measured at two points perpendicular to each other. The assay was performed in 
duplicates and the average zone of lysis was reported. 
 
3.2.11 Euglobulin Lysis Time 
Euglobulin lysis time (Nilsson and Olow, 1962) provides measurements of clot 
dissolution in the absence of inhibitors of plasmin such as α2-antiplasmin through 
precipitation of the euglobulin fraction, which comprises fibrinogen, plasminogen, 
active plasmin and plasminogen activators. Freshly collected citrated human plasma 
(0.5 ml) was added to 9.5 ml, 0.0017% acetic acid. pH 5.4 and incubated at 4oC for   
10 min. Subsequently the mixture is centrifuged for 10 min at 4oC for 2000 g. The 
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resultant supernatant was discarded and the euglobulin clot (pellet) was redissolved 
into 0.5 ml Owen's buffer, pH 7.3 (5.85 g/L sodium barbital, 7.3 g/L sodium chloride 
in 21.5% 0.1 N HCl). The euglobulin fraction was clotted with 0.5 ml thrombin          
(2 U/ml). Various concentrations of test samples were added into the clot, incubated at 
37oC and clot lysis was observed visually every 15 min. Lysis was taken as complete 
when the size of the clot was less than 5% of its original. 
 
3.2.12 Thrombelastography 
Thrombelastography is a measurement of viscoelastic changes associated with 
fibrin polymerisation, which is taken to be the end-point of blood coagulation. The 
resultant trace produced is termed thrombelastograph (TEG®) and it provides a 
complete evaluation of the process of clot initiation, formation and stability. The 
principle of TEG® is described at footnote of the diagram below (Figure 3.1). Citrated 
human blood was collected from healthy individual and assayed immediately. Three 
hundred and forty microlitres of fresh citrated whole blood was placed into disposable 
cups with its temperature constantly kept at 37oC in a TEG® instrument 
(Thrombelastograph Analyser 5000 series, Haemoscope Corporation, 6231 West 
Howard Street Niles, IL 60714-3403, US). Coagulation was initiated by addition of 20 
µl of CaCl2 (0.2 M) prewarmed to 37oC. Effects of crude venom and purified agkistase 
were assayed with varied concentrations or incubation time in whole blood. Traces and 
coagulation parameters were average values obtained from triplicates. 
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Figure 3.1: A simplified diagram of thrombelastography 
 
Principle of TEG detects the viscoelastic properties of real time measurements of 
blood coagulation initiation, clot formation as well as clot dissolution as detected 
by torsional stain formed from fibrin clot bridging between the rotating cup, 
which oscillates back and forth constantly at a set speed through an arc of 
4°45', and the stationary pin. Each rotation lasts ten seconds. The torsional 
strain generated is detected by a sensitive torsion wire holding the pin. As 
entire clotting and fibrinolysis processes occur in whole blood samples at 37oC, 
it provides a complete evaluation of clot initiation, formation and stability. 
Diagram obtained from Haemoscope website (http://www.haemoscope.com). 
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3.3 DATA AND RESULTS 
 
3.3.1 Enzymatic properties of agkistase 
Enzymatic properties of agkistase were determined using synthetic peptides of  
p-nitroaniline hydrochloride derivative (Chromogenix), which release p-nitroaniline 
(pNA) upon specific triple amino acid sequence cleavage. The extent of absorbance 
measured at 405 nm correlates to the amount of pNA released under the conditions of 
the experiment. The enzymatic activity can be calculated with the molar extinction 
coefficient of pNA (ε = 10,000 M-1 cm-1). Agkistase was assayed with the following 
substrates: 
 
Figure 3.2: Chromogenic peptides properties and their chemical structures 
 Brand name MW Formula Substrate for 
1. S-2222 734.3 (R = H); 
748.3 (R = CH3) 
Bz-Ile-Glu-(-OR)-Gly-Arg-pNA Factor Xa, trypsin 
2. S-2238 625.6 H-D-Phe-Pip-Arg-pNA Thrombin 




4. S-2288 577.6 H-D-Ile-Pro-Arg-pNA Broad spectrum of 
serine proteases 
5. S-2302 611.6 H-D-Pro-Phe-Arg-pNA Plasma kallikrein 
6. S-2366 539.0 <Glu-Pro-Arg-pNA Factor XI, APC 
















Serial dilutions of agkistase ranging from 156 ng to 10 µg per well provided a 
good and well-distributed absorbance for calculation of kinetic profile for all of the 
substrates (Figure 3.3). 
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Figure 3.3: Kinetic profile and colour absorbance range for chromogenic substrates 
 
Result from kinetics assay of agkistase on chromogenic substrate, S-2302. The graph on the 
left showed a kinetic plot of absorbance (405 nm) against time (sec). The coordinates were 
means of 3 replicates. The microplate on the right showed the triplicate assay with different 
dilutions of agkistase. Buffer was used as the control. 
 
 
Similar assays were performed on all the chromogenic substrates to determine 
tha sequence specificity of agkistase. Readings obtained were computed with a 
scientific statistical program, GraphPad Prism 4.0™, and plotted on double-reciprocal 
graphs to determine their KM and Vmax. All plots were constructed with Michaelis-
Menten assumptions. The efficiency of agkistase on other chromogenic substrates as 











Table 3.1: Enzymatic efficiency of agkistase against other venom proteinases 
Substrate Enzyme kcat KM kcat/KM 
  (min-1) (mM) (mM-1 min-1) 
H-D-Pro-Phe-Arg-pNA agkistase 140 6.95 x 104 2.01 x 10-3 
(S-2302) α-mucrofibrase 702.0 166.7 4.21 
  stejnefibrase-1 3438 100 34.4 
  stejnefibrase-3 137 53 2.61 
     
H-D-Phe-Pip-Arg-pNA agkistase 1.5 x 106 31.4 4.8 x 104 
(S-2238) α-mucrofibrase 594.6 245.7 2.42 
  stejnefibrase-1 1289 235 5.48 
  stejnefibrase-3 19 33 0.58 
     
H-D-Val-Leu-Lys-pNA agkistase 7.0 x 105 2.06 3.4 x 105 
(S-2251) α-mucrofibrase 624.2 1111.1 0.56 
  stejnefibrase-1 - - - 
  stejnefibrase-3 - - - 
A table summarising the kinetics parameters of agkistase against the three best substrates. 
 
Table 3.2 scores the overall specificity of agkistase against all tested 
chromogenic substrates by the amount of pNA released at the end of 30 min enzymatic 
assay. The relative enzymatic activities are graded in three different levels for 
simplicity in discussion. 
 
Table 3.2: Enzymatic activity of agkistase against all substrates 
Subst Chemical formula Substrate for Activity 
S-2302 H-D-Pro-Phe-Arg~pNA Plasma kallikrein, FXIIa +++ 
S-2238 H-D-Phe-Pip-Arg~pNA Thrombin +++ 
S-2251 H-D-Val-Leu-Lys~pNA Plasmin; streptokinase-activated plasminogen + 
S-2222 Bz-Ile-Glu-Gly-Arg~pNA FXa + 
S-2366 <Glu-Pro-Arg~pNA FXIa; activated Protein C ++ 
S-2288 H-D-Ile-Pro-Arg~pNA Broad spectrum SP ++ 
S-2403 <Glu-Phe-Lys~pNA Plasmin; streptokinase-activated plasminogen ++ 
 
 
3.3.2 Effects of agkistase on blood coagulation system 
The directs effects of agkistase on blood were analysed with the following 
assays – haemolysis, platelet aggregation, recalcification, prothrombin time (Quick and 
Hussey, 1955), thrombin time (Clauss, 1957), fibrinolysis, fibrinogenolysis (Shacter et. 
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al., 1995), fibrin plate (Souza et. al., 2001), euglobulin lysis time (Nilsson and Olow, 
1962), prothrombin activation and plasminogen activation – and their variants for 
determination of possible opposite or related effects, under various conditions in 
attempt to understand its influence on blood coagulation. 
 
3.3.2.1 Haemolysis assay 
The crude venom of Agkistrodon halys halys and its isolated snake enzyme, 
agkistase, were assayed for their haemolytic properties using a method described by 
Shin et. al (Shin et al, 1999). Concentrations of 2-1000 µg/ml were assayed for both 
crude venom and agkistase. As shown in the figure, both venom and agkistase showed 
no haemolysis on human (Figure 3.4) and rabbit (data not shown) erythrocyte 
suspensions up to 1 mg/ml even after 4 hr of incubation at 37oC. The strong lysis 
caused by Triton X-100 (positive control) clearly accentuated the negative response 
from the test samples. 
 
Figure 3.4: Hemolysis assay performed on human erythrocytes 
 
Picture of segments on a microtitre plate showing supernatants extracted from 
















with washed erythrocytes (0.4%), at 37οC up to 4 hours in triplicates prior to 
reading at 414 nm. Haemoglobin was visibly present in the supernatant of 
positive controls for both samples tested but was absent in all others. 
 
3.3.2.2 Platelet aggregation assay 
A single high concentration of crude venom (1 mg/ml) and agkistase (1 mg/ml) 
was used in determination of platelet aggregation activity in human whole blood 
sample. Figure 3.5 depicts the induction of aggregation by venom, agkistase and 
control collagen (5 µg). Platelet aggregation induced by collagen was taken as 100%. 
Crude venom induced slight aggregation (about 30-40%) presumably caused by 
undiscovered halysetin-like platelet aggregator proteins; there was no aggregation 
observed for agkistase. Platelet aggregating inhibitory studies were also conducted by 
pre-incubating test samples with prewarmed blood prior to addition of collagen. No 
inhibitory action was observed for both venom and agkistase at 1 mg/ml (data not 
shown). 
 
Figure 3.5: Platelet aggregation assay 
 
Impedance caused by platelet aggregation was recorded as a 




3.3.2.3 Recalcification, Prothrombin and Thrombin assay 
The three coagulation assays were usually conducted together as a preliminary 
means of establishing whether an agent is procoagulant or anticoagulant and the 
general effect of it on the major pathways of blood coagulation cascade, namely the 
intrinsic and extrinsic pathway before more specific assays towards each individual 
coagulation factor can be conducted. These assays were performed using a 
Fibrometer® and clotting times were shown in Table 3.3 below. It is evident that 
agkistase is an anticoagulant affecting both intrinsic and extrinsic pathways. 
 
Table 3.3: Fibrometer clotting times with agkistase 
Assays Clotting time (s) CTRL Std error 
TT > 300 23.9 1.1547 
PT > 300 20.4 0.2887 
aPTT > 300 21.3 0.8940 
Time was stopped after 300s of non-clotting blood 
for agkistase (10 µg). 
 
With the establishment of agkistase as an anticoagulant protein, we proceeded 
to construct a concentration-dependent response for recalcification and thrombin time 
to determine its effective clinical range. The graphs below show recalcification and 
thrombin time for agkistase concentrations from 0.001-1 µg/ml for a prolonged time 
of 40 min. 
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Figure 3.6: Concentration-dependent anticoagulation response of agkistase 
 
A. Recalcification time of crude venom and agkistase showing a gradual increase in clotting 
time for increasing concentration of venom but a sharp exponential increase in clotting time 
was observed for agkistase above 0.04 µg/ml. B. Thrombin time assay showed a similar 
increase in clotting time for both crude venom and agkistase. C. Decreasing fibrinogen content 
observed in thrombin time assay was plotted against protein concentration to demonstrate the 
reduction in fibrinogen level caused by agkistase. 
 
Results obtained from Figure 3.6 emphasised the strong anticoagulant property 
of agkistase, and when coupled with earlier results from Table 3.3, suggested a 
disruption in one or more of the factors residing in the common pathway of blood 
coagulation. The common pathway begins at the prothrombinase complex and ends 
with fibrin degradation by plasmin thereby indicating that agkistase can generally 
A. Recalcification time 
venom 
agkistase 
B. Thrombin time 
venom 
agkistase 




either prevent fibrin formation or induce fibrin clot dissolution, which leads to the 
same result. Hence subsequent experiments were focused on understanding the factors 
involved in the prothrombinase complex, fibrin formation, factor XIIIa and plasmin 
regulation – the prothrombinase complex and fibrinolytic pathway. 
 
3.3.3 Effects of agkistase on prothrombinase complex and fibrin formation 
The first assay conducted to understand the effect of agkistase on the 
prothrombinase complex and fibrin formation pathway was prothrombin activation 
employing chromogenic substrate, S-2238. The results are shown in Figure 3.7. 
 
Figure 3.7: Prothrombin activation assay  
 
There was no significant prothrombin activation observed for both venom and agkistase 
(levels of pNA release was comparable for each pair of assay groups). The concentration-
dependent response (8, 20 and 40 µg/ml) of agkistase and strong pNA release by venom 
are a direct result of enzymatic cleavage by agkistase and venom on substrate S-2238. 
 
The negative results from prothrombin activation assay was expected as 
agkistase was found to be an anticoagulant protein rather than a procoagulant, as all 
prothrombin activators isolated thus far were exhibiting procoagulant activity (Kini et 
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al, 2001). Logically, the next step was to analyse the proteinase’s effects on fibrinogen 
and fibrin. Fibrinogenolytic assay on purified fibrinogen was performed and the 
resulting cleavage pattern resolved on SDS-PAGE was depicted in Figure 3.8. 
 
Figure 3.8: Fibrinogenolytic assay (incubation time) 
 
The proteolytic cleavage pattern of fibrinogen by agkistase was resolved onto SDS-PAGE gel 
after 0, 10, 20, 30, 60, 90, 120 and overnight (a, b, c, d, e, f, g and h, respectively) incubation 
at 37oC. There was a gradual disappearance of the α-chain and β-chain fibrinogen bands with 
prolonged incubation with agkistase, leading to a complete disappearance of both bands after 
overnight incubation (h). 
 
 
The gel was then digitally photographed and band intensity of each lane was 
computed with Kodak Imaging software. The progressive loss of band intensity was 




a b h g f e d c 
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Figure 3.9: Decrease in band intensity in fibrinogenolytic activity 
 
The decrease in band intensity of all three fibrinogen chains was 
plotted against incubation time. Alpha-chain is represented with 
red dots and a solid line; β-chain is represented with blue dots 
and a dotted line; γ-chain is represented with green dots and a 
straight line. The calculated chain-degradation rate was 15.1 mg 




The fibrinogenolytic activity demonstrated by agkistase was further tested for 
its enzymatic efficiency and stability under different conditions of pHs and salt 
concentrations (Figure 3.10). The salt concentration was designed to determine the 
stability of agkistase under physiological conditions. 
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Gels on the left show the effects of pH on fibrinogenolytic activity whereas gel on the right 
shows the stability of the same activity under different concentrations of salt. Gel photo on top 
left shows the controls for different pHs. Generally agkistase retained its fibrinogenase 
efficiency under pH 5-9 and salt concentration up to 0.8 M. 
 
It can now be concluded that agkistase is a fibrinogen-affecting proteinase that 
promotes anticoagulation in recalcification assay and thrombin assay through direct 
cleavage of fibrinogen molecule, particularly on its α- and β-chains. To determine 
whether agkistase is a metalloprotease or serine protease (both classes are reported to 
affect fibrinogen in venom proteinases), an inhibition assay was performed on 
chromogenic substrate and fibrinogen, separately (Table 3.4). 
 
Table 3.4: Inhibitory studies on agkistase 
Inhibitor Residual amidolytic activity 
(%) 
Residual fibrin clot formation 
(%) 
Control 100.0 100.0 
EDTA 100.0 94.6 
PMSF 26.7 50.3 
l-cysteine 12.1 N.D. 
Benzamidine 22.6 N.D. 
Aprotinin 24.8 N.D. 
DTT 89.8 N.D. 
N.D. not determined 
 
As seen in the table, the amidolytic activity of agkistase is inhibited by serine 
protease inhibitors (e.g. PMSF, aprotinin) but not by metal chelators (e.g. EDTA). 
Similar inhibition is also observed for fibrin clot formation. This verified that it is a 
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serine protease, hence a fibrinogenase. Several venom proteins are reported to have 
more than one enzymatic activity, e.g. phospholipases (Kini and Evans, 1988), 
therefore it is still possible that agkistase possesses other undiscovered activities on the 
large amounts of proteins and pathway interactions in the tightly-interwoven blood 
coagulation system. 
 
3.3.4 Effects of agkistase on fibrinolytic pathway 
The fibrinolytic pathway comprises the fibrin clot, clot-strengthening factor 
XIIIa, the plasminolytic pathway and their regulatory components. To understand the 
effects of agkistase, we first analysed its possible effect on the activation of 
plasminogen to plasmin in a simple enzymatic assay (Figure 3.11). 
 
Figure 3.11: Plasminogen activation assay 
 
Equimolar volumes of plasminogen in each enzymatic reaction, with 
addition of various ‘activators’, was used to hydrolyse chromogenic 
substrate for plasmin, S-2403. a, blank control; b, plasminogen 
control; c, S-2403 control; d, crude venom; e, crude venom with 
plasminogen; f, agkistase; g, agkistase with plasminogen; h, t-PA 
with plasminogen. There were no plasminogen activation for both 
the venom and agkistase. 
 
 
Next, we proceeded to test for any direct fibrinolytic activity by conducting 
three well-established independent assays, namely (i) direct clot dissolution and 
a b c d e f g h 
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analysis of digestion pattern with SDS-PAGE (Figure 3.12), (ii) fibrin plate lysis 
(Figure 3.13), and (iii) euglobulin lysis time (Table 3.5). 
 
Figure 3.12: Clot dissolution resolved on SDS-PAGE 
 
Fibrin clots incubated with test samples were resolved on 
reducing SDS-PAGE gel. Lanes were incubated with: a, plasmin; 
b, agkistase; c, fibrin control; d, fibrinogen control with indicated 




Figure 3.13: Fibrin plate lysis 
 
Clockwise: a, 400 µg/ml agkistase; b, 40 µg/ml agkistase; c,       
4 µg/ml agkistase; d, 500 µg/ml venom; e, blank control; f, 2U/ml 
plasmin. A large clear zone was found for plasmin (d: 17 mm), 
followed by smaller ones for venom (d: 9 mm) and 400 µg/ml 
agkistase (d: 3 mm; not visible on digital picture). Results showed 



















Table 3.5: Euglobulin lysis time 
 Test sample 
Clot lysis time 
(min) 
1. CTRL 120 ± 15 
2. venom (10 mg/ml) 150 ± 15 
3. venom (1 mg/ml)  120 ± 15 
4. venom (0.1 mg/ml) 150 ± 15 
5. agkistase (1 mg/ml) 195 ± 15 
6. agkistase (0.4 mg/ml) 120 ± 15 
7. agkistase (0.1 mg/ml) 195 ± 15 
Table shows the mean time it takes for euglobulin clots to 
lyse in different concentrations of venom and agkistase 
separately. There was no significant accelerated or 
decelerated lysis observed for all samples. 
 
The three fibrinolysis assays collectively suggest that although agkistase 
showed mild fibrinolysis in controlled experimental set up with only purified 
components, it lacked the efficacy to significantly affect fibrinolysis in whole blood  
(at least at the concentrations tested). Hence it will be essential to assess the net effects 
cause by agkistase-induced fibrinogenolysis in whole blood in order to fully 
characterise its activity. 
 
3.3.5 Effects of agkistase on human haemostasis system 
The experiments to assess agkistase effects in whole blood were designed to 
mimic the plasma coagulation system as closely as possible. To discover the potential 
of agkistase as a possible therapeutic agent, we expand the standard clinical 
coagulation assays (RT, PT and TT) to determine the clinically effective range (EC50) 
of agkistase employing microtitre-based coagulation studies (Pratt and Monroe, 1992; 
Wolberg et. al., 2002) on human blood. Clotting time was calculated as time to reach 
maximum velocity, approximately the midpoint of the absorbance curve determined by 




Figure 3.14: Determination of EC50 on clinical coagulation assays  
 
 Indication EC50 (µg/ml) R2 
PT blue, - - - 5.1 ± 1.5 1.00 
RT yellow, . . . 0.26 ± 0.1 0.97 
TT red, –––– 0.5 ± 0.2 0.94 
 
 
Typical sigmoidal curves were obtained showing a correlation between increasing 
concentrations of agkistase to increased clotting time. EC50 are shown above together with the 
curve fitting R2. 
 
Thrombelastography was selected for its superior capability in measuring 
viscoelastic changes associated with fibrin polymerisation in a rapid, real-time 
complete evaluation of clot initiation, formation and stability as well as clot 
dissolution, all in a single experimental run (Luddington, 2005; Nicola, 1957). Fibrin 
polymerisation is taken as the end-point of blood coagulation. Traces of 
thrombelastograms for various assay conditions are depicted and interpretation of the 







Figure 3.15: A typical thrombelastogram showing the important parameters  
 
 
A typical thrombelastogram for normal blood clotting initiation, formation and 
dissolution from a healthy individual. Segments of the trace representing clot 
initiation, clot formation and clot dissolution are divided by dotted lines. 
 
Clot time, r First significant level of clot formation. End point of 
most coagulation assays. 
k-time, k Time taken from initial clot formation (2 mm 
amplitude) to a firm clot (20 mm). 
alpha angle, α The rate of clot growth. 
max amplitude, MA Max strength of clot. A combined function of fibrin 
clot & platelets. 
amplitude (at set time), Ax Clot strength at a set time. 
lysis (at a fixed time), CLx Clot lysis at a fixed time. 
 
 











Figure 3.16: Thrombelastograms of Ca2+ effects on venom 
 
Thrombelastograms showing the effects of Ca2+ with crude venom (0.1 and        
1 mg/ml) on blood clotting and dissolution. There were no visible effects of Ca2+ 
as seen by overlapping continuous and dotted line (at the centre line) on the 
traces. It is, however, interesting to note that at these concentrations, the venom 





Figure 3.17: Thrombelastograms of Ca2+ effects on agkistase 
 
 
Thrombelastograms showing the effects of Ca2+ with 1 mg/ml agkistase on blood 
clotting and dissolution. Traces of thrombelastogram with and without Ca2+ were 




venom without Ca2+ 
venom with Ca2+ 
agkistase with Ca2+ 
agkistase without Ca2+ 
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Effects of concentration (0.1-100 µg/ml) of venom on blood. A slight reduction of 
clotting time was observed for higher concentrations of venom (lighter traces); as 
concentration reduces, there was a marked prolongation of clotting time and 







Figure 3.19: Thrombelastograms on effects of concentration of agkistase 
 
 
Effects of concentration (0.1-100 µg/ml) of agkistase on blood clotting. There was 
no significant change in the different thrombelastographs. Traces were almost 
overlapping each other. The control is depicted by a broken line. 
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Figure 3.20: Thrombelastograms of exposure duration of venom 
 
 
Effects of incubation time (0-60 min) on 0.1 µg/ml of venom on blood clotting. 
Agkistrodon halys halys venom was found to completely inhibit clotting at the 
concentration tested. All traces of venom were overlapping the centre line. The 







Figure 3.21: Thrombelastograms of exposure duration of agkistase 
 
 
Effects of incubation time (0-60 min) on 0.1 µg/ml of agkistase on blood clotting. 
Clotting time was significantly prolonged with the increase in incubation time 
(fainter traces), as shown above. It should also be noted that the formation of a 
firm clot was also prolonged and weakened (shifting of traces towards the right). 
The control is depicted by a broken line. 
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3.4.1 Characterisation of the enzymatic properties of agkistase using synthetic 
peptides 
From the previous chapter, it was established that the newly purified agkistase 
from the venom of Agkistrodon halys halys is a medium-sized acidic protein (29 kDa) 
possessing strong proteolytic (hydrolysis of several chromogenic substrates, S-2222, 
S-2238 and S-2302) and defibrinating activities. The short peptide fragment sequences 
obtained showed certain homology to several larger toxins and metalloproteases from 
other reported viper venoms. Given the abundance of similar snake toxins discovered 
and emerging each day (not including other proteins with similar functions isolated 
from other sources), this protein must be sufficiently characterised biochemically and 
enzymatically to ascertain its ‘novelty’ amidst the rest. It is also equally important to 
pinpoint its site of action and stability; its role in venom and mammalian blood 
coagulation upon envenomation; its specific molecular site of action; its overall effects 
on coagulation; and last but not least, its potential as a clinical therapeutic and 
thrombolytic candidate. Hence the in vitro assays described in this chapter were 
designed to classify, characterise and evaluate the purified agkistase for all the 
objectives stated above. 
 
Briefly, these assays were systematically performed in a stepwise elucidation 
of agkistase’s enzymatic effects, followed by tracking its action site and finally 
studying its overall effects on the mammalian blood coagulation cascade. The simplest 
and most specific tripeptide cleavage of chromogenic substrates (3.3.1 Enzymatic 
properties of agkistase) was first carried out to provide a basic speculation on its role 
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in the coagulation system as some information was already obtained during the 
screening and purification phases. With the expansion on the chromogenic substrates 
with cleavage sequences specific for several coagulation factors and the scoring of 
agkistase’s preference towards them (Table 3.2), a rudimentary framework can be 
constructed (Figure 3.22). 
 
Figure 3.22: Schematic diagram of cell-based haemostatic system 
 
Schematic diagram of cell-based haemostatic system emphasises the role of phospholipid 
membrane (   ) with the protein complexes. Extrinsic tenase complex is made up of tissue 
factor (cofactor), factor IX and X (zymogens) and factor VIIa; intrinsic tenase complex is made 
up of light and heavy chain of factor VIIIa (cofactor), factor X (zymogen) and factor IXa; 
prothrombinase complex is made up of light and heavy chain of factor Va (cofactor), factor II 
(zymogen) and factor Xa. 
 
Despite the lack of specificity of these chromogenic substrates to many 
enzymes, they serve as a quick and quantitative measurement for measured enzymes.  
They are used to provide a general lead to the fibrinogenase’s enzymatic target in 
blood coagulation but not as a definitive evaluation of its specificity. The chromogenic 
substrates that agkistase was relatively more active towards are indicated as bold print 
on the figure. The immediate diagram gives an indication of the possible targets for its 
Crosslink Fibrin 
 









































action at the sublevels of FXIIa (S-2302), FXa (S-2238) and plasmin (S-2403) by 
indication that agkistase shares the similar tripeptide sequence preferences with those 
inherent coagulation serine proteases. Interestingly two of the three substrates pointed 
at cleavage sequences of a same molecule (but not necessarily the same molecular site) 
that resides in the fibrinolytic pathway – fibrinogen (or its derivatives)!  It is believed 
that this indication is more than a coincidence as it has long been known that enzymes 
catalyse reactions that are extremely specific. Thrombin and plasmin cleave 
completely different sites on a fibrinogen molecule (Figure 3.23). Will agkistase also 
enzymatically cleave multiple sites on the fibrinogen molecule as suggested by the 
synthetic-substrates tripeptide sequences? On the contrary, the specificity of agkistase 
towards substrate sequence of FXIIa (S-2302) is unlikely to be accurate as FXIIa is 
simply too distant, in the context of the coagulation cascade, from the other two 
sequences. It is postulated that the reason for preferential hydrolysis of the substrate 
was due to the presence of aromatic amino acid, Phe. All three chromogenic substrates 
contain Phe at the 2nd or 3rd position from the cleavage site. This may imply that the 
active site of agkistase is relatively neutral or even hydrophobic. 
 
Figure 3.23: Domain structure of fibrinogen molecule 
 
The trinodular arrangement of the Aα, Bβ, and γ chains, the thrombin 
cleavage sites (IIa) releasing FPA and FPB, as well as the plasmin 
cleavage sites (Pm) yielding Fragment D and Fragment E are shown. 
Adapted from Haematologic Technologies Inc., VT USA. 
(http://www.haemtech.com/Platelet_Proteins/Fibrinogen.htm) 
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3.4.2 Determination of agkistase’s target molecule in plasma coagulation system 
Haemolysis and platelet aggregation assays provided the basis for 
understanding the effects of agkistase on thrombocytes in the plasmatic coagulation. 
The negative results from both assays restrict agkistase effects to only the plasma 
coagulation cascade, which is most widely targeted by snake venom proteins 
(Markland, 1998b). The last component on vessel walls will be discussed in Chapter 
4: In-vivo studies of agkistase in reference to thrombosis and coagulopathy. 
 
Analysis of the effect of agkistase on the plasmatic coagulation component was 
first conducted with three standard clinical assays using the BBL Fibrometer®. Fibrin 
polymerisation was completely inhibited in all three assays with 10 µg of agkistase 
(for a maximum of 5 min) verifying the influence of the proteinase on the converging 
part of coagulation system. A proteinase with target molecules in upstream factors of 
either the intrinsic tenase or extrinsic tenase, or both, would show a prolonged clotting 
time in either the PT or aPTT but rarely both. In the dose-response graphs (Figure 3.6), 
the effect of agkistase on recalcification time had an exponential correlation in protein 
range 0.001 – 0.5 µg/ml; compare with only a slight increase in clotting time up to 10 
µg/ml of crude venom. A similar correlation was observed in thrombin time for both 
crude venom and agkistase but, however, the increase in clotting time was not as rapid 
and sharp. At the same time, there was a marked decrease in fibrin clots present 
(observed as reductions in turbidity, A655) in the final reaction well, especially in those 
with higher concentrations of agkistase. A negative correlation was found when a 
graph of fibrin content against agkistase concentration was plotted (Wolberg et al, 
2002); a similar negative correlation was also noticeable for the crude venom, albeit 
with a gentler slope. This is the first clear evidence that agkistase can either directly or 
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indirectly ‘prevent’ fibrin clot formation and/or ‘remove’ it from detection –  
exhibition of fibrinogenolytic and fibrinolytic activity, respectively. Logically, the 
most direct method to answer the question is to screen for direct and indirect 
fibrinogenolytic and fibrinolytic activities. 
 
3.4.3 Fibrinogenolytic and fibrinolytic assays for agkistase 
Prothrombin activation assay performed showed that agkistase is not an 
activator of prothrombin or an inhibitor of thrombin (Figure 3.7). This served an 
important basis prior to fibrinogenolytic assays as it proved any effect on fibrinogen 
was solely exhibited by agkistase, and not due to prothrombin/thrombin. The most 
compelling evidence that agkistase is a fibrinogenase lies with direct fibrinogenolysis 
and resolution of the digested fibrinogen α- and β-chains on SDS-PAGE gel (Figure 
3.8). The loss of α-chain from the gel was seen as early as 10 min after incubation and 
the subsequent loss of β-chain was seen after 90 min. The α- and β-fibrinogenase rate 
of 15.1 and 0.25 mg min-1 mg prot-1, respectively, was at half the velocity reported for 
another α,β-fibrinogenase from Trimeresurus gramineus (31 and 7, respectively) 
(Ouyang and Huang, 1979). The α,β-fibrinogenase activity of agkistase was 
unaffected by salt (up to 0.8M NaCl) and pH (5 – 9) (Figure 3.10), although it seemed 
that the enzyme activity was slightly better at alkaline pH. The enzyme was shown to 
be a serine protease, and not metalloprotease, by an inhibitory enzymatic assay 
involving synthetic peptides. The active site that cleaved the synthetic peptide was 
correlated to possibly the same active site for fibrinogenase activity through a simple 
demonstration of inhibition by PMSF and aprotinin. 
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Fibrinolytic proteins can either exert their effect by activating plasminogen or 
having innate fibrinolytic active site themselves (Liu et al, 2006; Markland, 1998a; 
Zhang et al, 1995a). To find out if agkistase belonged to the former or latter, several 
fibrinolytic assays and a plasminogen activation test were conducted. Plasminogen 
activation activity was ruled out on agkistase with the amidolytic activity assay (Figure 
3.11). Intriguingly, agkistase demonstrated slight fibrinolytic activity (clot dissolution 
(Figure 3.12) and fibrin plate lysis (Figure 3.13)) but this activity was lost when tested 
upon euglobulin lysis time (Table 3.5). This observation implied the mild fibrinolytic 
activity can only be detected when the regulation of blood coagulation factors are not 
functional. Therefore this fibrinolytic activity is present on the enzyme but may not be 
clinically significant. 
 
3.4.4 Agkistase is a new serine protease 
In the BLAST results from chapter 2 (Figure 2.8), 68% of the similar sequences 
belonged to mainly medium-size (571-620 amino acids) putative P-III snake venom 
metalloproteinases (SVMPs) from Bothrops, Crotalus, Agkistrodon, Deinagkistrodon 
and Echis. Two other smaller SVMPs are scutiarin from Crotalus atrox (177 a.a.) 
(Soto et. al., 2007b) and catroriarin from Crotalus scutulatus scutulatus (175 a.a.) 
(Soto et. al., 2007a). The remaining 32% consists of a platelet-inhibiting 
catrocollastatin precursor from Crotalus atrox (609 a.a.) (Zhou et. al., 1995), a 
disintegrin-like protein from Agkistrodon halys Pallas (212 a.a.) (Liu et. al., 2000), 
two FX-activating enzymes from Daboia russellii siamensis (429 a.a.) (Takeya et. al., 
1992) and Bothrops erythromelas (612 a.a.) (Silva et. al., 2003), as well as a vascular 
apoptosis-inducing protein from Crotalus atrox (607 a.a.) (Masuda et. al., 2006). 
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Surprisingly, the sequence has no homology to snake venom serine proteases (SVSPs) 
– even as low as the lowest score of 42 bits and an E value of 0.023 from BLAST. 
 
With the significant similarities in structure with the SVMPs, one would expect 
agkistase to be a small metalloprotease with fibrinolytic and haemorrhagic properties. 
However, the cumulative results obtained from the synthetic-peptide proteolytic 
assays, in vitro coagulation assays, fibrino(geno)lysis assays and thrombelastography 
reported above showed agkistase to have direct, specific and distinct enzymatic 
activity against one particular molecule in the entire coagulation system – soluble 
fibrinogen. Agkistase has no effects on prothrombin, thrombin, plasminogen, plasmin, 
fibrin clot, erythrocytes, platelets and showed highest amidolytic activities towards 
synthetic substrates for thrombin and plasmin. Most SVMPs are α-fibrinogenases 
whose enzymatic activity can be abolished by common metal chelators like EDTA 
(Markland, 1998a). Although agkistase showed amidolytic and α,β-fibrinogenase 
activity, these were effectively abolished by the serine protease inhibitors, PMSF and 
aprotinin (in contrast to metal chelators)!  It is interesting to note that agkistase is 
structurally similar to SVMPs but enzymatically similar to SVSPs. Moreover, in the 
classification by Markland, SVSPs are commonly thrombin-like enzymes (TLEs) that 
cause abnormal clot fibrinogen, whereas SVMPs are commonly fibrino(geno)lytic 
enzymes that degrade fibrinogen/fibrin and render fibrinogen unclottable by thrombin. 
Agkistase has a sequence similar to SVMPs but showed enzymatic properties which 
are more characteristic of SVSPs.  
 
The absence of fibrinolytic activity further implied its specificity towards 
amino acid sequences residing exclusively in the intact fibrinogen molecule but not in 
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soluble fibrin monomer, after the release of the α- and β-chain of fibrinopeptides by 
thrombin. Hence it is apparent that the recognition sequence of agkistase is either only 
present in the intact fibrinogen molecule but not in the fibrin clot, or its access to the 
cleavage site has been blocked by the conformational changes in the process of fibrin 
formation. It has been shown that thrombin releases four peptides from fibrinogen. 
From the Aα chain, polypeptide A and its analog AP (both consisting of 16 amino 
acids – Ala on the NH2 terminal, Arg on the COOH terminal) and AY (15 amino acids 
– Asp on the NH2 terminal) in a ratio of A:AP:AY of 7:2:1. From the Bβ chain, 
fibrinopeptide B is cleaved in an equimolar amount to fibrinopeptide A. Ewart and 
coworkers first demonstrated that the same three peptides (AP, AY and A) from 
fibrinogen were released by arvin/ancrod (Ewart et. al., 1970). This provided the initial 
evidence that snake venom proteases target the same amino acid sequences hydrolysed 
by α-thrombin during haemostasis. It was further shown that ancrod and batroxobin 
release fibrinopeptides from the α-chain in the same amount and rate as thrombin 
(Blomback et. al., 1966; Ewart et. al., 1970; Holleman and Coen, 1970). These 
molecular cleavage patterns in conjuction with the fact that these proteases clot 
fibrinogen gave them the name ‘thrombin-like’ enzymes (TLE). 
 
The coagulation studies and thrombelastography results showed generalised 
sustained low fibrinogen levels and prolonged anti-clotting condition. In both in vitro 
set ups, there were absence of clotting in prothrombin time, clotting time and thrombin 
time as well as a prolonged clot time (↑r) and decreased clot strength (↓MA) in the 
thrombelastograms. All of these observations are consistent with a typical clinical 
condition of hypofibrinogenaemia. In the exhaustive blood sample (where hydrolysed 
blood factors are not replaceable), soluble fibrinogen was hydrolysed in a competitive 
 88 
manner by indigenous α-thrombin and agkistase. The fibrinogen that was hydrolysed 
by agkistase was rendered unrecognisable and unclottable by thrombin, thereby 
reducing the critical concentration of fibrinogen available for fibrin formation. 
Consequently, this phenomenon explained the observed hypofibrinogenaemia 
condition in both experimental set ups. 
 
No snake venom proteins have been reported with these characteristics. This 
makes agkistase a novel protein and one that is worth studying, especially in terms of 
structure-function relationship, active-site enzyme catalysis and evolution of venom 
proteases. 
 
3.4.5 Clinical implications of α, β-fibrinogenase of agkistase activity 
A complete analysis of the α, β-fibrinogenase activity, with special reference to 
clinical application, in the presence of all plasma coagulation components is first 
established with EC50s for the most common clinical clotting assays – PT, RT and TT. 
In RT and TT, the fibrinogenase has an effective range in the submicrogram region 
whereas in PT, the range was highly increased to microgram region (Figure 3.14). 
 
Thrombelastography is the most comprehensive measurement method to study 
coagulation as it permits the measurement of changes in viscosity and elastic 
properties of the clot during the whole coagulation process under conditions that are 
constant and reproduceable. Many important dynamic processes in blood coagulation 
like clot initiation, clot strengthening, clot deformation and fibrinolysis, which cannot 
be studied previously, are all recorded in a single measurement as they occur 
(Luddington, 2005; Nicola, 1957). The remarkable short turnover time as well as the 
 89 
simplicity of this method has made it possible for monitoring a patient's coagulation 
status while undergoing operation in the theatre.   Since its first introduction by Hartert 
in 1948, this diagnostic method proved to be a valuable tool in haemostasis research 
for many fields, i.e. (i) monitoring blood component during hepatic (Harper et. al., 
1989; Kang et. al., 1985a; Steib et. al., 1994) and cardiac (Cammerer et. al., 2003; 
Moulton et. al., 1996; Royston and von, 2001) surgery, (ii) monitoring obstetrics and 
neonates (Harnett et. al., 2002; Kettner et. al., 2004; Koh et. al., 1993; Orlikowski et. 
al., 1996a; Rai et. al., 2003; Sharma et. al., 1997), (iii) laboratory screening of 
hypercoagulable (Handa et. al., 1997) and hypocoagulable (Sorensen et. al., 2003; 
Yoshioka et. al., 1996) states, (iv) monitoring of pharmacological agents (Barabas et. 
al., 1993; Dambisya et. al., 1995b; Grosse et. al., 1991; Khurana et. al., 1997; 
Summaria, 1995; Walenga et. al., 1991), (v) monitoring of thrombolytic therapy (Koh 
et al, 1993), and (vi) studying of venom effects on human blood coagulation and 
fibrinolysis (Dambisya et al, 1994; Dambisya et. al., 1995a). The paradoxical biphasic 
effects of Calloselasma rhodostoma (Malayan pit viper) venom was ultimately verified 
through a comprehensive evaluation of haemostasis parameters using this technology 
(Dambisya et al, 1994). It has been evaluated against and found to have good 
correlation to laboratory coagulation tests (Gonano et. al., 1998; Kang et. al., 1985; 
Orlikowski et. al., 1996b; Oshita et. al., 1999; Paulissian et. al., 1997; von Kier and 
Royston, 1998; Zambruni et. al., 2004; Zuckerman et. al., 1981). 
 
Both crude venom and agkistase showed responses typical to 
thrombelastograms peformed on haemophilic samples (i.e. prolonged reaction time, r, 
and k value but have a normal MA) and were not affected by addition of Ca2+. 
However it should be noted that crude venom displayed strong anticoagulant activity 
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with the increase of its concentration and exposure time to whole blood while 
agkistase only displayed remarkably strong anticoagulant activity upon prolongation 
of exposure time (max. 60 min) at only concentration of 0.1 µg/ml. It drastically 
prolonged clot initiation and delayed clot formation kinetics, but did not change the 
overall clot strength (Figures 3.19 and 3.21). These thrombelastograms again verified 
the observations made on earlier in vitro assays that agkistase is an anti-clotting         
α,β-fibrinogenase with undetectable or absent platelet aggregation. It also has no effect 
on other blood factors directly affecting fibrin formation and/or lysis in the common 
pathway. This efficiency and specificity make agkistase a good candidate for 
anticoagulant and anti-thrombotic therapy as it will offer cheaper treatment, better 
response and fewer side effects. 
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CHAPTER 4: IN-VIVO STUDIES OF AGKISTASE  




4.1.1 THROMBOSIS AND COAGULOPATHIES 
During the twentieth century, thrombosis was recognised as a major cause of 
morbidity and mortality in the world. A thrombus can partially or fully occlude blood 
vessels, potentially depriving tissues of oxygen and nutritional supply. Thrombosis can 
manifest itself in many ways, including deep vein thrombosis (DVT) and pulmonary 
embolism (PE), known collectively as venous thromboembolism (VTE), thrombotic or 
embolic stroke, and myocardiac infarction (MI). Estimates place the annual incidence 
of VTE in Caucasians in excess of 1 case per 1000 persons (White, 2003); ~1.3-4.1 
persons in 1000 experience a first stroke (Feigin et. al., 2003) and ~5 in 1000 
experience a MI annually (Fang and Alderman, 2002). There are 3 major groups of 
risk factors: (i) blood hypercoagulability (as a result of genotype, cancer, hormone 
changes, surgery, trauma, etc), (ii) blood flow stasis (caused by immobility, atrial 
fibrillation, etc), and (iii) vessel wall damage (such as arteriosclerosis). The risk of 
thrombosis increases dramatically with age, and the total incidence in people 70 years 
or older is 3-5 times higher than the average.  
 
This, however, does not mean that thromboembolism is only common for 
Westerners and Caucasians. The incidence of asymptomatic VTE after major 
orthopaedic surgery in Asians is not low but comparable to rates observed in Western 
countries. In a study conducted in hospitals in Hong Kong, Korea and Philippines 
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between April 2001 and July 2002 involving 2420 patients hospitalised for total hip or 
knee replacement or hip fracture surgery without thrombophylaxis, the rate of 
symptomatic VTE or sudden death as notified by investigators was 2.3% (55 patients) 
and 1.2% (28 patients) (Leizorovicz et. al., 2005), respectively. In Singapore between 
January 1996 and December 1997, there were 338 cases of confirmed DVT, where 320 
patients had acute thrombosis (82.5%) and 68 patients had non-acute thrombosis 
(17.5%) (Lee et. al., 2002). The overall frequency rate of acute DVTs was 15.8 per 
10,000 hospital admissions with 9.2% of patients developing PE. The most frequently 
recorded clinical predispositions were immobilisation (67%), malignancy (33%) and 
recent surgery (30%). The average age of patients was 58.2 years. Clearly, given the 
prevalence and serious consequences of thrombosis, there is a great need for effective 
prophylaxis and treatment. 
 
4.1.2 ANTI-THROMBOTIC AGENTS FROM TOXINS 
Anti-thrombotic agents isolated from toxins, particularly from snake venoms, 
have been studied for more than 40 years. Probably the most notable of such toxins is 
ancrod (also known as Arvin®, Arwin®, Viprinex®; EC 3.4.21.28), a thrombin-like 
enzyme isolated from the venom of Malayan pit viper (Calloselasma rhodostoma; 
formerly Agkistrodon rhodostoma) that induces defibrination following snake bite first 
reported clinically by Reid and coworkers (Reid et. al., 1963). Hence our discussion 
will generally involve it as an example for all other such enzymes. Ancrod was found 
to have no influence on other clotting factors except fibrinogen (Nolan et al, 1976), no 
induction of platelet aggregation or release reaction of platelets, no activation of 
plasminogen nor any direct fibrinolytic activity (Pitney et. al., 1969a). Viprinex® is the 
first thrombin-like enzyme isolated from a snake venom approved by U.S Food and 
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Drug Administration (FDA) on 20th October 1989 to Knoll Pharmaceutical for 
therapeutic treatment of acute ischaemic stroke after a favourable study conducted by 
Stroke Treatment with Ancrod Trial (STAT) (n = 500) involving 48 different medical 
centres. This was a randomized, parallel-group, double-blind, placebo-controlled trial, 
conducted between August 1993 and January 1998 (Sherman et. al., 2000). In addition, 
ancrod is also used for treatment of various other coagulation-related problems like (i) 
deep vein thrombosis, (ii) pulmonary hypertension,  (iii) central retinal and branch vein 
thrombosis, (iv) various embolisms (Kwaan, 1973), (v) ischaemic stroke (Atkinson, 
1997; Atkinson, 1998), (vi) thrombocytopenia and thrombosis (Cole et. al., 1990; 
Lathan and Staggers, 1996; Soutar and Ginsberg, 1993; Yurvati et. al., 1994), and also 
(vii) priapism (Bell, 1997). However, several side effects have been attributed to 
ancrod including haemorrhage, uncontrolled arterial hypertension, uncontrolled 
fibrinolysis and resistance in subjects (Pitney et. al., 1969b). Commonly, patients with 
a history of stroke within the past two months, having an active bleeding lesion, 
haemophilia, von Willebrand's disease, or any other known bleeding tendency will be 
excluded from anti-thrombotic therapy during the pre-screening process. The risk of 
bleeding is also increased in patients who have had biopsies or surgery within the 
previous 10 days; in patients who have advanced renal insufficiency or severe liver 
disease, or a recently active peptic ulcer, or other diseases with a tendency to bleed; 
and in patients who have had recent trauma including surgery and cardiopulmonary 
resuscitation. 
 
Animal studies and clinical trials with ancrod have shown it to promote mild 
fibrinolysis, particularly within small vessels of tissues (Silberman et. al., 1973)  Since 
then the development of defibrinating agents or fibrinogen-depleting agents, enzymes 
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purified from snake venoms like ancrod, have been extended to application in many 
clinical conditions, i.e. thromboembolism (Kwaan, 1973) anti-coagulant therapy 
(Soutar and Ginsberg, 1993), patients with heparin-induced thrombocytopenia and 
thrombosis undergoing coronary artery bypass grafting (Cole et al, 1990; Lathan and 
Staggers, 1996), acute ischaemic stroke (Atkinson, 1997; Atkinson, 1998), and 
heparinless cardiopulmonary bypass (Yurvati et al, 1994). Through these tests, it was 
found that such specific defibrinating enzymes provided an effective means of treating 
clinical coagulopathies as compared to conventional anti-coagulant therapy using 
heparin, warfarin and coumarins, ximelagatran (Exanta; AstraZeneca) or even 
contemporary thrombolytic agents like streptokinases (SK), urokinase (UK), tissue 
plasminogen activator (t-PA), anisoylated plasminogen streptokinase activator 
complex (APSAC) or a combination of them. An approximate 2% incidence of allergic 
reaction occurs with SK and APSAC, with 0.2% being of an anaphylactoid type 
(Sherry, 1992). Aspirin has been used after treatment to reduce the incidence of 
rethrombosis, a risk prevalent among thrombolytic treatment especially for 
recombinant t-PA (rt-PA) therapy. 
 
Thrombolytic therapy is a complicated process involving a lot of patient 
management, i.e. supportive therapy, prevention of thrombus extension and 
embolization, early restoration of blood flow, monitoring possible onset of side effects 
like internal haemorrhage, DIC or associated risks (Sherry, 1992). The most important 
part of initial therapy is aimed at removing the obstructive thrombus to restore 
circulation and return the anatomy and physiology to normal; then secondly, at 
prevention of occurrence. The author of the above book, Sol Sherry, M.D., D.Sc. 
(Hon.), Distinguished Professor of Medicine Emeritus, Temple University School of 
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Medicine, Philadelphia, Pennsylvania, made the following three important conclusions 
for thrombolytic therapy: (i) when it produces major or complete thrombolysis early 
after the onset of the disorder, thrombolytic therapy followed by anticoagulant 
appears to be more effective in preventing late sequelae than treatment with 
anticoagulant alone, (ii) although thrombolytic therapy frequently restores normal 
circulation rapidly and prevents chronic venous hypertension, it is not uniformly 
successful, and (iii) improvements in current therapeutic regimens [in 1992] or in the 
availability of more effective or safer agents [apart from SK and UK with heparin], 
better case selection, and more prompt treatment will be required to improve the 
results of thrombolytic therapy. 
 
Hence the need to search for other potential thrombolytic and/or anti-
thrombotic enzymes, with fewer side effects and high specificity, for such treatment is 
prudent. The race for finding these new, effective drugs is mainly taking two major 
directions – isolation of new proteases from rich natural sources like animal venoms, 
which have evolved and been fine-tuned through the selection process, and molecular 
engineering. We hereby describe the evaluation of our protease, agkistase, isolated and 
purified from the venom of the pit viper Agkistrodon halys halys, on mice to 
understand further its in vivo effects and its potential as a thrombolytic agent against a 
thromboplastin-induced mouse thrombosis model. 
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4.2 METHODS AND MATERIALS 
 
4.2.1 In-vivo Assays and Animal Species 
The in-vivo assays were performed in accordance to protocols approved by 
NUS Institutional Animal Care and Use Committee (NUS-IACUC), project number 
935/05. The training certificate number for proper handling and care of animals is 
155/05. ARC Swiss albino and C57BL strain of mice used in these studies, aged 4-5 
weeks old, weighing about 30 g each, were obtained from the Centre for Animal 
Resources (CARE), Animal Holding Unit, NUS. 
 
4.2.2 Blood Collection and Treatment 
Blood from each anaesthesised mouse was collected by cardiac puncture into 
citrated (0.38%) tubes, immediately placed on ice and kept separately. Within an hour, 
the blood was fractionated into plasma and blood cells by centrifugation (100 g,        
10 min). The plasma was used for thrombin time, platelet count and/or D-dimer assays 
as indicated. 
 
4.2.3 Microplate-based Coagulation Assay 
Microplate-based coagulation assays were adapted from the respective 
established coagulation assays, e.g. TT, PT, etc, by scaling down the requirement of 
both test sample and collected plasma. The changes in turbidity of plasma content, 
which directly corresponds to the amount of fibrin clot formation, was continually 
monitored on a microplate reader (BioRad, model 680) with accompanying software 
Microplate Manager 5.2 at 37oC, 655 nm for 60 min. Triplicates of reaction wells 
were performed and results obtained were compared to a standard curve of fibrin clot. 
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4.2.4 D-Dimer (DD) Assay 
Coamatic® D-dimer (Chromogenix, Italy) assay is a latex enhanced 
immunoassay for the quantitative determination of D-dimer in human citrated plasma 
for detection of a neoantigen (D-dimer domain) on soluble fibrin degradation product 
with a mouse monoclonal antibody (MA-8D3). This agglutination assay, which 
measures elevated levels of D-dimer found in clinical conditions such as deep vein 
thrombosis, pulmonary embolism and disseminated intravascular coagulation, is 
becoming a widespread tool for diagnosing thrombosis and monitoring thrombolytic 
therapy. The assay was performed in accordance to the manufacturer’s specifications. 
Briefly, various dilutions of citrated plasma were incubated with equivolume of latex 
reagent for 30 min at room temperature. Readings were then taken at 405 nm. The 
degree of agglutination, which is directly proportional to the concentration of D-dimer 
in the sample, was determined from a calibration curve. 
 
4.2.5 Platelet count 
Plasma collected was serially diluted with sterile 0.9% sodium chloride 
solution, loaded onto a haemacytometer and counted under a high magnification 
microscope (Olympus, CH-2) in triplicates. 
 
4.2.6 Collection and Histological Sectioning of Organs 
Major organs, namely heart, lungs, liver, kidneys and spleen, were examined, 
removed from sacrificed animal, rinsed and fixed in formalin (10% formaldehyde) for 
at least 12 hours. Fixed organs were dehydrated by immersing into the following 
chemicals sequentially for 30 min each – 50% ethanol, 70% ethanol, 80% ethanol, 
90% ethanol, 100% ethanol, 100% ethanol, 1:1 ethanol:toluene, and two washes of 
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toluene. Dehydrated organs were embedded into paraffin blocks, which were then 
mounted on a rotary microtome (Leica RM2165, Leica Microsystems Nussloch 
GmbH, Germany). Trimming of tissues was done at 12 µm thickness whereas cutting 
was done at 5 µm. Care was taken to produce at least 5 slides for each staining from 
different sections of each organ, i.e. proximal, median and distal. Histological sections 
were dewaxed for 30 min in each of the following solvents sequentially: 
xylene/histoclear 1, xylene/histoclear 2, xylene/histoclear:alcohol (50:50), absolute 
alcohol 1, absolute alcohol 2, 90% alcohol, 70% alcohol, 50% alcohol and deionised 
water. 
 
4.2.6.1 Haematoxylin and Eosin (H&E) Staining 
Dewaxed histological slides were stained with H&E by the following steps 
sequentially: 
1. Shandon’s haematoxylin 10 min 
2. deionised water rinse 
3. Differentiating fluid (0.25% HCl in 70% alcohol) 30 sec 
4. deionised water rinse 
5. tap water (blue-ing) 15 min 
6. deionised water rinse 
7. Eosin (1%) 15 min 
8. 90% ethanol rinse 
9. 100% ethanol rinse 
10. 100% ethanol rinse 
11. xylene/ histoclear 1 rinse 
12. xylene/ histoclear 2 rinse 
13. xylene/ histoclear 3 rinse 
14. Permount with coverslip  
 
4.2.6.2 Masson’s Trichrome Staining (MTS) 
Dewaxed histological slides were stained with MTS by the following steps 
sequentially: 
1. Shandon’s haematoxylin 15 min 
2. deionised water rinse 
3. Differentiating fluid (0.25% HCl in 70% alcohol) 30 sec 
4. deionised water rinse 
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5. tap water (blue-ing) 15 min 
6. deionised water rinse 
7. Ponceau Red (1%) in 1% acetic acid 2 min 
8. tap water rinse 
9. phosphomolybdic acid (1%) 20 min 
10. Fast Green stain (0.2%) in 0.2% acetic acid 10 min 
11. 90% ethanol rinse 
12. 100% ethanol rinse 
13. 100% ethanol rinse 
14. xylene/ histoclear 1 rinse 
15. xylene/ histoclear 2 rinse 
16. xylene/ histoclear 3 rinse 
17. Permount with coverslip  
 
4.2.6.3 Microscopy and Histological Pictures 
Histological pictures were taken with different magnifications (4X, 10X, 40X 
and 100X; objective lense) on an Olympus BX60 microscope (Olympus Optical Co. 
GmbH, Hamburg, Germany) attached to a computer installed with Image Pro-Plus 
Analysis software (Media Cybernetics, Inc., Silver Spring, MD 20910-5611 USA) 
 
4.2.6.4 Data Processing and Statistical Analyses 
All statistical analysis of data (t-tests, ANOVA, etc) was performed using 
GraphPad Prism 4.0 software (GraphPad Software, Inc., San Diego, CA 92130 USA). 
 
4.2.7 In-vivo Haemorrhagic Effects and Systemic Toxicity 
C57BL mice were separated into 3 groups (n = 6, per group). Group 1 was 
injected with 50 µg (1.67 mg/kg) of venom, group 2 was injected with 50 µg         
(1.67 mg/kg) of agkistase and group 3 was injected with sterile saline (control). All 
injections were performed intravenously and mice were sacrificed after 24 hours. 
Citrated mouse blood was collected by terminal cardiac puncture, pooled and assayed 
for various disseminated intravascular coagulation (DIC) indicators – TT, PT, RT, DD 
and platelet count. Organs of the mice were examined and extracted for histological 
analysis. 
 100 
4.2.8 In-vivo Effects of Agkistase Concentration 
Groups of six C57BL mice were subjected to intravenous injections of 
agkistase at concentrations of 0, 1, 5, 10, 50 and 100 ng per kg of mouse. The mice 
were then kept at a cool, dark place with free access to food and water. At 3 hours 
post-injection, the mice were anaesthesised with intraperitoneal injections of 1 mg/kg 
medetomidine and 75 mg/kg ketamine cocktail (0.1 ml per 10 g mouse). The toe pinch 
method was used to determine whether mice were in deep anaesthesia and ready for 
exsanguination. Blood from each mouse was extracted through cardiac puncture with a 
22½-inch gauge needle fixed onto a 5 ml syringe prefilled with 0.38% citrate solution 
as described in 4.2.2 Blood Collection and Treatment above. Blood collected from 
these mice was used to assay for TT and platelet counts. The five organs were then 
surgically removed, rinsed and placed into formalin as described in 4.2.6 Collection 
and Histological Sectioning of Organs above, prior to the appropriate staining. 
 
4.2.9 In-vivo effects of Agkistase Exposure Time 
Groups of six C57BL mice were subjected to intravenous injections of 
agkistase at concentrations of 50 ng/kg per mouse. The mice were then kept in a cool, 
dark place with free access to food and water. The mice were anaesthesised with 
intraperitoneal injections of 1 mg/kg medetomidine and 75 mg/kg ketamine cocktail 
(0.1 ml per 10 g mouse) 0, 3, 5, 7, 9 and 11 hours after injection with agkistase. The 
toe pinch method was used to determine whether mice were in deep anaesthesia and 
ready for exsanguination. Blood from each mouse was extracted through cardiac 
puncture with a 22½-inch gauge needle fixed onto a 5 ml syringe prefilled with 0.38% 
citrate solution as described in 4.2.2 Blood Collection and Treatment above. Blood 
collected from these mice was used to assay for TT and platelet counts. The five 
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organs were then surgically removed, rinsed and placed into formalin as described in 
Collection and Histological Sectioning of Organs above, prior to the appropriate 
staining. 
 
4.2.10 Thromboembolic Model Challenge 
Forty eight C57BL mice were subjected to intravenous injections of 20 ng/kg 
thromboplastin and exposed for 24 hours to induce clinical symptoms of thrombosis 
and DIC. Subsequently these mice were separated randomly into 2 groups of 24 each. 
One group was subjected to a single intravenous injection of 50 ng/kg agkistase, which 
we termed as TMAG; whereas the other group was subjected to a single intravenous 
injection of sterile 0.9% saline for control, which we termed as TMC. The mice were 
then kept in a cool, dark place with free access to food and water. At 5, 24, 48 and 72 
hours post-injection, six mice from each group were anaesthesised with intraperitoneal 
injections of 1 mg/kg medetomidine and 75 mg/kg ketamine cocktail (0.1 ml per 10 g 
mouse) sequentially. The toe pinch method was used to determine whether mice were 
in deep anaesthesia and ready for exsanguination. Blood from each mouse was 
extracted through cardiac puncture with a 22½-inch gauge needle fixed onto a 5 ml 
syringe prefilled with 0.38% citrate solution as described in Blood Collection and 
Treatment above. Blood taken from this set of experiments was used for determination 
of TT and D-dimer levels. The five organs were then surgically removed, rinsed and 
placed into formalin as described in Collection and Histological Sectioning of Organs 
above, prior to the appropriate staining. 
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4.3 DATA AND RESULTS 
 
4.3.1 In-vivo Haemorrhagic Effects and Systemic Toxicity 
Mice C57BL and ARC Swiss albino were used to determine any haemorrhagic 
effects and systemic toxicity that may be associated side effects with internal 
administration of a direct-coagulation affecting venom and its protease. ARC Swiss is 
a ‘general purpose’ mouse recommended for dissection and any work not requiring the 
special qualities of inbred strains. It provides a good assessment of general systemic 
defects and highly contrastic haemorrhages, if present, due to its colour. C57BL is a 
widely used species in coagulation model studies worldwide (Hogan et. al., 2002) due 
to the characteristics of its various mutant genes (eg. nude, beige, etc) as well as 
having very low incidence of mammary tumours, its resistance to toxic effect of 
chloroform, its high rate of spontaneous mutations at the agouti and W loci. It is also 
susceptible to the development of atheromatous lesions after 20 weeks on high fat 
diets, development of non-insulin-dependent diabetes mellitus and hypertension when 
fed high fat, high simple carbohydrate diet. 
A high dosage of approximately 1.67 mg/kg (about 50 µg per mouse) of either 
the venom of Agkistrodon halys halys or the purified agkistase was injected 
intravenously. The venom-injected mice showed signs of distress, i.e. unresponsive, 
lethargic, over-grooming, uncontrollable convulsion, disorientation as well as hyper-
ventilating right after administration, and had a 33% mortality rate (n = 6). The 
agkistase-injected mice appeared healthy, without any symptoms of distress, after 
administration and zero mortality. Pathologic investigations further revealed that the 
venom caused massive internal haemorrhage (Figure 4.1), which could be the main 
cause of mortality.  
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Figure 4.1: Haemorrhagic effect and systemic toxicity of Agkistrodon venom and agkistase 
 
Representative pictures showing the haemorrhagic effects of Agkistrodon halys halys venom 
and agkistase (intravenously injected) on systemic organs. A, Arrow indicating the absence of 
haemorrhage on tail of Swiss albino mouse injected with 1.67 mg/kg agkistase; B, Arrow 
indicating haemorrhage on tail of Swiss albino mouse injected with 1.67 mg/kg venom; C, 
Massive haemorrhage in lungs extracted from mouse injected with 1.67 mg/kg venom; D, 
Dissected C57BL mouse injected with 1.67 mg/kg agkistase, with exposed abdomen, showing 
absence of internal haemorrhage. No haemorrhagic nor systemic toxicity were observed in all 
injected mice for agkistase. 
 
Organs removed from both groups of mice were sectioned and stained with 
haematoxylin and eosin (H&E) (Figure 4.2) for histopathologic studies. Thrombi 
formation was found in more than half of all the obstructed vessels, in all five organs, 
viewed under the microscope for venom-injected mice. The vessels observed 
harboured different stages of occlusion, ranging from scattered initial deposition of 
fibrin clots to predominant large thrombi, almost complete obstruction of blood flow. 
For example, figure 4.2A showed an initial deposit of fibrin clot in the heart, which 
may serve as a 'seed' for further propagation of a thrombus when given enough time 
with the right condition; figure 4.2B showed two blood vessels in the lungs, where one 
was partially (upper arrow) whereas the other was fully obstructed (lower arrow). 
These histological sections clearly illustrated the widely reported clinical symptoms of 
venom coagulopathy, commonly manifesting as DVT, PE, VTE and DIC (Boyer et. 





Figure 4.2: Histological sections of mouse organs injected with venom under 
haematoxylin and eosin staining (H&E) 
 
Haematoxylin and eosin-stained histological sections showing visible thrombi 
formation (as indicated by arrows) for mice injected with venom. A, heart 
100X (magnification); B, lung 100X; C, kidney 400X; D, spleen 400X. 
 
However, it was fairly difficult to study the exact detailed composition of the 
obstructing bolus as the red eosin stain picked up by fibrin clots was almost 
indistinguishable from its surrounding tissues as well as any presence of attached 
hemoglobins and platelets. Masson’s Trichrome stain (MTS) was subsequently 
selected to circumvent the problem. It provided remarkable contrast between fibrin and 
connective tissues, which stain green (by Fast green stain), and surrounding tissues, 
which commonly stain red (by Ponceau Red), as verified by Figure 4.3 below. With 
this stain, the degree of thrombus formation as well as the extent of fibrin and platelet 
contribution could be determined. We were also able to differentiate between a 
thrombus or embolus formed within a vessel and a fibrous plaque formed during a 
wound healing process. Under MTS, histological sections from the same organs, 
revealed additional information not discernible by H&E stain previously. Partial and 
complete obstruction of vessels by advanced stage thrombi (Figure 4.3 C, D and E) 




mesh (Figure 4.3 A and B) in many other vessels, possibly the onset for vascular 
obstruction. Such phenomenon was also found in agkistase-injected mice albeit with 
much lower distribution. Figure 4.3F presented a massive thrombus formation in a 
ventricular heart chamber and Figure 4.3I presented an initiation of fibin clot 
formation inside a microvascular vessel in kidney. There were no vascular obstruction 
seen for most of the other organs (Figure 4.3 G, H and J). Nevertheless these 
seemingly disadvantageous haemostatic effects of agkistase in vivo must be interpreted 
with prudence as the injected concentration of 1.67 mg/kg was 1.2 times (calculation 
based on 15.4% of total dry venom protein mass in Table 2.4: Purification table of 
agkistase, Chapter 2) beyond its reported average LD50 value (Agkistrodon halys) of 
9.2 µg/g (Latifi, 1984). Hence it would be more meaningful to study such effects of 
agkistase in the range of its appropriate therapeutic concentrations. 
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Figure 4.3: Histological sections of mouse organs injected with venom and agkistase under 
Masson’s trichrome staining (MTS) 
 
 
Masson's Trichrome-stained histological sections showing visible thrombi formation (as 
indicated by arrows) for mice injected with venom (A, heart 200X; B, lung 200X; C, liver 
400X; D, kidney 400X; E, spleen 400X) and agkistase (F, heart 400X; G, lung 400X; H, liver 











4.3.2 In-vivo Studies of Agkistase Effects on Administrative Concentration and 
Exposure Time 
 
The following animal assays were performed using agkistase on C57BL mice 
alone as described in 4.2.1 In-vivo Assays and Animal Species. All concentrations of 
agkistase (0, 1, 5, 10, 50 and 100 ng/kg) injected intravenously through the tail vein 
did not cause any visible haemorrhage to mice for the duration (0, 3, 5, 7, 9, 11 hours) 
of the assays. The mice also did not show any symptoms of discomfort, pain, 
disorientation nor abnormal behavioural changes as described above (for venom). 
Upon sacrificing, visible inspection of collected blood and removed organs were 
normal and healthy, and similar to those of control mice (data not shown). The 
thrombin time (TT) and platelet count performed on the plasma collected for the 
effects of agkistase concentrations on mice are presented in Figure 4.4, which showed 
a concentration-dependent prolongation of clotting time beginning with agkistase 
dosage of 50 ng/kg, without any symptoms of thrombocytopenia. At a dosage of 100 
ng/kg, the TT measured was almost 10 times delayed compared with the mean of 
control values. In order to further understand the absolute circulating fibrinogen 
content, a standard correlation graph with thrombin-clotted fibrinogen was contructed 
and absorbances measured for fibrin clots were intrapolated to their respective 
estimated fibrinogen concentrations (Figure 4.5). The data obtained thus showed an 
exponential decrease in fibrinogen content from 177 mg/dL down to 5 mg/dL with 
increase of agkistase exposure, further verifying the in vitro fibrinogenase activity of 
agkistase. 
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Figure 4.4: Concentration-dependent effects of agkistase 
 
 Platelet counts (x108 /ml) 
agkistase (ng/kg mouse) 0 1 5 10 50 100 
Mean 0.63 0.66 0.83 0.80 0.63 0.69 
S.E. - ±0.05 ±0.06 ±0.05 ±0.04 ±0.03 
 
Graph depicting the concentration-dependent effects of agkistase on 
mice (n = 6) after 3 hours administration. No significant changes in 
thrombin time was observed from dosages 1-10 ng/kg, when compared 
to saline control, but a sharp increase occurred at higher dosages from 
50-100 ng/kg (p value, two-tailed = 0.0156). Thrombin time at dosage 
100 ng/kg (23.1 min) was almost 10 times longer than the mean of 
control value (2.4 min). The table above showed no significant changes 
in platelet counts for all the dosages administered. 
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Figure 4.5: Depletion of circulating fibrinogen with increasing 
concentration of agkistase 
 
Graph depicting the effects of agkistase dosage on estimated 
soluble circulating fibrinogen in mice after 3 hours administration 
(p value, two-tailed = 0.0066). Embedded graph correlated 
absorbance measured for fibrin clot (655 nm) to estimated soluble 
fibrinogen concentration in circulation. Linear range was found to 
be from 0.05-0.8 µg per 200 µl (0.25-4 µg/ml). R2 for the fitting 
curve was 0.9999. 
 
Aside from the effect of different concentration of agkistase on mice after 3 
hours, it is also important to determine whether prolonged exposure to agkistase will 
trigger any undesirable consequences, e.g. DIC, as well as the duration of its effects on 
circulation, in particular. Mice exposed to agkistase over a period of 0, 3, 5, 7, 9 and 
11 hours had their TT prolonged maximally greater than 7 fold after 5 hours and 
gradually normalised over a longer period (Figure 4.6). The estimated fibrinogen 
concentration dropped from 177 mg/dL to a lowest of 13.5 mg/dL after 5 hours of 
agkistase administration. For comparison, the estimated concentration of fibrinogen 
for the previous experiment in Figure 4.4 of same agkistase dosage over 3 hours had a 
value of 9.1 mg/dL. 
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Figure 4.6: Time-dependent effects of agkistase 
 
 Platelet counts (x108 /ml) 
agkistase (hr administration) 0 3 5 7 9 11 
Mean 0.63 0.73 1.97 0.90 3.34 1.21 
S.E. - ±0.03 ±0.80 ±0.06 ±1.37 ±0.14 
 
Graph depicting the time-dependent effects of agkistase (50 ng/kg) on mice 
(n = 6). A sharp rise in thrombin time, from an average control value of 2.4 
min, was observed up to 5 hours after agkistase administration (18.3 min), 
which gradually levelled off until 11 hours (6.9 min) (p value, two-tailed = 
0.0049). The table showed an elevation in platelet counts particularly after 5, 
9 and 11 hours after agkistase administration to about 3.1, 5.3 and 1.9 times 
above the average control value (2.4 min), respectively. 
 
Histopathological analyses of mouse organs for both sets of experiments are 
listed in Figure 4.7 to Figure 4.16. Note that mild thrombi formation were present in 
some of the organ vessels, however, these appeared non-symptomatic and were most 
likely not detrimental nor causing lasting effects on mice. In the later photographs for 
time-dependent effects, the reduction and disappearance of these thrombi were evident 
as exposure time increased. These results established the effective dosage and 
exposure time for the following mouse thrombosis model challenge to determine the 
suitability of agkistase for use as an anti-thrombotic agent. 
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A, Saline control (0 ng/kg), 400X, an almost completely occluded vessel; B, 1 ng/kg, 100X, 
large fibrin clot with erythrocytes deposition at a corner; C, 5 ng/kg, 400X, a small fibrin clot 
formation; D, 10 ng/kg, 40X, fibrin clot with erythrocytes; E, 50 ng/kg, 200X, scattered small 
fibrin clots with erythrocytes; F, 100 ng/kg, 200X, an almost completely occluded vessel. 










A, Saline control (0 ng/kg), 100X, no thrombus present; B, 1 ng/kg, 100X, tiny fibrin clot in 
vein; C, 5 ng/kg, 100X, no thrombus present; D, 10 ng/kg, 200X, visible thrombus in vessel; 
E, 50 ng/kg, 100X, thrombi present in vessels as indicated; F, 100 ng/kg, 40X, no thrombus 









A, Saline control (0 ng/kg), 100X, no thrombus present; B, 1 ng/kg, 100X, several thrombi in 
smaller vessels; C, 5 ng/kg, 100X, initial deposition of 'loose' thrombi; D, 10 ng/kg, 100X, 
initiation of a thrombus formation; E, 50 ng/kg, 100X, no thrombus present; F, 100 ng/kg, 












A, Saline control (0 ng/kg), 100X, several thrombi present in smaller vessels; B, 1 ng/kg, 40X, 
thrombus seen in nephritic glomerulus; C, 5 ng/kg, 100X, no thrombus present; D, 10 ng/kg, 
100X, no thrombus present; E, 50 ng/kg, 100X, thrombi present in vessels as indicated;        









A, Saline control (0 ng/kg), 200X, no thrombus present; B, 1 ng/kg, 200X, no thrombus 
present; C, 5 ng/kg, 100X, no thrombus present; D, 10 ng/kg, 200X, no thrombus present;   












A, Saline control, 40X, a small thrombus forming at the side of cardiac wall; B, 3 hr, 100X, 
possible small emboli in cardiac chamber; C, 5 hr, 40X, large thrombi formations; D, 7 hr, 40X, 
independent large thrombi formations in separate heart chambers; E, 9 hr, 40X, no thrombus 













A, Saline control, 200X, no thrombus present; B, 3 hr, 100X, two small thrombi as indicated; 
C, 5 hr, 40X, no thrombus present; D, 7 hr, 40X, no thrombus present; E, 9 hr, 40X, initiation 
of thrombi observed; F, 11 hr, 100X, no thrombus present. Visible thrombus formation is 












A, Saline control, 100X, tiny fibrin clot forming in vessels; B, 3 hr, 100X, embolus or partially 
obstructed vessel with thrombus; C, 5 hr, 40X, thrombus in one of large vessels; D, 7 hr, 40X, 
thrombus partially obstructing vessel; E, 9 hr, 100X, no thrombus present; F, 11 hr, 100X, no 












A, Saline control, 100X, thrombi found in glomeruli and capillaries; B, 3 hr, 40X, thrombi 
present in few gromeruli; C, 5 hr, 40X, thrombus in glomerulus; D, 7 hr, 40X, thrombus 
partially obstructing a vessel; E, 9 hr, 40X, many thrombi found in vessels and glomeruli;      












A, Saline control, 100X, no thrombus present; B, 3 hr, 40X, no thrombus present; C, 5 hr, 
100X, no thrombus present; D, 7 hr, 100X, no thrombus present; E, 9 hr, 200X, no thrombus 





4.3.3 Thromboembolic challenge and clinical therapeutic evaluation of agkistase 
Two sets of mice were used in this experiment. One set, in groups of 6, were 
intravenously injected with 20 ng/kg thromboplastin for 24 hours prior to challenging 
with 50 ng/kg agkistase (determined from 4.3.2 In-vivo Studies of Agkistase Effects on 
Administrative Concentration and Exposure Time) for 5, 24, 48 and 72 hours. The 
other set of mice were challenged with sterile 0.9% saline as control. The D-dimer 
levels determined from collected mice plasma are shown in Figure 4.17. The 'basal'   
D-dimer levels after induction by thromboplastin averaged about 4 µg/ml, maintaining 
its level for up to 72 hours. This level dropped steadily upon intravenous injection of 
agkistase down to a low of 1.3 µg/ml, 48 hours after injection, but quickly increased to 
almost its original level within the next 24 hours. This was a significant change and 
implied improvement on the circulation from induced thrombosis. However, no 
confirmation can be certain without data from histopathological sections of the mouse 
organs. 
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Figure 4.17: Mouse thromboembolic model challenge 
 
Graph depicting the changes in D-dimer measured in thrombosis model mice 
(n = 6) for saline control ( - - - ) and agkistase-challenged (50 ng/kg)          
( –––– ) after 5, 24, 48 and 72 hours of administration. D-dimer levels 
remained constant at around 3.9±0.6 µg/ml throughout 72 hours after 
control saline challenge. In agkistase-challenged group, the level of D-dimer 
dropped to a lowest point (1.3±0.5 µg/ml) after 48 hours and climbed back 
to the original level (3.4±0.4 µg/ml) after 72 hours of administration. The 
significance of 48-hour treatment point against others was statistically 
analysed by ANOVA (p value < 0.0001) and Bonferroni’s Multiple 
Comparison Test (p value < 0.001). 
 
The mouse organs collected were fixed, sectioned and stained to examine for 
any effects on their thrombosis state, as induced by thromboplastin. Treatment with 
agkistase generally resulted in good prognosis of the condition. 
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Figure 4.18: Heart sections (mouse thrombosis model challenge) 
 
A, 24 hr saline control, 40X, large thrombus (possibly embolus); B, 24 hr agkistase-treated, 
40X, large thrombus with massive fibrin structure; C, 48 hr saline control, 40X, fibrin clot 
sealed off heart chamber; D, 48 hr agkistase-treated, 40X, large thrombus lodged at cardiac 
wall; E, 72 hr saline control, 40X, large thrombus (possibly embolus); F, 72 hr agkistase-
treated, 40X, long fibrin mesh with trapped erythrocytes and presumably platelets. Visible 









A, 24 hr saline control, 40X, massive thrombus; B, 24 hr agkistase-treated, 40X, thrombus 
formation; C, 48 hr saline control, 100X, thrombi forming in various inter-aveoli 
compartments; D, 48 hr agkistase-treated, 40X, thrombi forming in inter-aveoli compartments; 
E, 72 hr saline control, 100X, necrosis of aveoli leading to haemorrhage (pulmonary 
embolism); F, 72 hr agkistase-treated, 40X, greatly reduced necrosis, confined to a small 
anterior part (indicated by arrow ); presence of thrombi still detected. Visible thrombus 












A, 24 hr saline control, 40X, thrombi present in most vessels; B, 24 hr agkistase-treated, 40X, 
thrombi present in most vessels; C, 48 hr saline control, 40X, completely obstructed vessels 
with thrombi; D, 48 hr agkistase-treated, 40X, obstruction still present but several vessels 
have been cleared; E, 72 hr saline control, 100X, obstruction still prevalent; F, 72 hr 
agkistase-treated, 100X, all vessels almost cleared of obstruction except the partially clogged, 












A, 24 hr saline control, 100X, thrombi present in most vessels; B, 24 hr agkistase-treated, 
100X, partially and completely obstructed vessels; C, 48 hr saline control, 100X, thrombi 
present in most vessels; D, 48 hr agkistase-treated, 100X, thrombi clearing from large vessels; 
E, 72 hr saline control, 100X, complete obstruction still present in most vessels; F, 72 hr 
agkistase-treated, 100X, most large vessels were cleared of obstruction; smaller vessels 












A, 24 hr saline control, 100X; B, 24 hr agkistase-treated, 100X; C, 48 hr saline control, 100X; 
D, 48 hr agkistase-treated, 100X; E, 72 hr saline control, 100X; F, 72 hr agkistase-treated, 







The laboratory mouse, Mus domesticus domesticus (previously Mus musculus 
dometicus) is an excellent subject for in vivo studies, with hundreds of inbred strains  
(Festing, 1993), due to the many advantages it confers:- (i) small and easy to 
manipulate, (ii) inexpensive to maintain, (iii) requires minimal space for upkeep, (iv) 
short reproductive cycle, short life span and prolific breeder, (v) better physiologically 
and genetically defined than any other species, and (v) there is already an enormous 
amount of literature published concerning it. Mouse models in coagulation are very 
extensively developed and robustly evaluated. The phenotypes they exhibit, which 
deficiencies are also found in human, include gene mutation alteration(s)/deficiencies 
in coagulation factors II, V, VII, VIII, IX, X, XI and tissue factor (TF) (promoting 
thrombin formation); gene mutation alteration(s)/deficiencies in fibrinogen (Fbg), 
fibrinogen motif bound by integrin alpha IIb beta 3 (γ∆5 Fbg), elevated fibrinogen and 
von Willebrand factor (vWF) (clot formation); as well as gene mutation 
alteration(s)/deficiencies in tissue factor pathway inhibitor (TFPI), thrombomodulin 
(TM and TM Pro/Pro), protein C (PC), factor V Leiden (FV Leiden), anti-thrombin III 
(AT III) and protein Z (PZ) (Hogan et al, 2002). From these models, it was found that 
the prethrombotic state mice generated by a targeted point mutation in 
thrombomodulin (Weiler et. al., 2001a; Weiler, 2004b; Weiler-Guettler et. al., 1998) 
can serve as the most accurate model to study the development and/or removal of 
thrombosis. Briefly this single amino acid substitution (Glu-404  Pro) in 
thrombomodulin gene dissociates the developmental function of the receptor from its 
role as a regulator of blood coagulation, whereby homozygous mutant mice have 
severely reduced capacity to generate activated protein C or inhibit thrombin develop 
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to term causing increased fibrin deposition in selected organs as well as defects in 
fibrinolysis (Weiler et. al., 2001b; Weiler-Guettler et al, 1998). Unfortunately, our 
discussion to acquire the mouse strain from Dr Weiler, which was positive initially, 
was abruptly terminated, presumably due to conflict of interest. 
 
Consequently we decided to chemically induce a thrombotic state in mice 
C57BL by intravenous injection of thromboplastin to create clinical symptoms of 
thromboembolism and disseminated intravascular coagulation in adaptation from a 
similar rat model reported by Bernat (Bernat et. al., 1994). In our adapted model, 
histological sections of mouse organs showed extensive formation of thrombi in heart 
(Figure 4.18), lung (Figure 4.19), liver (Figure 4.20) and spleen (Figure 4.22) upon 
induction with thromboplastin, which demonstrated the success of our own model. 
However, thrombi formation in the heart has to be evaluated with prudence because of 
the experimental procedure involved, it might be a direct result of cardiac puncture 
conducted on mice during blood withdrawal. In which case, it will be an experimental 
artifact rather than a direct cause of induced coagulopathy. This speculation is 
supported by the presence of thrombi in all the heart samples of control mice, 
regardless of treatment with thromboplastin, venom or agkistase. These thrombi 
formation is unlikely the direct cause of cell fixation, although perfusion fixation 
would be a better method, because: (i) the mice were exsanguinated leaving little or no 
blood residue in the vessels, (ii) the presence of thrombi in the organs is not evenly 
distributed as one would expect in artefact, (iii) spontaneous thrombosis normally 
forms in smaller vessels where blood flow is more sluggish, and (iv) the organs of 
thromboplastin-treated and non-thromboplastin treated sections showed different 
severity of thrombosis. 
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It has long been known viper and pit viper snake envenomation can cause life-
threatening coagulopathies to their victims. These conditions are even reported to 
intensify into recurrent and persistent coagulopathy, in non-lethal instances to a high 
percentage (53%) of snakebite patients (Boyer et al, 1999), possibly leading to 
secondary complications like thrombocytopenia, hypofibrinogenaemia, internal 
haemorrhage and DIC, which manifest into clinical symptoms of renal damage, venous 
thrombosis, myocardiac infarction and multiple organ failure. Snakebite is not an 
uncommon cause of acute renal failure in developing countries, with reported 
incidences of 1.4%-28% between 1960s ~ 1980s (Basu et. al., 1977; Chugh et. al., 
1984; Reid, 1961; Seedat et. al., 1974; Steinbeck, 1960). This pathological symptoms 
of renal necrosis is hardly surprising as severe snake envenomation has long been 
linked to acute renal failure, a leading cause of mortality in such patients (Aung-Khin, 
1978). Such symptoms were also observed for mice kidneys injected with 1.7 mg/kg of 
Agkistrodon halys halys venom (Figure 4.23) but not those injected with agkistase. 
The exact mechanisms of renal failure due to snake envenomation is currently 
unknown although many hypotheses are available (Karthik and Phadke, 2004; Sitprija 
and Chaiyabutr, 1999). From our histopathological results, it is apparent that the likely 
cause of this may be due to microvessel occlusion by thombi or emboli leading to 
ischaemic damage to tissues distal to the obstruction site thereby depriving 
downstream tissues of oxygen and nutrient. These tissues are slowly ‘starved’ by the 
blockade presumably undergoing necrosis and lysis hence propagating further damage 
to their surrounding tissues. Alternatively acute renal failure can also be caused by 
direct nephrotoxicity agents that may be present in the venom of Agkistrodon halys 
halys as other such toxins from viperids have been reported (Ratcliffe et. al., 1989; 
Schneemann et. al., 2004; Swe et. al., 1997). Comparing the histopathological pictures 
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of mouse kidney on effects of agkistase dosage (Figure 4.10) and exposure (Figure 
4.15), it can be seen that symptoms for tissue necrosis were more prominent in mouse 
kidney after prolonged exposure (11 hours after injection) distal from several 
completely occluded vessels but not immediately observable from increased dosage 
(100 ng/kg). It should also be noted that necrotic tissues were only seen in the vicinity 
of occluded vessels and not widespread throughout arterial vessels where toxins, or 
any toxic metabolites, first come into contact with renal tissues. These suggested the 
necrosis developed over a substantial period of time and was not a direct result of toxic 
effect – which we believe is the symptoms of a secondary effect of disseminated 
intravascular coagulation. 
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Figure 4.23: Histological sections of necrotic kidney from venom-injected mice 
Different 
 
Conventional anti-coagulants, particularly heparin, were found to affect directly 
or indirectly almost every plasmatic coagulation factors, protease inhibitors, cofactors 
as well as components of vessel wall and hematocytes. In contrast, isolated snake 
toxins often have a more restricted effect. For example, ancrod was found to have no 




Increasing magnifications of kidney sections from venom-injected mice showing renal 
vein thrombosis accompanied by cellular necrosis. Note that the regular structure of 
glomerulus, tubules and tissues were indistinguishable. A, 40X; B, 40X; C, 100X;       
D, 200X; E, 400X; F, 400X. 
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induction of platelet aggregation or release reaction of platelets, no activation of 
plasminogen nor any direct fibrinolytic activity (Pitney et al, 1969a). It is this property 
of the snake venom toxins which makes them ideal agents for treating coagulation-
related anomalies because they have no undesirable side effects, e.g. haemorrhage, 
thrombocytopenia, etc, commonly associated with conventional drugs. 
 
When thromboplastin-treated mice (after 24 hours exposure) were challenged 
with 50 ng/kg agkistase (TMAG) and compared to saline control (TMC) group, 
improvements were apparent in all the organs, both in reduction of obstructed vessels 
and reduction in thrombi size (Figures 4.18 - 4.22). For instance, most of the vessels in 
liver sections after 72 hours of exposure for TMAG were significantly clear of thrombi 
when compared to those found in TMC (Figure 4.20). This observation was supported 
by an almost 67% drop in D-dimer levels in mouse blood after 48 hours of agkistase 
exposure (Figure 4.17) compared to the controls. This transient drop in D-dimer levels 
demonstrated the efficacy of a bolus intravenous injection of agkistase in promoting 
fibrinolysis in thrombotic mice at the concentration tested.  The return of its level back 
to normal at 72 hr was probably caused by a cumulative effect in a loss of agkistase 
activity (through inactivation) and rethrombosis in the treated mice (Figure 4.24). The 
elevated levels of D-dimer detected were evident for successful thrombosis induction 
by thromboplastin injection in mice, following an adapted procedure reported by 
Bernat (Bernat et al, 1994) on rats. In humans, the upper normal range was averaged at 
278 ng/ml (n = 240) by the manufacturer. Unfortunately no such data was available for 
mice hence we interpreted the trend of the absolute values obtained to construct a basis 
of comparison between ‘treated’ and control mice groups. The single bolus of 
concentrated thromboplastin injected into the mice triggered a rapid depression in 
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fibrinogen level thereby activating a cascade of compensatory events in haemostasis, 
utilising and depleting all reserves of fibrinogen, platelets, coagulation factors and 
fibrinolytic enzymes resulting in bleeding, shock and vascular obstruction. These 
conditions in turn impaired the haemostatic processes and create a self-perpetuating 
vicious cycle (Rutherford, 1996). Consequently, amplified fibrinolysis that led to an 
elevated level of D-dimer maintained for over 72 hours as seen for TMC group. With 
the challenge of agkistase, soluble fibrinogen in the circulation of the TMAG group was 
rendered unrecognisable by thrombin and hence exhausted although fibrinolysis was 
unaffected. The net result showed a remarkable reduction in thrombi occlusion due to 
the putative effects of continuous fibrinolysis. 
 
Figure 4.24: Histological sections of lung from agkistase-injected mice showing 
rethrombosis at 72 hr 
 
Low magnifications of lung sections from agkistase-injected mice showing rethrombosis 
of the upper lung at 72 hr post-injection (indicated by arrows). A, 24 hr post-injection, 





Taken together with the results from in-vitro biochemical assays, coagulation 
assays and thrombelastography, we postulated the mechanism of action for agkistase 
involved a direct reduction of soluble, circulating fibrinogen thereby reducing the 
blood viscosity and improving flow to the occluded vessel(s). This promotes more 
efficient fibrinolysis by inherent plasmin activity through rapid replacement of inactive 
enzymes with fresh ones and minimises the chance of thrombus enlargement. 
Nevertheless, there is also a possibility that agkistase aids fibrinolysis through 
secondary activation of the haemostasis system (vessel wall, etc). Hence it is prudent 
to make three summarising conclusions on these observations: (i) agkistase, when 
administered for prolonged duration may trigger minor imbalance in haemostasis in 
healthy subjects possibly leading to slight DIC symptoms, (ii) agkistase is not 
nephrotoxic, and (iii) when agkistase is administered to subjects with existing 
thrombosis, its fibrinogenase activity essentially depletes circulating fibrinogen, 
prevents further accumulation of thrombi and alleviates the condition. This 
phenomenon is presumably achieved by a combinatory effect of: (i) lowering blood 
viscosity thereby improving blood flow to the affected sites, (ii) depletion of 
circulatory fibrinogen concentration that prevents further growth of existing thrombi, 
as well as (iii) promotion of fibrinolysis through reduction in local α-thrombin activity 
as fibrinogen is competed away thus preventing further enlargement of thrombus. 
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CHAPTER 5: IMPLICATIONS AND FUTURE STUDIES 
 
5.1 CONTRIBUTIONS OF SNAKE TOXINS 
Many advances in science and medical diagnostics and therapeutics will not be 
available today without the discovery made through studies of snake venoms and 
toxins. Since 1900, there has been an explosive interest in snake toxin research and 
many new groups of snake toxins have been isolated and characterized. These toxins, 
which are originally suggested to be part of a strategy for prey immobilization, can 
cause many spectacular effects on the mammalian haemostasis system. These toxins 
are usually classified by virtue of their net effects and they include the: (i) coagulants: 
snake venom thrombin-like enzymes (SVTLEs) (Markland, 1998a), prothrombin 
activators (Kini, 2005), (ii) anticoagulants: fibrinogenases (Markland, 1998a), protein 
C activators (Gempeler-Messina et. al., 2001), (iii) platelet effectors: C-type lectins 
(Clemetson et al, 2005; Kamiguti, 2005), (iv) fibrinolysis activators: plasminogen 
activator (Liu et al, 2006; Zhang et al, 1995a), (v) haemorrhagins (Marsh et al, 1995), 
etc. These toxins have made tremendous contributions to understanding the basics of 
coagulation, to the development of diagnostics reagents and treatment of haemostatic 
disorders. 
 
Coagulants – SVTLEs are used for assays involving fibrinogen and fibrinogen 
breakdown product and in the detection of dysfibrinogenaemias in clinical laboratory. 
The advantage of SVTLEs is due to their resistance against heparin inhibition allowing 
them to be used in antithrombin III assays with heparin-containing samples. The most 
well-known of such enzymes is probably the batroxobin-derived reagent, more 
commonly known by its generic name Reptilase®-R, which has become widely 
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recognised and is used in most coagulation laboratories as a diagnostic tool due to its 
resistance to heparin, hirudin and anti-thrombin III. Reptilase also does not activate    F 
VII and F XIII, and has no effects on platelets (De Gaetano et. al., 1974; Egberg, 1973; 
Funk et. al., 1971; Latallo et. al., 1981; Stocker, 1983). Russell’s viper venom (RVV), 
which was one of the first snake venoms to be recognized as a procoagulant can be 
used to assay clotting factors V (Keller et. al., 1995), VII (Quick, 1971), X (Stuart-
Prower disease) (Hougie, 1956) and lupus anticoagulants (LA) (Thiagarajan et. al., 
1986). 
 
Anticoagulants – Fibrinogenases are a relatively new class of toxins and have 
been proposed for their clinical potential for treating occlusive vascular disease. 
Several of these enzymes have been tested in vivo with promising results (Ahmed et al, 
1990; Loayza et. al., 1994; Markland, 1996; Willis et. al., 1989; Toombs, 2001b; 
Deitcher and Toombs, 2005). Generally, fibrinogenases have certain advantage over 
plasminogen activators, i.e. they exert plasmin-like activity thereby promoting 
fibrinolysis, but they do not cause plasmin-related secondary effects like platelet 
activation, and no adverse demonstrable pathological and histological effects have 
been reported. Protac®, a potent fast-acting protein C activator from the venom of A. 
contortrix contortrix, has been used in a chromogenic method (Nathan et. al., 1987), in 
functional clotting assays (Martinoli and Stocker, 1986) and in a new global clotting 
assay (ProC Global) (Toulon et. al., 2000). 
 
Platelet effectors – Snake venoms consist of many components affecting 
platelet function (Ouyang et. al., 1992) including the metalloprotease-disintegrins 
which inhibit platelet aggregation via interference with surface glycoprotein receptors 
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and the C-type lectins (Andrews and Berndt, 2000). These proteins offer an 
opportunity for studies of platelet-platelet and platelet-endothelium interactions mainly 
for research purposes, as there are currently no routine haemostasis test that utilizes a 
disintegrin. 
 
Fibrinolysis activators – This group of proteins affect haemostasis by direct 
fibrinolytic enzymatic activity and are thought to be of valuable use as thrombolytic 
agents, although similar haemostatic result can be achieved by most fibrinogenases and 
metalloproteases (Bell, 1997). 
 
Haemorrhagins – There is currently no interesting clinical application for 
venom haemorrhagins besides studies in vessel endothelium structure and physiology. 
 
5.2 DEFIBRINATING PROTEINS FROM SNAKE VENOMS 
The most well studied subject of snake venoms, or purified components from 
their venoms, is the clinical effects asserted on the mammalian haemostasis system 
over the last 150 years. And the field that receives most attention from researchers 
involves the effects of these venom components on fibrinogen/fibrin in the plasmatic 
coagulation system. Over a hundred such enzymes, divided into two distinct class of 
metalloproteases and serine proteases, have been reported (Markland, 1998a; Swenson 
and Markland, 2005). The suggestion that anticoagulation can be achieved through 
complete removal of plasma fibrinogen from the coagulation by means of a SVTLE    
– ‘therapeutic defibrination’ – was first suggested in 1968 (Reid and Chan, 1968). 
More accurately termed as ‘defibrinogenation’, the SVTLE acts by converting plasma 
fibrinogen into a non-clottable form of fibrin which is then easily removed by various 
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enzymatic processes. These enzymes were hailed as potential therapeutic agents to 
treat occlusive thrombi manifesting as clinical symptoms of deep vein thrombosis 
(DVT), pulmonary embolism (PE), myocardial infarction (MI), etc because it was 
found that reduction of plasma fibrinogen leads to reduced blood viscosity (hence 
increase blood flow) and may prevent clot formation or extension (Hossmann et. al., 
1983). They also appear to promote the release of endogenous tissue plasminogen 
activator (t-PA) and therefore have some indirect thrombolytic activity. The risk of 
haemorrhage may be less than treatment with conventional anti-thrombotic agents. The 
first and most extensively studied enzyme that has been isolated is a SVTLE from the 
venom of Malayan pit viper (Calloselasma rhodostoma) (discussed earlier in 4.1.2 
Thrombolytic Agents from Toxins). Ancrod has been used in a variety of conditions for 
a number of years and the risk of major haemorrhage appears to be small (Latallo, 
1983). Another similar enzyme, batroxobin isolated from the venom of Bothrops atrox 
asper, with essentially identical pharmacological properties and effect on blood 
coagulation, has also been tested for clinical use (Stocker and Barlow, 1976). 
Thrombolytic therapy does appear to be promising in acute ischaemic stroke, 
particularly in the very early phase, and has been used to treat patients in some 
countries but it is associated with a definite early hazard, mainly due to increased 
intracranial haemorrhage (Wardlaw et. al., 2002). Some double-blind and open 
unblended clinical trials on the effect of ancrod (Lowe et. al., 1982) and batroxobin 
(Liu et. al., 2003; Martin et. al., 1976) did not confirm the beneficial effect observed in 
uncontrolled studies. No difference between ancrod and heparin, or a greater effect of 
streptokinase than ancrod, were reported by the following authors (Davies et. al., 1972; 
Kakkar et. al., 1969; Tibbutt et. al., 1974). However, the great majority of controlled 
studies indicated the considerable value of these drugs for the threatment of 
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thromboembolic states, especially for DVT. These drugs cannot be recommended as a 
general haemostatic, since it seems to depend for their effect on the induction of low 
grade disseminated intravascular coagulation (DIC) in the patient’s plasma. The extent 
and complications of this drug-induced DIC would be impossible to predict and the 
possibility of a cardiovascular incident would always exist; this would be particularly 
so when the drug is used therapeutically. The use of these drugs, whose effectiveness 
as a haemostatic has been mainly demonstrated only in the field of minor and micro-
surgery, could possibly delay the use of more effective haemostatic regimens in cases 
of serious blood loss. Such a delay could have serious consequences for the patient 
undergoing major surgeries. Consequently the popularity of SVTLEs as therapeutic 
agents for occlusive thrombi and as thrombolytic agents has largely diminished. A 
summarised list of SVTLEs developed and clinically tested for their therapeutic and/or 
thrombolytic potentials is given in Table 5.1. 
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Table 5.1: Well-defined and purified SVTLEs with clinical and therapeutic use 
Snake species 
Names* (EC no for 




(four main) Other enzymatic activities 








35,000 29 Asp, Arg, Gly, Ile BAEE, TAME, AME, AAME, 
BAA, BA-p Na Not: LYSME, 
casein, haemoglobin, 
insulin, glucagon 
No other factors, plasminogen 
or thrombocytes 
Bothrops atrox asper 4,5,6 Batroxobin, Reptilase 
®, Hemostase  
(EC 3.4.21.29) 
32,000 − Asp, Gly, Pro, Ile As above  
Bothrops atrox moojeni 7 Defibrase, Defibrol, D-
Fibrol 





41,500 10.2 Asp, Gly, Pro, Ile As above Activates FXIII and FX with 
phospholipids 
Crotalus adamanteus 8,9 Crotalase® 
(EC 3.4.21.30) 
32,700 5.4 Asp, Gly, Pro, Ile Esters of basic amino acids, 
esters of aromatic and 
aliphatic amino acids 
Weak fibrinolytic activity on b-
chain, kininogens, prothrombin 
and PTVKA 
* Names approved by W.H.O. Generic names: ancrod, batroxobin, crotalase; all other are trade names. 
 
Reptilase®-R is a diagnostic reagent. 
 
1 – Esnouf and Tunnah, 1967 
2 – Hatton, 1973 
3 – Nolan et al, 1976 
4 – Stocker and Barlow, 1976 
5 – Aronson, 1976 
6 – Hessel and Blomback, 1971 
7 – Funk et al, 1971 
8 – Markland and Damus, 1971 
9 – Markland, 1976 
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With the seemingly negative reports for SVTLEs, currently a new promising 
group of snake venom toxins receiving special attention for clinical defibrinogenation 
is the fibrinogenases (Markland, 1998a; Toombs, 2001b). This group of enzymes is 
capable of cleaving specifically one or more fibrinogen chains both in vitro and in 
vivo, rendering the molecules unclottable by endogenous thrombin when used 
therapeutically. Several of these enzymes have even been shown to possess additional 
fibrinolytic activity, making them excellent candidates for treating vascular occlusive 
disorders and as thrombolytic agents. A good example is fibrolase, a direct-acting 
fibrinolytic enzyme purified from the venom of A. contortrix contortrix (Guan et. al., 
1991b; Pretzer et. al., 1993; Retzios and Markland, 1988), and its recombinantly-
produced truncated form, alfimeprase (Deitcher and Toombs, 2005; Toombs, 2001a), 
which is already in phase III clinical trial (by the time of this writing) and has been 
showing promising results thus far. In phase I clinical trial, alfimeprase was found to 
be well tolerated by patients with chronic peripheral arterial occlusion (PAO) up to 
concentrations of 0.5 mg/kg without signs of adverse effects (Ouriel et. al., 2005). 
However, three transient treatment-related adverse events were reported in the same 
patient: one incidence each of increased blood fibrinogen level, skin rash, and 
headache. In another independent phase II randomised, double-blind, multicentre 
clinical trial, alfimeprase was found to improve the condition for occluded central 
venous access devices (CVAD) patients (Moll et. al., 2006). More clinical trial data 
need to be gathered before alfimeprase can be marketed globally. It is reasonable to 
speculate that fibrolase/alfimeprase will cause resistance in patients with repeated 
treatments (unfortunately such clinical data is still unavailable) hence the need for 
developing similar agents is essential; the one principal source for acquiring these 
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enzymes is naturally from the fibrinogenases. Table 5.2 lists some currently purified 
fibrinogenases and their characteristics. 
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Table 5.2: Fibrinogenases from snake venoms 
Snake species Fibrinogenase MW Other enzymatic activities Reaction with inhibitors References 
Agkistrodon halys halys 
(agkistase) 
α, β 29,200 Synthetic substrates specific for 
thrombin, plasmin, kallikrein; no platelet 
aggregation; exclusively fibrinogenolytic 
and mildly fibrinolytic; non-haemorrhagic 
PMSF, aprotinin, 
cysteine, benzamidine; 
EDTA and DTT = 0 
Current study 
A. halys pallas1 β, α  N.D.  EDTA, metal chelators (Guan et. al., 1984) 
A. halys brevicaudus2          
(α-Fibrinase) 
α, β 51,000 Fibrinolytic DFP (Markland, 1998a) 
A. halys brevicaudus2 
(Protease L4) 





(Fujimura et. al., 1995) 
A. halys brevicaudus2 
(Fibrinase) 
+ 39,200 Fibrinolytic N.D. (Qian and Ma, 1991) 
A. acutus3 N.D. N.D. Fibrinolytic, caseinolytic Aprotinin, EDTA, EACA, 
cysteine 
(Ouyang and Huang, 
1977) 
A. acutus3 (α-Fibrinase) α 24,100 Fibrinolytic, haemorrhagic EDTA (Ouyang and Huang, 
1976; Ouyang and 
Huang, 1977) 
A. acutus3 (Acurhagin) α, β 48,133 Caseinolytic, inhibits ADP-, collagen-, 
and riscocetin-induced platelet 
aggregation 
EDTA (Wang and Huang, 2002) 
A. contortrix N.D. 32,000 
25,000 
Synthetic substrates specific for 
thrombin, plasmin, kallikrein 
N.D. (Dyr et. al., 1983) 
A. contortrix N.D. 26,000 No amidolytic activity on synthetic 
substrates, caseinolytic 
Inhibited by plasmatic 
antiproteinases, EDTA 
(Moran and Geren, 
1981a) 
A. c. contortrix (Fibrolase) α, β 23,000 Fibrinolytic, non-haemorrhagic, does not 
activate plasminogen 
EDTA, penanthroline (Moran and Geren, 
1981b) 
A. c. mokasen (Fibrinogenase) α 22,900 No other proteins except fibrin, non-
haemorrhagic 
EDTA, metal chelators (Guan et. al., 1991a; 
Moran and Geren, 1981b) 
A. c. laticinctus 
(Fibrinogenase) 
N.D. 23,000 N.D. N.D. (Selistre de Araujo and 
Ownby, 1995) 
A. piscivorus piscivorus        
(β-Fibrinogenase) 
β 33,500  DFP (Nikai et. al., 1988) 
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A. p. piscivorus (Piscivorase I) α, β 23,400 Fibrinolytic, no platelet activity, weak 
haemorrhagic 
EDTA (Hahn et al, 1995) 
A. p. piscivorus (Piscivorase II) α, β 29,000 Fibrinolytic, no platelet activity EDTA (Hahn et al, 1995) 
A. p. conanti (Apcfib) N.D. 23,000 Fibrinolytic EDTA (Retzios and Markland, 
1990) 
Calloselasma rhodostoma α 25,300 Fibrinolytic, caseinolytic, no esterolytic 
(TAME) 
EDTA, cysteine, no 
amino caproic acid 
(Ouyang et. al., 1983b; 
Ouyang et. al., 1983a) 
Ca. rhodostoma (Kistomin) α, γ 21,800 Fibrinolytic, inhibits ristocetin-induced 
platelet aggregation, non-haemorrhagic 
EDTA (Huang et. al., 1992) 
Bothrops asper N.D. 23,500 
15,300 
Casein, haemoglobin, fibrinogen, fibrin, 
collagen 
EDTA = + 
Cysteine = 0 
(Kornalik, 1991) 
Bothrops asper (Proteinase G) α, β 23,500 Non-haemorrhagic EDTA (Aragon-Ortiz and 
Gubensek, 1987) 
B. jararaca (Jararafibrase I) α, β 47,000 Weak fibrinolytic, strong haemorrhagic EDTA (Maruyama et. al., 
1992b) 
B. jararaca (Jararafibrase II) α, β 21,400 Strong fibrinolytic, weak haemorrhagic EDTA (Maruyama et al, 1992b) 
B. jararaca (Jararafibrase III) α, β 20,400 Strong fibrinolytic, weak haemorrhagic EDTA (Maruyama et. al., 1993) 
B. jararaca (Jararafibrase IV) α, β 21,200 Strong fibrinolytic, weak haemorrhagic EDTA (Maruyama et al, 1993) 
B. moojeni (Protease A) α, β 22,500 Fibrinolytic, weak haemorrhagic EDTA (Assakura et. al., 1985; 
Reichl et. al., 1993) 
B. moojeni (MSP 1) α, β, γ 34,000 Fibrinolytic, hydrolyses TAME, enhances 
ADP-induced platelet aggregation 
PMSF, SBI (Serrano et. al., 1993a; 
Serrano et al, 1993b) 
B. moojeni (MSP 2) α, β, γ 38,000 Fibrinolytic, hydrolyses TAME PMSF, SBI (Serrano et al, 1993a; 
Serrano et al, 1993b) 
B. moojeni (MPB) α, β, γ 55,000 & 
65,000 
Fibrinolytic EDTA (Serrano et al, 1993a; 
Serrano et al, 1993b) 
Crotalus atrox N.D. 60,000 
21,500 
No S-2251 lysis (plasmin substrate)  (Bajwa et. al., 1980) 
Cr. atrox (α-Fibrinogenase) α 30,000  PMSF (Chiou et al, 1992) 
Cr. atrox (Atroxase) α, β 23,500 Fibrinolytic, no platelet activity, non-
haemorrhagic 
EDTA (Willis and Tu, 1988) 
Cr. atrox (Catroxase) α, β 24,000  EDTA (Chiou et al, 1992) 
Cr. atrox (Protease I) α, β 20,000  EDTA, phenanthroline (Pandya and Budzynski, 
1984) 
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Cr. atrox (Protease II) β 31,000  PMSF, DFP (Pandya and Budzynski, 
1984) 
Cr. atrox (Protease III) β 24,000  PMSF, DFP (Pandya and Budzynski, 
1984) 
Cr. atrox (Protease IV) α, β 46,000  EDTA, phenanthroline (Pandya and Budzynski, 
1984) 
Cr. atrox (Fibrinogease A) α, β 33,000  PMSF (Hung and Chiou, 1994) 
Cr. atrox (Fibrinogenase) α, β 31,000 Non-haemorrhagic DFP (Nikai et. al., 1983) 
Cr. atrox (β-Fibrinogenase) β 22,900 No lysis of fibrin, casein, arginine esters PMSF = ++ 
EDTA = 0 
(Sapru et. al., 1983) 
Cr. basiliscus basiliscus 
(Basilase) 
α, β 23,000 Fibrinolytic, non-haemorrhagic, no 
thrombin-like, factor X-like, protein C 
activating, urokinase-like nor platelet 
activity 
EDTA, α2-macroglobulin (Datta et. al., 1995) 
Cr. b. basiliscus         
(Basilicus-fibrase 1) 
α, β 23,500 Fibrinolytic, non-haemorrhagic EDTA (Retzios and Markland, 
1992; Retzios and 
Markland, 1994) 
Cr. b. basiliscus         
(Basilicus-fibrase 2) 
α, β 23,500 Fibrinolytic, non-haemorrhagic EDTA (Retzios and Markland, 
1992; Retzios and 
Markland, 1994) 
Cr. b. basiliscus         
(Basilicus-fibrase 3) 
α, β 22,500 Fibrinolytic, non-haemorrhagic EDTA (Retzios and Markland, 
1992; Retzios and 
Markland, 1994) 
Cr. molossus N.D. N.D. Aggregation of thrombocytes N.D. (Corrigan et. al., 1983) 
Cr. molossus molossus (M4) α, β 27,000 Fibrinolytic, non-haemorrhagic EDTA (Rael et. al., 1992) 
Cr. viridis oreganus          
(CVO protease V) 
α, β 61,000 Fibrinolytic, weak haemorrhagic EDTA (Mackessy, 1996) 
T. mucrosquamatus             
(α-Fibrinogenase) 
α 22,500 Fibrinolytic, inhibits ADP-induced platelet 
aggregation, haemorrhagic 
EDTA (Ouyang and Huang, 
1977; Teng et. al., 1985) 
T. mucrosquamatus             
(β-Fibrinogenase) 
β, α 25,500 Fibrinolytic, no platelet activity, non-
haemorrhagic 
PMSF (Ouyang and Huang, 
1977; Teng et al, 1985) 
T. mucrosquamatus (P-1) β, α 23,000 Non-haemorrhagic EDTA (Sugihara et. al., 1985) 
T. mucrosquamatus (P-2) α, β 23,500 Non-haemorrhagic EDTA (Sugihara et al, 1985) 
T. mucrosquamatus (P-3) α, β 23,000 Non-haemorrhagic EDTA (Sugihara et al, 1985) 
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T. mucrosquamatus (ME-1) β, α 27,000 Fibrinolytic, non-haemorrhagic Benzamidine (Sugihara et. al., 1984; 
Sugihara et. al., 1986) 
T. mucrosquamatus (ME-2) β, α 29,800 Fibrinolytic, non-haemorrhagic Benzamidine (Sugihara et al, 1984; 
Sugihara et al, 1986) 
T. mucrosquamatus (ME-3) α, β 33,000 Fibrinolytic, non-haemorrhagic DFP (Sugihara et al, 1984; 
Sugihara et al, 1986) 
T. mucrosquamatus (ME-4) α, β 28,500 Fibrinolytic, non-haemorrhagic DFP (Sugihara et al, 1984; 
Sugihara et al, 1986) 
T. mucrosquamatus (TM-1) α, β 27,000  EDTA, phenanthroline, 
β-ME 
(Huang et. al., 1993; 
Huang et. al., 1995) 
T. mucrosquamatus (TM-2) α, β 27,000  EDTA, phenanthroline, 
β-ME 
(Huang et al, 1993; 
Huang et al, 1995) 
T. mucrosquamatus (TM-3) α, β 27,000  EDTA, phenanthroline, 
β-ME 
(Huang et al, 1993; 
Huang et al, 1995) 
T. mucrosquamatus             
(β-Fibrinogenase) 
β, α 28,000 Non-fibrinolytic PMSF (Hung and Chiou, 1994) 
T. mucrosquamatus (FP) β, α 22,000 Fibrinolytic, haemorrhagic EDTA (Markland, 1998a) 
T. gramineus                      
(α-Fibrinogenase) 
α 23,500 Strong fibrinolytic, haemorrhagic EDTA, l-cysteine (Ouyang and Huang, 
1979) 
T. gramineus                      
(β-Fibrinogenase) 
β, α 25,000 Weak fibrinolytic PMSF (Ouyang and Huang, 
1979) 
Echis carinatus α, β 60,000 No esterolytic, no amidolytic No aprotinin, SBI, 
hirudin 
(Kornalik et. al., 1979) 
E. carinatus (Fibrinogenolysin) α, β 20,000  EDTA (Tseng et. al., 1989) 
Cerastes cerastes (F-4) α, β 22,500 Fibrinolytic, weak haemorrhagic EDTA (Daoud et. al., 1986a; 
Daoud et. al., 1986b; 
Daoud et. al., 1987) 
Ce. C. cerastes α, β 22,500 Caseinolytic, prothrombinolytic N.D. (Kornalik, 1991) 
Naja nigricollis (Proteinase F1) α 58,000 Fibrinolytic, inhibits WBP aggregation, 
inactivates α2-macroglobulin and 
fibronectin 
EDTA, phenanthroline (Evans, 1981; Evans, 
1984; Kini and Evans, 
1991) 
Vipera lebetina (Lebetase) α, β 23,700 Fibrinolytic, weak haemorrhagic EDTA (Siigur and Siigur, 1991) 
V. lebetina (Fibrinogenase) β, α 26,000 Fibrinolytic, inhibits ADP-induced PRP 
aggregation, non-haemorrhagic 
EDTA (Gasmi et al, 1991) 
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V. lebetina (β-Fibrinogenase) β, α 52,500 Weak caseinolytic, hydrolyses BAEE, 
TAME and BAPNA 
PMSF, DFP (Siigur and Siigur, 1991) 
Bitis arietans (PAV protease) α, β 25,000 Fibrinolytic (γ-chain of X-linked D-dimer) EDTA (Purves et. al., 1987) 
Philodryas olfersi (ProfibC1) α 47,000 Fibrinolytic, non-haemorrhagic EDTA, DTT (Assakura et. al., 1994) 
Philodryas o. (ProfibC2) α 47,000 Fibrinolytic, non-haemorrhagic EDTA, DTT (Assakura et al, 1994) 
Philodryas o. (ProfibC3) α, β 45,000 Fibrinolytic, non-haemorrhagic EDTA, DTT (Assakura et al, 1994) 
Philodryas o. (ProfibH) α 58,000 Fibrinolytic, non-haemorrhagic EDTA, DTT (Assakura et al, 1994) 
Philodryas o. (ProfibS) α, β 36,000 Fibrinolytic, non-haemorrhagic EDTA, DTT (Assakura et al, 1994) 
Lachesis muta muta (LHF-II) α 22,300 Fibrinolytic, weak haemorrhagic EDTA, EGTA, 
phenanthroline, l-
cysteine 
(Sanchez et. al., 1991) 
N.D. = Not determined; DFP = diisopropylfluorophosphate; SBI = soybean trypsin inhibitor; β-ME = β-mercaptoethanol; WBP = whole blood platelet; BAEE = 
α-N-benzoyl-L-arginine ethyl ester; TAME = p-tosyl-L-arginine methyl ester; BAPNA = α-N-benzoyl-DL-arginine-4-nitroanilide 
Taxa of Agkistrodon Complex vipers in the above table in accordance to Hoge and Romano-Hoge tribal classification (see Appendix) 
1 = possibly another Siberian pit viper (A. halys halys) 
2 = possibly Korean mamushi (A. blomhoffii brevicaudus) 
3 = possibly hundred-paced viper (Deinagkistrodon acutus)  
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5.3 AGKISTASE AS A NEW SOURCE OF FIBRINOGENASE 
 
Therefore the potential of fibrinogenases in producing novel and more effective 
therapeutic and anti-thrombotic agents cannot be emphasised enough. Many research 
groups are already shifting their focus towards isolating new fibrinogenases and/or 
switching into molecular engineering of known enzymes. In this dissertation, we have 
reported the purification, characterisation and in vivo studies to establish the potential 
of agkistase as a new candidate for this purpose. It has been shown that agkistase has a 
mid molecular size range common to most fibrinogenases (Table 5.2) and has 
prominent α,β-fibrinogenase activity that can be inhibited by PMSF, aprotinin,           
l-cysteine and benzamidine but not by EDTA nor DTT (Table 3.4). It hydrolyses 
synthetic substrates specific for thrombin, plasmin and plasma kallikrein (Table 3.2); 
has no haemolytic (Figure 3.4) and haemorrhagic (Figure 4.1) activities; no platelet 
aggregation activity (Figure 3.5); does not affect other blood coagulation factors; and 
is exclusively fibrinogenolytic (Figures 3.8, 3.9 and 3.10) and mildly fibrinolytic 
(Figures 3.12, 3.13 and Table 3.5). Agkistase was also found to have a EC50 value of 
5.1 ± 1.5 µg/ml, 0.26 ± 0.1 µg/ml and 0.5 ± 0.2 µg/ml for PT, RT and TT, respectively 
(Figure 3.14). Thrombelastographic traces displayed an exceptionally prolonged 
reaction time (r) and clot initiation (k), but normal clot strength (MA) with increasing 
exposure time to whole blood, particular to clinical haemophilic samples. In vivo 
studies on mice showed a sharp and rapid (minimum reached after 5 hours post-
injection; Figure 4.6) reduction in plasma fibrinogen concentration at relatively low 
protein range beginning at 10 ng/kg mouse body weight (Figure 4.4). It significantly 
reduced both the amount and size of thrombi formation in various mouse organs (heart, 
lung, liver, kidney and spleen) at nanogram concentration (50 ng/kg) in just 48 hours 
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post-injection (Figures 4.18 – 4.22). D-dimer levels were seen to drop by 67% after 48 
hours of agkistase administration compared with control thromboplastin-induced mice 
(Figure 4.17). These observations strongly suggest the unique biochemical, 
physiological and pharmacological effects exerted by agkistase on the mammalian 
blood coagulation system, thereby making it a fibrinogenase with interesting properties, 
with potential for development into a therapeutic and anti-thrombotic agent. With the 
substantial differences compared with other current fibrinogenases, as well as the high 
efficiency and low dosage requirements, agkistase poses itself not as “another 
alternative agent on the shelf” but a worthy toxin (or as a scaffold design) to be 
clinically tested and developed further. 
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5.4 FUTURE WORK 
The most crucial and important work following this discovery will be to extend 
the clinical tests in order to fully evaluate the potential of agkistase in various clinical 
models of vascular occlusive disorders. Many models are already well-developed by 
various research groups involving animals ranging from mouse, rat, rabbit, dog, etc 
(and even transgenic animals) exhibiting many clinical symptoms found in human, e.g. 
prethrombotic state (Weiler, 2004a), venous thrombosis (Bernat et al, 1994; Willis et 
al, 1989), DVT (Bernat et al, 1994), DIC in rat (Asakura et. al., 2002), and DIC in 
rabbit (Scherer et. al., 1995). Only through rigorous evaluation of these models can we 
expand our understanding on the detail mechanism of action, the resulting 
physiological changes, possible side effects, animal tolerance and resistance to the 
fibrinogenase. 
 
Cloning and possible recombinant production for agkistase will be as important 
as evaluation of its clinical effects. The most critical part of this project, which should 
be approached with care and diligence, is in the acquisition of the liver or venom 
glands of pit viper A. halys halys. Identification purposes should be done by an 
experienced herpetologist to avoid any misidentification as snake toxins have high 
homology especially among its Agkistrodon family members, which could complicate 
getting the same fibrinogenase; it is highly possible that there are more than one 
fibrinogenase in the same venom of A. halys halys alone!  With the right venom gland 
to start with, construction of a cDNA library followed by ‘fishing out’ the right mRNA 
and PCR can be done rapidly as there are many kits available in the market that offers 
results obtainable in a day or two, if one is lucky. The challenging part of the work is 
expected to be expressing an active protein with correct folding and retaining the 
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native enzymatic activities. There have been several reports on successful venom 
protein expression recently hence it is highly feasible that agkistase can be 
successfully expressed with one of those models, e.g. fibrolase in E.coli (Zhang et. al., 
2006), salmobin on cell surface of E.coli (Jeong et. al., 2001), acutolysin in E.coli 
(Xiang et. al., 2002), and human integrin-metalloprotease chimeric protein in human 
cell line (Wei et. al., 2001). It is a shame that we were not able to obtain the venom 
gland for this project due to many difficulties in obtaining samples, biological hazard 
shipping and international law. 
 
With successful cloning, one can also engineer its recombinant protein to either: 
(i) improve its native enzymatic efficiency, (ii) improve its stability in physiological 
conditions (whereby prolonging its effects), (iii) include a short protein sequence to 
enhance its substrate targeting, etc. There will be tremendous possibilities with the 
successful cloning of a functional protein. 
Construction of its cDNA library and cloning also enables the sequencing of 
DNA for its putative amino acid sequence determination. This will undoubtedly prove 
to be a quicker, cleaner and much cheaper method of obtaining its full-length sequence 
apart from conducting protein sequencing through either Edman degradation chemistry 
or de novo MS/MS spectroscopy. 
 
Last but not least, it will be interesting to elucidate the cleavage site(s) of 
agkistase on fibrinogen molecule and to understand and compare this to the thrombin-
recognition site. Many enzymological and structural questions can be answered when 
sufficient protein can be purified or, likelier, generated through mass expression. 
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APPENDIX I: Taxonomic Status of the Agkistrodon Complex 
(Hoge and Romano-Hoge tribal name, 1981) 
 
The four genera of Agkistrodon Complex are listed below with full name of each 







Species rhodostoma [Malayan pit viper] F. Boie, 1827 
 
Genus Deinagkistrodon 
Species acutus [Hundred-pace viper] Günther, 1888 
 
Genus Hypnale 
Species hypnale [Hump-nosed viper] Merrem, 1820 
Species nepa [Sri Lankan hump-nosed viper] Laurenti, 1768 




Subspecies bilineatus [Cantil] Günther, 1863 
Subspecies howardgloydi [Castellana] Conant, 1984 
Subspecies russeolus [Yucatecan cantil] Gloyd, 1972 
Subspecies taylori [Taylor’s cantil] Burger and Robertson, 1951 
 
Species blomhoffii 
Subspecies blomhoffii [Japanese mamushi] H. Boie, 1826 
Subspecies brevicaudus [Short-tailed mamushi] Stejneger, 1907 
Subspecies dubitatus [Tung Ling mamushi] Gloyd, 1977 
Subspecies siniticus [Yangtze mamushi] Gloyd, 1977 
Subspecies ussuriensis [Ussuri mamushi] Emelianov, 1929 
 
Species caliginosus [Dusky mamushi] Gloyd, 1972 
 
Species contortrix 
Subspecies contortrix [Southern copperhead] Linnaeus, 1766 
Subspecies laticinctus [Broad-banded copperhead] Gloyd and Conant, 1934 
Subspecies mokasen [Northern copperhead] Palisot de Beauvois, 1799 
Subspecies phaeogaster [Osage copperhead] Gloyd, 1969 
Subspecies pictigaster [Trans-pecos copperhead] Conan and Gloyd, 1943 
 
Species halys 
Subspecies halys [Siberian pit viper] Pallas, 1776 
Subspecies caraganus [Karaganda pit viper] Eichwald, 1831 
Subspecies cognatus [Alashan pit viper] Gloyd, 1977 
Species himalayanus [Himalayan pit viper] Günther, 1864 
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Species intermedius 
Subspecies intermedius [Central Asian pit viper] Strauch, 1868 
Subspecies caucasicus [Caucasian pit viper] Nikol’skii, 1916 
Subspecies saxatilis [Rock mamushi] Emelianov, 1937 
Subspecies stejnegeri [Gobi pit viper] Rendahl, 1933 
 
Species monticola [Likiang pit viper] Werner, 1922 
 
Species piscivorus 
Subspecies piscivorus [Eastern cottonmouth] Lacépède, 1789 
Subspecies conanti [Florida cottonmouth] Gloyd, 1969 
Subspecies leucostoma [Western cottonmouth] Troost, 1836 
 
Species strauchi [Tibetan pit viper] Bedriaga, 1912 
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Prof Peter Simon Pallas – page 3 
 
“The license Wikipedia uses grants free access to our content in the same sense as free 
software is licensed freely. This principle is known as copyleft. That is to say, 
Wikipedia content can be copied, modified, and redistributed so long as the new 
version grants the same freedoms to others and acknowledges the authors of the 
Wikipedia article used (a direct link back to the article satisfies our author credit 
requirement). Wikipedia articles therefore will remain free forever and can be used by 
anybody subject to certain restrictions, most of which serve to ensure that freedom. 
To fulfill the above goals, the text contained in Wikipedia is copyrighted 
(automatically under the Berne Convention) by Wikipedia contributors and licensed to 
the public under the GNU Free Documentation License (GFDL). The full text of this 
license is at Wikipedia:Text of the GNU Free Documentation License. This text should 
not be changed for legal reasons. 
Permission is granted to copy, distribute and/or modify this document 
under the terms of the GNU Free Documentation License, Version 1.2 or 
any later version published by the Free Software Foundation; with no 
Invariant Sections, with no Front-Cover Texts, and with no Back-Cover 
Texts. 
A copy of the license is included in the section entitled "GNU Free 
Documentation License". 
Content on Wikipedia is covered by disclaimers.
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Yenisey river, Russia – page 3 
 
 
From: Jennie Hommel [mailto:JHOMMEL@wri.org]  
Sent: Tuesday, July 10, 2007 21:57 
To: Yau Yin Hoe 
Subject: Fwd: Permission to reproduce copyright material 
 
Dear Yau Yin Hoe,  
 
Thank you for your request for permission to reproduce the map (referenced in your 
email below) in your thesis. Permission is hereby granted for use of the material as 






4 July 2007 
World Resources Institute 
10 G Street, NE (Suite 800) 




I am writing to seek your kind permission to use and reproduce, for purposes of 
submission, publication and distribution of my thesis as described above, the following 
works for which I understand you to be the copyright owner: 
 
Watersheds of the World: Asia and Oceania - Yenisey Watershed 
http://earthtrends.wri.org/images/maps/p2_105_md.gifhttp://earthtrends.wri.org/image
s/maps/p2_105_md.gif” 
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The chemistry of Edman degradation – page 32 
 
From: ISU Protein Facility [mailto:protein@iastate.edu]  
Sent: Wednesday, July 11, 2007 20:37 
To: Yau Yin Hoe 




You may use the diagram if you wish. I don't have a copyright on it, I made it in 





29 June 2007 
The Protein Facility of the Iowa State University Office of Biotechnology 
1182 Molecular Biology Building 




I am writing to seek your kind permission to use and reproduce, for purposes 
of submission, publication and distribution of my thesis as described above, 
the following works for which I understand you to be the copyright owner: 
 
The diagram on Edman degradation on the Perkin Elmer Applied Biosystems 
Model 494 Procise protein/peptide 
(http://www.biotech.iastate.edu/facilities/protein/nseq_fig1.html). 
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Thrombelastography – page 58 
 
From: Irene Navickas [mailto:Irene@haemoscope.com]  
Sent: Thursday, July 12, 2007 4:08 
To: Yau Yin Hoe 
Subject: RE: Permission to reproduce copyright material 
You have our permission to use any of the information or graphics from our 
website, providing you acknowledge Haemoscope. I can provide higher 
resolution graphics if you need them for a printed version. You may also find 
some graphics in the User Manual that are useful to you as well. Just let me 
know. 
  
I would appreciate a copy of any documents in which you publish our 
materials. 
  






Irene A Navickas  
Director of Clinical Affairs  
Haemoscope Corporation -- Home of the TEG(R) Hemostasis System  
6231 W Howard St  
Niles IL 60714-3403  
800-GET-A-TEG / 847-588-0453 x 216  
847-588-0455 fax  
   
The information contained in this message and any attachments hereto may be privileged, confidential, and protected from 
disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this 
message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this 
communication and any attachments hereto is strictly prohibited. If you have received this communication in error, please 
notify us immediately by replying to the message and permanently delete the original and any copy of this message, including 
any attachments to this message, and any printout thereof. 
29 June 2007 
Home of the TEG® Hemostasis System 
6231 West Howard Street 
Niles, IL 60714-3403  
Dear Sir/Madam, 
I am writing to seek your kind permission to use and reproduce, for purposes 
of submission, publication and distribution of my thesis as described above, 
the following works for which I understand you to be the copyright owner: 
All three diagrams for TEG® Haemostasis Analyser 
(http://www.haemoscope.com/technology/teg_analyzer.html).  
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Sent: Wednesday, July 11, 2007 19:10 
To: Yau Yin Hoe 
Subject: RE: Permission to reproduce copyright material 






11 July 2007 
Chromogenix 
Instrumentation Laboratory S.p.A. 
Viale Monza, 338  
20128 Milano - Italy 
Telephone: +39 02 25 22 880 
Fax: +39 02 25 22 889  
Dear Sir/Madam, 
I am writing to seek your kind permission to use and reproduce, for purposes 
of submission, publication and distribution of my thesis as described above, 
the following works for which I understand you to be the copyright owner: 
All the chemical structures for trademarked chromogenic synthetic peptides  
(S-2222, S2238, S-2251, S-2288, S-2302, S-2366 and S-2403). 
